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Abstract 
 
The polycyclic polyprenylated acylphloroglucinols (PPAPs) are a class of naturally 
occurring compounds with a characteristic bicyclo core system (either [3.3.1]nonane 
or [3.2.1]octane).  This class of compounds have been shown to have significant 
biological activity, including activity against cancer, HIV, bacterial infection and 
depression.  The biological activity and the structural challenges that these 
compounds pose have led to significant interest from the synthetic chemists.  A 
review of the previous synthetic work and the biological activity of the PPAPs is 
contained within Chapter 1. 
A total synthesis of the type A PPAP nemorosone (4) is described, using a modified 
Effenberger cyclisation as the key bicyclo[3.3.1]nonane forming step.  Further 
functionalisation was performed through a difficult bridgehead iodination, followed by 
halogen-metal exchange and benzoylation.  Chapter 2 describes our total synthesis 
of nemorosone (4) in 13 synthetic steps and 6% overall yield. 
Chapter 3 describes the first total synthesis of the type C PPAP nemorosone II (150) 
in 10 synthetic steps and 1.5% overall yield.  Once more the key 
bicyclo[3.3.1]nonane core was formed using the modified Effenberger cyclisation. 
Alongside the synthesis, biological studies have been performed on the final 
compounds and a range of intermediates (Chapter 4).  Investigations into the difficult 
bridgehead substitution and resulting halogen-metal exchange reactions are 
discussed in Chapter 5.  Preliminary studies were undertaken into a new shorter 
route to nemorosone (4) using a Dieckmann condensation as the key 
bicyclo[3.3.1]nonane forming step.  (Chapter 6). 
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Chapter 1 
Polycyclic Polyprenylated Acylphloroglucinols 
 
Recently, there has been much interest in the natural products from the plants and 
trees of the Clusiaceae (Guttiferae) family, particularly the polycyclic polyprenylated 
acylphloroglucinols (PPAPs), due to their varied and significant biological activity.1  
This activity, combined with their characteristic bicyclo[3.3.1]nonane-trione core, 
bearing additional acyl and prenyl substituents make PPAPs a challenging and 
interesting target for the synthetic chemist.  Examples that have received recent 
attention include garsubellin A (1), hyperforin (2), clusianone (3) and nemorosone (4).   
 
Figure 1.0.1 
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1.1 Introduction to PPAPs 
The bridged bicyclic core is common to all the PPAPs, most have a 
bicyclo[3.3.1]nonane core although a few have a bicyclo[3.2.1]octane core.  In some 
of these compounds further cyclisation takes place between the ß-diketone and the 
pendant olefinic groups, forming secondary ring systems on the bicyclic core, e.g. 
garsubellin A (1) (Figure 1.0.1).  Numbering of the ring system has varied between 
publications but here the numbering will start with the bridgehead carbon next to the 
quaternary centre, which is commonly a geminal dimethyl, being denoted as C-1 
(Figure 1.1.1). 
 
Figure 1.1.1 
 
A recent review by Grossman collated all the isolations of PPAPs, which resulted in 
data on 119 individual species, although this number has grown considerably since 
the review was published.1-5  Grossman organised them into three subgroups based 
on the position of the acyl group in relation to the quaternary C-8 centre 
(Figure 1.1.2). 
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Figure 1.1.2 
 
Type A structures, such as nemorosone (4), are the most common, with 80 known 
structures. These are characterised by having the acyl group at the C-1 bridgehead 
position adjacent to the C-8 quaternary centre.  Type B structures, such as 
clusianone (3), are approximately half as prevalent as type A structures, and have 
the characteristic acyl group at the C-3 vinylic position.  Type C is the least common 
of the sub groups with only three known compounds in the class. It is possible that 
these are mis-assignments of other products, as the corresponding type A analogues 
have already been isolated from the same plant source.  Type C structures have the 
acyl group in the C-5 position, at the bridgehead position distal to the quaternary 
centre at C-8.  Other variations in the groups of the PPAP family include extended 
alkyl chains at the C-8 geminal dimethyl position and compounds epimeric at the C-7 
position. 
PPAPs can often be found in propolis (a resinous substance) which is produced from 
plants and buds by honey bees.6  Recent studies into Cuban propolis have divided 
them into three groups: brown, red and yellow.  Brown propolis was found to be rich 
in PPAPs, particularly nemorosone (4).  The wide ranging bioactivity of propolis, 
much of which is attributed to the PPAP content, led to its use as a health drink and 
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in various creams and gels.  An extensive database on the toxicological and 
biological activity of propolis indicates that it may be effective against bacteria, fungal 
infections, viruses and tumours.  More specific health effects attributed to the propolis 
drink include prevention of heart disease, inflammation, diabetes and cancer.7 
 
1.2 Medicinal Properties of PPAPs  
PPAPs have been used as a treatment of many ailments since 300 BC, as either an 
extract direct from the plant or as a propolis extract.7  The most common use of a 
PPAP as a medicinal remedy is the use of St. John’s Wort; a “herbal” remedy used in 
the treatment of mild depression and skin injuries, the active ingredient of which is 
hyperforin (2).8-9  Initially it was the antibacterial effects that were of interest but 
hyperforin’s (2) major anti-depressant effects in St. John’s Wort have become a 
leading area of interest.  Subsequent studies have been performed to discover if 
there is any activity in other areas, especially due to its low human toxicity and 
pharmacokinetic profile.  So far only two biological targets of hyperforin (2) have 
been discovered, a neuronal [Na+]/[Ca2+] exchanger and the pregnane 
X-receptors.10-12  These activities appear to be involved in the anti-depressant effects 
as well as unfavourable drug interactions.  Other interesting activity includes action 
against cancer cell lines,13 viral strains, Alzheimer's disease,14 HIV15 and well 
documented antidepressant effects.16  More recently hyperforin (2) has been 
discovered to have anti malarial properties.17  In vitro studies have shown an IC50 of 
1.5 μM against antiplasmodial effects of Plasmodium falciparum.  Further studies into 
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the SAR were also performed and the activity was shown not to be dependent on the 
phenol like part or the prenyl double bonds of hyperforin (2). 
Clusianone (3) has been known since 1976 and recent screening has ascribed 
potent anti-HIV and cancer chemopreventive properties.15,19  Against HIV infection in 
C8166, clusianone (3) showed a 0.02 μM EC50 value. 
Garsubellin A (1) has shown positive activity against Alzheimer’s disease.14  
Treatment with a 10 μM concentration of garsubellin A (1) produced an increase of 
154% of acetylcholine in P10 rat septal neuron cultures.  Some anti-inflammatory 
properties have also been attributed to garsubellin A (1) including inhibition of β-
glucuronidase and histamine at IC50 = 15.6 μM.
19 
Nemorosone (4) displays a range of biological activities which are discussed in 
Chapters 2 and 4. 
Various other PPAPs (Figure 1.2.1) have shown biological activity and are 
summarised in Table 1.2.1. 
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PPAP Disease Cell Line Activities 
Propolone A (5) HIV C8166 human T 
lymphoblastoid cells 
EC50 = 0.32 μM
15
 
7-epi-clusianone (6) HIV C8166 human T 
lymphoblastoid cells 
EC50 = 2.0 μM
15
 
7-epi-clusianone (6) Chagas’ disease Trypanosoma cruzi LC50 = 260 μM
20
 
Hyperibone J (7) Cancer Breast and lung IC50 = 17.8 and >20 mM
21
 
Papuaforins A-E (8-12) Cervical cancer KB cell line IC50 = 4.9-13.0 mM 
Garcinol (13) Antibiotic Methicillin-resistant 
S. Aureus 
MIC = 3-12 μg/ml
22
 
Garcinol (13)  Topoisomerases I and II IC50 = 43 and 55 mM
23
 
Xanthochymol (14) Antibiotic Methicillin-resistant 
S. Aureus 
MIC = 6-25 μg/mL
22
 
Xanthochymol (14)  Topoisomerases I and II IC50 = 33 and 40 mM
23
 
Guttiferone F (15) HIV-1 HIV-1 EC50 23 μg/mL
24
 
Table 1.2.1 
 
As can be seen from the range of activities shown in the Table 1.2.1 above the 
PPAPs have demonstrated biological properties in many of the key areas of current 
pharmacological research.  By looking at the compounds that are effective against 
the various diseases it becomes obvious that both type A and type B PPAPs are 
potential drug candidates.  Even the more elaborate PPAPs show biological activity, 
suggesting that this class of compounds have a lot to offer in future drug 
development. 
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Figure 1.2.1 
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1.3 Review of Previous Synthetic Work Towards the 
Bicyclo[3.3.1]nonane Core 
Although the PPAP class of compounds have attracted much synthetic and biological 
attention, very few total syntheses have been completed due to the complexity of 
forming the bicyclo[3.3.1]nonane-trione core with the correct positioning of the 
substituents.  As a result, much of the synthetic work has been in constructing the 
bicyclo[3.3.1]nonane core of these molecules.  Among the notable achievements in 
this area are the works of Spessard and Stoltz,25 K. C. Nicolaou,26 G. A. Kraus,27-28 
R. Grossman,29 G. Mehta and M. K. Bera,30-31, 34  R. Takagai,32 and J.P. Sleeman.13  
In fact only clusianone (3), garsubellin A (1) and more recently nemorosone (4) have 
succumbed to synthesis (Sections 1.4 and 1.5).   
Early 2002 saw Spessard and Stoltz's diastereoselective synthesis of the 
bicyclo[3.3.1]nonane core (Scheme 1.3.1).25  Their work used a modified version of 
the Effenberger cyclisation as the key bicyclo[3.3.1]nonane forming reaction, a 
reaction which would become widely applied to synthetic approaches in this field.33  
Effenberger had shown that it was possible to form the bicyclo system 18 in good 
yields (84%) using an excess of enol ether 17 with malonyl dichloride (16) 
(Scheme 1.3.1).   
 
Scheme 1.3.1 
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For PPAP synthesis using an excess of valuable enol ether was not favourable, and 
therefore Spessard and Stoltz modified the procedure to use only one equivalent of 
enol ether 20 (Scheme 1.3.2).  However, the isolated yields of bicyclo[3.3.1]nonane 
core 21 were modest, at only 36%.  Fortunately, the ketone 19 was recovered 
alongside the bicyclo[3.3.1]nonane system 21, which provided 95% yield based on 
recovered ketone 19.  By recycling the recovered ketone 19 a yield of 55% of the 
bicyclo[3.3.1]nonane-trione 21 was achieved over two cycles.  Crucially the 
cyclisation had been completed diastereoselectively and only the anti-isomer at C-7 
was formed, which would become advantageous for syntheses completed later by 
other groups.  
 
Scheme 1.3.2 
 
Work by the Nicolaou group led to another approach to synthesising the 
bicyclo[3.3.1]nonane core.26  This was performed via annulation of a diketone 22 with 
an α,β-unsaturated aldehyde 23, followed by oxidation of the secondary alcohol 24. 
Treatment with KHMDS and PhSeBr followed by oxidation with m-CPBA and 
subsequent elimination gave enone 27 (Scheme 1.3.3).  
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Scheme 1.3.3 
 
George Kraus and his team have shown that it is possible to make the 
bicyclo[3.3.1]nonane core using a manganese mediated cyclisation (Scheme 1.3.4). 
27-28  Starting with keto ester 28 which underwent intramolecular cyclisation using 
manganese acetate and copper acetate the bicyclo[3.3.1]nonane 29 was formed.  
Treatment of intermediate 29 with NBS led to the dibromide intermediate 30 (Scheme 
1.3.4).  Further addition of NBS gave the tribromide 31 which was transformed into 
32 using aqueous acetic acid at 115 °C.  The sodium salt of allyl alcohol underwent 
1,4-addition followed by a Claisen rearrangement to provide C-3 allylated 
bicyclo[3.3.1]nonane core 33. 
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Scheme 1.3.4 
 
Grossman produced his intermediate 38 through the use of a three carbon 
α,α’-annulation of a sterically hindered cyclic β-keto ester 34 with alkynylation using 
tributylstannylated 3,3-diethoxypropyne.  This was followed by syn reduction with 
Co2(CO)8 and Et3SiH and an intramolecular aldol to give the bicyclo[3.3.1]nonane 38 
(Scheme 1.3.5).29 
 
Scheme 1.3.5 
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Mehta and Bera have explored two different approaches to the bicyclo[3.3.1]nonane 
core structure, initially using a palladium catalysed Kende cyclisation 
(Scheme 1.3.6).30-31,34 
 
Scheme 1.3.6 
 
In later work they have used a DIBAL-H mediated reduction of a ring fused lactone to 
generate a metallated lactol that can fragment and then undergo intramolecular aldol 
reaction, much as in the Nicolaou example (Scheme 1.3.7).  
 
Scheme 1.3.7 
 
Having performed a proof of concept in 2006, the Mehta group took their DIBAL-H 
reduction methodology and applied it to the syntheses of the bicyclo[3.3.1]nonane 
core of guttiferone A (43) and hypersampsone F (44) (Figure 1.3.1).34  They were 
able to selectively construct products with the correct stereochemistry at the C-7 and 
C-8 positions. 
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Figure 1.3.1 
 
The natural product targets both contain an endo C-7 prenyl group and an exo 
homoprenyl C-8 group.  Therefore, the Mehta group synthesised 1,3-diketone 52 with 
the correct substitution pattern that they could submit to their DIBAL-H 
rearrangement conditions (Scheme 1.3.8). 
Scheme 1.3.8 
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Readily available 1,3-diketone 45 was easily methylated to give the methyl enol ether 
46.  Further prenylation was performed using kinetic enolate conditions to give a 
diastereomeric mixture of enol ethers 47 and 48 which were separated and 
hydrolysed to their respective 1,3-diketones 49 and 50 using concentrated HCl.  
Initially only the 1,3-diketone 50 was further functionalised before being submitted to 
the DIBAL-H reduction conditions (Scheme 1.3.9). 
 
Scheme 1.3.9 
 
Successive DBU promoted alkylations were carried out in one pot using 
3-bromoethyl propionate and prenyl bromide to give the single diastereomer 51.  This 
pentalkylated diketone was hydrolysed using concentrated HCl to give the carboxylic 
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acid 52.  Lactonisation took place to form the enol lactone 53 which would be 
subjected to the rearrangement conditions the group had described in previous 
papers.  The rearrangement took place as shown previously in Scheme 1.3.7 in the 
presence of DIBAL-H and gave the desired bicyclo[3.3.1]nonane 54 with concurrent 
reduction of the ketone carbonyl.  PPC oxidation of the diol gave the 
bicyclo[3.3.1]nonane core structure 55 with the correct configurations at C-7 and C-8 
for the natural products guttiferone A (43) and hypersampsone F (44).  Attention then 
turned to the 1,3-diketone 49 and the bicyclo system it would form under these 
conditions (Scheme 1.3.10). 
 
Scheme 1.3.10 
 
By applying the same conditions as above to 1,3-diketone 49 it was possible to form 
the bicyclo[3.3.1]nonane system 56 in which both C-7 and C-8 were endo.  This 
stereochemical arrangement has yet to be encountered in the natural PPAPs. 
Takagi showed that a mixture of bicyclo[3.3.1]nonane core structures can be made 
through annulation of 2-cyclohexanone (57) with acrylate 58 by successive Michael 
reactions (Scheme 1.3.11).32 
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Scheme 1.3.11 
 
The Barriault group have published a gold catalysed method for producing 
bicyclo[3.3.1]nonane systems.35  They envisaged a gold catalysed 6-endo-dig 
cyclisation of a triple bond containing cyclic silyl enol ether 63.  The gold complex of 
the silyl enol ether is available to both 6-exo and 6-endo-dig cyclisations but by 
adjusting the conditions, it was possible to make the reaction 6-endo-dig selective 
(Scheme 1.3.12). 
 
Scheme 1.3.12 
 
By using this method, the Barriault group were able to access a range of different 
bicyclo[3.3.1]nonane systems, some with substituents applicable to natural product 
synthesis.  This route offered quick access to the bicyclo[3.3.1]nonane core but 
Chapter 1                                               Polycyclic Polyprenylated Acylphloroglucinols 
 
17 
 
needs further introduction of the oxygen functionalities before a complete PPAP will 
be realised. 
The Couladouros group in Greece have published a route to the type A PPAP 
bicyclo[3.3.1]nonane core using a C-alkylation, cation cyclisation method 
(Scheme 1.3.13).36  Starting from an acylphloroglucinol 65, a series of analogues of 
colupulone were formed by diprenylation of 65 and subsequent reaction with bromide 
67. 
 
Scheme 1.3.13 
 
The colupulone analogue 68 was selectively acylated before being subjected to 
conditions for the cation cyclisation.  The cation proved elusive under conditions of 
direct cation formation with the use of acids.  However, it was possible to make the 
methanesulphonic ester 70 which underwent unexpected and direct transformation to 
the bicyclo[3.3.1]nonane 71 (Scheme 1.3.14). 
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Scheme 1.3.14 
 
A by-product 72 resulting from O-cyclisation was also isolated but this route still 
offers a quick way of making PPAPs with all of the quaternary centres and oxygen 
functionalities. 
The Nakada group have studied a route to nemorosone (4) using an enantioselective 
intramolecular cyclopropanation.37  Starting with three different α-diazo-β-keto esters 
(74a-74c) with different substitution at R1, they aimed to select the route with the 
highest yields of the desired bicyclo[3.3.1]nonane system (76a-76c) (Scheme 
1.3.15). 
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Scheme 1.3.15 
 
By optimising the conditions for each of the reactions, they were able to access the 
bicyclo[3.3.1]nonane 76c system in good yields for the successive intramolecular 
cyclopropanation, dimethylation and ring opening (Scheme 1.3.16).  The 
bicyclo[3.3.1]nonane 76c was successfully converted into the iodide 77 via a 
hydrazone under Barton’s conditions.  This was converted into the carboxylic acid 78 
by reduction from the least hindered side with LiAlH4, removal of the TBDPS group, 
acetonide formation of the resultant diol, lithiation via halogen-metal exchange and 
trapping with CO2.  Birch reduction gave the mixture of diastereomeric acids 79 and 
80 which could be transformed into the alcohol 81. 
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Scheme 1.3.16 
 
The resulting alcohol 81 was converted to the triflate and coupled with divinylcuprate 
to give the triallylated compound 82.  Although discovering further transformations 
were limited, a further reaction was performed with NBS under conditions of allylic 
bromination to give a mixture of compounds 83 and 84 (Scheme 1.3.17). 
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Scheme 1.3.17 
 
Intermediate 83 has the correct stereogenic substitution for conversion to 
nemorosone (4), however the route is overly long and contains many low yielding 
steps.  
A final strategy that has been used for synthesis of analogues of the PPAP structure 
was developed by Sleeman, who performed various transformations directly on 
hyperforin (2) to make analogues.13  By using H2 (g) with a Pd/C catalyst they were 
able to hydrogenate the alkenes of the prenyl chains to make derivative 84 
(Scheme 1.3.18). 
 
Scheme 1.3.18 
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In another approach to derivatisation, hyperforin (2) was alkylated using 
bromoacetate.  In this way the C-alkylated 85 and the O-alkylated derivative 86 were 
synthesised.  The O-alkylated derivative 86 was then taken on for further 
transformations (Scheme 1.3.19). 
 
Scheme 1.3.19 
 
The ester 86 was cleaved using basic conditions to give the synthetic hyperforin 
derivative aristoforin (87), which was further transformed by hydrogenating the 
double bonds to give fully saturated 88 (Scheme 1.3.20).  The solubility and stability 
of the range of derivatives were then investigated as well as their activity as an anti 
cancer agent.  The group discovered that aristoforin (87) was more stable and 
soluble than hyperforin (2) but offered the same anti tumour properties.  
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Scheme 1.3.20 
 
1.4 Review of Total Syntheses 
Very few of the 119 known PPAPs have been synthesised, due to the inherent 
complexity of the bicyclo[3.3.1]nonane core and the difficulty of carrying bridgehead 
components through key cyclisations.  The appendage of C-1, C-3 and C-5 groups at 
a late stage of the synthesis, particularly at bridgehead positions, also poses a 
problem to the synthetic chemist.  Late 2005 saw the first syntheses of garsubellin A 
(1) published, independently performed by the groups of Shibasaki and 
Danishefsky.38-39  The Shibasaki group managed the first synthesis of garsubellin A 
(1) through a mechanism utilising ring closing metathesis as the key 
bicyclo[3.3.1]nonane forming cyclisation (Scheme 1.4.1).  Through a series of 
enolate reactions, protections, deprotections and aldol reactions the intermediate 90 
was constructed in 13 steps and 6% yield.  Ring closing metathesis was affected with 
Hoveyda-Grubbs catalyst to give the heavily functionalised bicyclo[3.3.1]nonane 
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system 91.  The resulting alkene was oxidised at the allylic position with (PhSe)2 and 
PhIO2.  Both protecting groups were removed and the alcohol and enone were 
condensed via an intramolecular Wacker oxidation.  Iodination at the vinylic position, 
dehydration of the tertiary alcohol and Stille coupling with prenyltributyltin gave 
racemic garsubellin A (1) in 21 steps and a 4% overall yield. 
 
Scheme 1.4.1 
 
Danishefsky’s approach used an iodocarbocyclisation in the key bicyclo[3.3.1]nonane 
forming reaction, from 93 to 94 (Scheme 1.4.2).  The iodocarbocyclisation was used 
by Danishefsky later in the clusianone (3) and nemorosone (4) syntheses and will be 
discussed later in Chapter 2.  With bicyclo[3.3.1]nonane 95 in hand an intriguing C-1 
bridgehead iodination was performed.  By using I2 as the electrophile and performing 
a TMS protection of the alcohol concurrently it was possible to substitute at the 
sterically hindered C-1 position.  Halogen-metal exchange was used to form the C-1 
isopropyl alcohol 97.  Although, Danishefsky chooses not to discuss this 
transformation in this publication it provides a manner in which to substitute the C-1 
position and would play a vital role in our nemorosone (4) synthesis (Chapters 2 
and 5).  Completion of the synthesis was performed using a DMP oxidation of the 
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isopropyl alcohol and a fluoride cleavage of the TMS ether to yield garsubellin A (1) 
in 15 steps and 1% overall yield. 
 
Scheme 1.4.2 
 
The first syntheses of clusianone (3) have been performed by our group (see 
Section 1.5), using an Effenberger cyclisation,40-41 as well as more recently, by the 
Marazano group in France using a similar pathway.42  Both syntheses started from 
cyclohexane-1,3-dione (98), which undergoes a series of deprotonations and 
electrophilic quenches to install the substituents around the cyclohexanone ring 
(Scheme 1.4.3).   
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Scheme 1.4.3 
 
The key bicyclo[3.3.1]nonane forming step in both these syntheses was the 
cyclisation step following the Effenberger reaction.  This is the reaction of an enol 
ether with malonyl dichloride as pioneered in PPAP synthesis by Spessard and Stoltz 
(Scheme 1.4.4). 25,33 
 
Scheme 1.4.4 
 
The syntheses differ in the extent of the substitution of the enol ether intermediate 
that enters the Effenberger reaction.  Our synthesis used an enol ether intermediate 
101 that was not fully substituted and a series of reactions at the bridgehead C-5 and 
vinylic C-3 position were employed to complete the synthesis in nine steps with a 
12% overall yield.  The Marazano group used a fully substituted intermediate 102 in 
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the Effenberger cyclisation which led to clusianone (3) as the product in 7 steps and 
a 14% overall yield (Figure 1.4.1) 
 
Figure 1.4.1 
 
An alternative route to clusianone (3) was demonstrated by Porco using an alkylative 
dearomatisation–annulation.43  The synthesis commenced with C-prenylation of 
acylphloroglucinol 103 with prenyl bromide under basic conditions to give 
clusiaphenone B (104) in modest yield (Scheme 1.4.5). 
 
Scheme 1.4.5 
 
To install an aldehyde that could be further functionalised to form the C-7 prenyl 
group and invoke the annulation, α-acetoxy enal was used with KHMDS 
(Scheme 1.4.6).  The methyl vinylogous ester 105 was synthesised so that the 
annulation product could be isolated and characterised.  The methyl vinylogous ester 
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was isolated as a mixture of diastereoisomers, both of which were progressed 
through the synthesis. 
 
Scheme 1.4.6 
 
With the bicyclo[3.3.1]nonane system synthesised in good yield it remained to 
convert the C-7 position into the desired prenyl group and hydrolyse the vinylogous 
ester.  Reaction of the aldehyde 105 with vinyl magnesium bromide gave the 
secondary alcohol that was converted to the acetate 106 (Scheme 1.4.7).  The 
acetate was removed with a palladium catalysed formate reduction which was 
followed by olefin cross-metathesis with Grubbs’ second generation catalyst which 
gave O-methylated clusianone (107). 
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Scheme 1.4.7 
 
Hydrolysis of the methyl vinylogous ester was performed using LiOH in dioxane and 
afforded clusianone (3) in good yield.  The complete synthesis gave clusianone (3) in 
eight steps and 11% overall yield and offers an alternative to the Effenberger 
annulation for PPAP synthesis. 
 
1.5 Previous Research by Our Group 
Our group have worked in the area of bridgehead functionalisation for some time.  
Our work with forming bicyclo[3.3.1]nonane bridgehead enolates and effectively 
quenching them with a variety of electrophiles opened up work on PPAPs as a target 
driven test of this chemistry.44  Bridgehead lithiation at this position should be 
forbidden due to Bredt’s rule, “the high strain of planar bridgehead carbons means 
that double bonds can rarely be formed at the bridgehead carbons in bicyclic 
systems” (Scheme 1.5.1).45 
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Scheme 1.5.1 
 
However, our group have previously shown that it is possible to deprotonate at the 
bridgehead and perform an electrophilic quench when there is a carbonyl 
functionality α- to the bridgehead.44,46  This allows the formation of a "bridgehead 
enolate", with the use of a lithium amide base to deprotonate and an external quench 
with the desired electrophile enables substitution of the bridgehead position 
(Scheme 1.5.2). 
 
Scheme 1.5.2 
 
Our group published our first paper of specific PPAP synthetic work in 2006 with the 
total synthesis of clusianone (3).40-41,47  Having observed the Spessard and Stoltz 
modification of the Effenberger annulations and its quick access to the core 
bicyclo[3.3.1]nonane, but also noting that it is limited further by addition of α or α’ 
substituents on the starting enol ether which left the need for bridgehead substitution.  
However, having already shown that it was possible to append various groups via 
bridgehead lithiation-substitution, accessing PPAPs by an Effenberger route would 
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be a suitable showcase for these ideas.  The idea of constructing unnatural 
derivatives or natural PPAPs from one core structure is an attractive one, as it opens 
the door to quick access to many compounds that could be used to probe SAR in the 
PPAP systems.  Synthesis of the core by Effenberger cyclisation allows for this.  With 
this in mind, suitable enol ethers 101 and 113 were synthesised from known methyl 
enol ether 99 in four steps (Scheme 1.5.3).   
 
Scheme 1.5.3 
 
Considering the substitution at the C-1 bridgehead as an extreme test of the 
bridgehead enolate methodology, an enol ether was formed with the prerequisite C-1 
prenyl group.  This allowed the C-1 bridgehead prenyl group to be carried through 
the formation of the bicyclo[3.3.1]nonane core.  With the bicyclo[3.3.1]nonane system 
formed using the modified Effenberger annulations, the C-5 bridgehead prenyl and 
the C-3 benzoyl group were installed using deprotonation chemistry (Scheme 1.5.4). 
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Scheme 1.5.4 
 
The Effenberger cyclisation gave low yields as expected with 24% of the 
O-methylated bicyclo[3.3.1]nonane 108 being isolated. However, if the recovered 
ketones 111 and 112 are included then the process is actually 60% efficient.  
Bridgehead alkylation proved to be a highly effective reaction, yielding 91% of the 
C-5 prenylated product 109.  The acylation of C-3 position was equally efficient under 
LiTMP deprotonation and benzoyl chloride quench.  The synthesis of racemic 
clusianone (3) achieved a 12% overall yield over nine steps, with spectroscopic data 
that matched the reported data of the natural material. 
Having established an effective route to clusianone (3), a kinetic resolution was 
employed to separate the enantiomers of a late stage intermediate 108.  These could 
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then be taken on to synthesise clusianone’s (3) enantiomers separately and therefore 
assign the absolute configuration of the natural material.41  It was noted that only 
three members of the PPAP family have had their absolute configurations 
experimentally determined.  Hyperforin (2) had been determined using X-ray 
crystallography on an enol ether derivative and it is this configuration in which PPAPs 
are most commonly presented.  The kinetic resolution was possible by using a bis 
lithium amide base for metalation and quenching with prenyl bromide.  This gave the 
prenylated product (-)-109 in 65% yield and 50% e.e., starting material was 
recovered as (+)-108 in 24-27% yield and in >98% e.e. (Scheme 1.5.5). 
 
Scheme 1.5.5 
 
With the enantiomerically enriched material it was possible to append a benzoyl 
bromide to the C-5 bridgehead using LDA and p-bromobenzyl bromide to give 
(-)-115. This was reduced using NaBH4 to give (+)-116 which was suitable for X-ray 
crystallography allowing the absolute configuration to be assigned (Scheme 1.5.6). 
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Scheme 1.5.6 
 
With the absolute configuration of (+)-116 assigned, it was possible to assign the 
absolute configurations of 115 and 108.  To establish the absolute configuration of 
clusianone (3), intermediate (+)-108 was converted into the natural product (Scheme 
1.5.7).  In this way it was possible to assign the absolute configuration of (+) isomer 
of clusianone (3). 
 
Scheme 1.5.7 
 
Chapter 1                                               Polycyclic Polyprenylated Acylphloroglucinols 
 
35 
 
Comparing the optical rotations shows that the (+) configuration is that of the 
clusianone (3) isolated from Clusia torresii.18  Data from another paper reports an 
extract from various sources was analysed as the O-alkylated derivative but showed 
(+) rotation, the opposite of which had been found in the Clusia torresii sample.  To 
establish that the data was correct, the (-) derivative 109 was converted to the 
O-methylated clusianone 107 and the NMR spectra matched.  By comparing the 
optical rotation of this and the deprotected compound, it was shown that the optical 
rotation is inverted between O-methylated derivative and the final compound.  This 
suggests that clusianone (3) can be isolated from natural sources as either 
enantiomer. 
Alongside the synthesis of clusianone (3) a formal synthesis of garsubellin A (1) was 
completed by the group.47  It was thought that the use of the Effenberger cyclisation 
would give rapid access to the tricyclic intermediate 128 of Danishefsky’s garsubellin 
A (1) synthesis.39  Starting with known enone 117, conversion to ketone 118 was 
possible by copper catalysed Michael addition of MeMgBr.  The ketone 118 was then 
effectively converted into the silyl enol ether 119 that would be used in the 
Effenberger cyclisation.  The Effenberger cyclisation was conducted under our 
standard conditions of malonyl dichloride at -20 °C for 24 h followed by basic workup 
to afford the bicyclo[3.3.1]nonane system that was immediately protected as the 
methyl enol ether 121 under acidic conditions (Scheme 1.5.8). 
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Scheme 1.5.8 
 
Bridgehead prenylation of 121 proved to be less efficient than the bridgehead 
prenylations of the clusianone (3) synthesis.  However, the difficulty in bridgehead 
substitution at the C-1 position and the relative sluggishness of C-3 prenylation when 
not in the presence of copper made it unlikely that competing reactions were taking 
place.  No products were isolated with substitution at either the C-1 or C-3 positions.  
Stereocontrol of the oxidation of the bridgehead prenyl group for the THF ring had 
not been possible in this system.  By using an epoxidation - epoxide opening strategy 
with a novel ring forming reaction using TMSCl, an efficient formation of a 1:1 mixture 
of diastereomers 123 and 124 was possible.  These were then converted to the silyl 
enol ethers 125 and 126 under standard conditions (Scheme 1.5.9). 
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Scheme 1.5.9 
 
The correct isomer 125 was subjected to lithiation and allylation using the higher 
order cuprate conditions that had been described before giving a protected form of 
Danishefsky’s intermediate 127.  Treatment with Et3N-HF provided an identical 
compound to that of Danishefsky (128) (Scheme 1.5.10). 
 
Scheme 1.5.10 
 
Though it was step efficient, the above route produced poor yields at key steps and 
lacked stereoselectivity in the side chain oxidation.  Therefore, an alternative route 
was devised.  Starting from the same enone 117, silyl enol ether 131 was prepared in 
a similar way to the previous enol ether 119.  Prenylation of enone 117 gave 129, 
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which was methylated using the copper catalysed Grignard reaction to give ketone 
130.  The ketone was efficiently converted to the silyl enol ether 131 and underwent 
cyclisation to the bicyclo[3.3.1]nonane 132 under the typical Effenberger conditions.  
Rather than purifying the unprotected 1,3-diketone at this stage, it was submitted to 
epoxidation with m-CPBA and led to the diastereomeric alcohols 123 and 124 but 
this time in a more favourable 2:1 ratio (Scheme 1.5.11). 
Scheme 1.5.11 
 
With this revised approach the modest bridgehead prenylation was avoided, as was 
methyl vinylogous ester formation.  The epoxidation step also had an increase in its 
selectivity.  Overall, this gave quite a step-efficient process, allowing rapid access to 
the advanced tricyclic structures 123 and 124.  
 
1.6 Nemorosone as a Target 
Nemorosone (4) is the most prevalent PPAP found in the Clusia rosea, and a 
regioisomer of clusianone (3), with the acyl group at the C-1 bridgehead as opposed 
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to the vinylic C-3 position.  The first isolation was performed by C.M.A de Oliveira et 
al. in 1996 and they assigned nemorosone (4) with a type C structure. However, this 
was later revised by Cuesta-Rubio to the accepted type A structure (see Chapter 2 
for more detail).6,48-49  Nemorosone (4) has already shown some interesting biological 
effects, displaying antiseptic properties that have been known about since the time of 
Aristotle.50  Studies into the antibacterial effects of nemorosone (4) and O-methylated 
nemorosone (149) have shown that the presence of the enone is important for the 
antibacterial effect, as is the prenylation pattern.51  Alongside the antimicrobial 
activity, nemorosone (4) has been shown to have some cytotoxic and antioxidant 
effects.  It showed 3.3-7.2 μM IC50 values against four cancer cell lines, also targeting 
DNA topoisomerase and telomerase.6  EC50 values of 0.8 μM have been found 
against HIV infection of C8166 human T lymphoblastoid cells.18  Alongside the 
activity against the HIV infection, nemorosone (4) was tested against uninfected cells 
to measure cytotoxicity, with a TC50 of 5.0 μM being measured.
  
As our group had already synthesised clusianone (3), nemorosone (4) was to be 
synthesised using a similar procedure.  Some preliminary studies had been 
performed by Dr. V. Rodeschini aiming to use the Effenberger cyclisation, 134 to 
133, for rapid access to the bicyclic core of nemorosone (4), followed by bridgehead 
enolate chemistry to substitute the C-5 position and more traditional deprotonation 
chemistry to substitute the C-3 (Scheme 1.6.1). 
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Scheme 1.6.1 
 
The silyl enol ethers 137 and 138 could be made from known enone 134 through 
conjugate addition of methyl cuprate, quenching with benzaldehyde and DMP 
oxidation of the resulting alcohol.  The silyl enol ethers 137 and 138 were formed 
using TBSCl under thermodynamic conditions and gave the nonconjugated enol 
silanes (Scheme 1.6.2).  This was due to the steric interaction of the benzoyl 
group and the geminal-dimethyl and would result in noncoplanar carbonyl 
functions. 
   
Scheme 1.6.2 
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Installation of the C-1 bridgehead acyl group would be a severe test of our 
bridgehead lithiation chemistry due in part to the steric hindrance of the geminal 
dimethyl group.  Therefore, it was hoped that the acyl group could be taken through 
the Effenberger cyclisation.  The inclusion of the benzoyl functionality before the 
cyclisation would be a complete change in the electronics of the starting ketone, but it 
was hoped that this change in electronics would promote the Effenberger annulation.  
However, when submitting the silyl enol ether 137 or 138 to the Effenberger 
conditions no reaction took place (Scheme 1.6.3).  
 
Scheme 1.6.3 
 
Therefore, a route with C-1 bridgehead enolate chemistry was devised.  Dr. 
Rodeschini synthesised a suitable silyl enol ether 142 for the cyclisation that would 
install the C-5 and C-7 prenyl groups (Scheme 1.6.4).  He also showed that C-3 
substitution was more favoured than C-1 substitution but trying to perform further 
bridgehead enolate substitutions would lead to alkene formation in the C-3 prenyl 
rather than C-1 substitution. 
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Scheme 1.6.4 
 
With a route to the bicyclo[3.3.1]nonane core of nemorosone (4) established by Dr. 
Rodeschini it was intended to perform C-1 bridgehead acylation and subsequent C-3 
prenylation to form O-methylated nemorosone (149).  For this to be selective it would 
be necessary to protect the C-3 position with TMS first.  After completing C-1 
benzoylation the C-3 TMS group could be removed by the use of TBAF.  C-3 
prenylation would give O-methylated nemorosone (149) which would then be 
hydrolysed to nemorosone (4) using similar conditions to those of the clusianone (3) 
synthesis (Scheme 1.6.5). 
Chapter 1                                               Polycyclic Polyprenylated Acylphloroglucinols 
 
43 
 
 
Scheme 1.6.5 
 
This would give nemorosone (4) in ten steps from known enone 134.  This synthesis 
would also allow for different substitution at the C-3 and C-5 positions which would 
enable a range of derivatives to be synthesised.  The results of this proposed 
synthesis can be found in Chapter 2 along with more information about nemorosone 
(4), its isolation, characterisation and biological activity. 
 
1.7 Nemorosone II as a Target 
Currently, there is no literature describing the synthesis of a type C PPAP or its 
bicyclo[3.3.1]nonane core.  Nemorosone (4), clusianone (3) and nemorosone II (150) 
are all regioisomers of each other and make up a set of type A, B and C PPAPs with 
the same components (Figure 1.7.1).  Nemorosone II (150) is a type C PPAP that 
was proposed as a possible structure for nemorosone (4) but was later rejected when 
the type A structure was confirmed by NMR experiments.  
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Figure 1.7.1 
 
As nemorosone II (150) is an unknown compound in nature, its synthesis would allow 
an insight into the structure-activity relationship of these compounds and may give an 
insight into why the type C structures are rarely isolated.   
To synthesise nemorosone II (150) should be relatively straightforward as the 
bicyclo[3.3.1]nonane core has a C-1 prenyl group like clusianone (3).  To complete 
the synthesis it is necessary to append the acyl group at C-5 bridgehead and 
prenylate the C-3 vinylic position (Scheme 1.7.1).  This could be achieved using 
similar conditions to the clusianone (3) synthesis. 
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Scheme 1.7.1 
 
Bridgehead enolate formation would be accessed using LDA, and a benzoyl chloride 
quench would give the correct benzoylation of the C-5 position.  LiTMP, followed by 
prenyl bromide, would give O-methylated nemorosone II (152).  The synthesis of 
nemorosone II (150) would be attempted alongside that of nemorosone (4), the 
results of which can be seen in Chapter 3.  Preliminary studies into the synthesis of 
nemorosone II (150) had all ready been performed in our group by Peter Crick. 
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Chapter 2 
Synthesis of Nemorosone 
 
With a successful synthesis of the natural compound clusianone (3) completed by 
our group, it seemed appropriate to challenge our methodology and approach the 
synthesis of nemorosone (4), a regioisomer of clusianone (3) (Figure 2.0.1).40  With 
an acyl group at the C-1 bridgehead position, adjacent to a geminal dimethyl group 
(C-8) and a bridgehead ketone (C-9) nemorosone (4) offered a significant challenge 
to our bridgehead enolate methodology. 
 
Figure 2.0.1 
 
2.1 Isolation and Characterisation 
Nemorosone (4) is a natural product that was isolated by C. M. A. de Oliveira et al. in 
1996, through the extraction of floral resins of Clusia rosea, grandiflora, insignis and 
nemorosa which are a family of trees found in tropical and subtropical regions.48  The 
resins were collected directly from the plants and extracted using diethyl ether or 
ethyl acetate and then treated with diazomethane to methylate the 1,3-diketone 
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which allowed for better separation on silica gel.  Both the known compound, 
clusianone (3), and the new structure of nemorosone (153) were reported.  
Somewhat surprisingly only one regioisomeric enol ether derivative was mentioned 
for each of these compounds.  In the case of nemorosone, the structure of the enol 
ether 154 was assigned as shown, with a benzoyl substituent at the C-5 position 
(Scheme 2.1.1).  It was noted by the author that the methyl enol ether derivatives 
were more stable to acidic conditions than the unprotected tetra ketones which were 
susceptible to polymerisation and decomposition.  
 
Scheme 2.1.1 O-methylated nemorosone configuration as described by C. M. A. de 
Oliveira in 1996. 
 
The evidence for the proposed structure came from nOe NMR experiments.  Thus 
irradiation of the methoxy group led to the observation of positive nOe at the allylic 
methylene at δ 3.25 and 3.34 (1.3%), vinyl at δ 5.00 (2.1%) and aromatic protons at δ 
7.62 (1.4%).  These combined with long range correlations, led the de Oliveira group 
to assign the configuration shown in Scheme 2.1.1.  In a subsequent paper in 1999, 
the same research group described further O-methylated derivatives from the same 
floral resins.  Evidence was provided for a compound called nemorosone II (155), 
based on the NMR data of the O-methylated derivative 156. This compound has the 
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bridgehead substituents exchanged with respect to the proposed structure of 
nemorosone (153), and so is a type A PPAP (Scheme 2.1.2). 
 
Scheme 2.1.2 O-methylated nemorosone II configuration as described by C. M. A. 
de Oliveira in 1996. 
 
Further study in 2001 led to revision of the perceived configuration of nemorosone (4) 
and nemorosone II (150).  Cuesta-Rubio et al. studied the constituents of the floral 
resin of Clusia rosea without previous treatment of the resin with diazomethane, 
therefore isolating nemorosone (4) as the tetra ketone rather than the methyl enol 
ether.  They discovered that nemorosone (4) exists as a pair of keto-enol tautomers 
in its natural state.54  In-depth NMR analysis showed that the structures of the 
keto-enol tautomers were not in accordance with the structure of the methylated 
derivative that de Oliveira et al. reported.  By performing nOe difference experiments, 
it was possible to determine the position of the benzoyl group and the vinylic prenyl 
group.  Saturation at the frequency of the geminal dimethyl (C-13) led to positive nOe 
at the aromatic protons (C-26a and C-26b) and methylene (C-14).  Further to this, 
saturation at the methylene proton frequency (C-19) saw positive nOe of the 
methylene at C-6 and methyl at C-25, unequivocally qualifying the structure of 
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nemorosone (4) with the benzoyl at C-1 and a prenyl in the C-5 position 
(Figure 2.1.1).  
 
Figure 2.1.1 
 
They proceeded to methylate using diazomethane to confirm whether the NMR 
spectrum of the methylated derivative would match that of de Oliveira (Scheme 
2.1.1).48-49  They found that both regioisomers could be isolated, in a 3:1 ratio 
favouring the compound 157 with the methoxy adjacent to the C-1 bridgehead acyl 
group.  From these results it appears that de Oliveira mis-assigned the position of the 
methoxy group (C-10) and therefore, the nOe experiments led them to believe the 
C-1 and C-5 groups were in the opposite regiochemical arrangement. 
 
Scheme 2.1.3 
Chapter 2  Synthesis of Nemorosone 
 
 50 
  
By comparison of the NMR spectra from the methylated products with that of de 
Oliveira it was possible to establish that nemorosone had the structure 4, a structure 
that fits the data of both groups.  Further to confirming the structure of nemorosone 
(4) Cuesta-Rubio compared the NMR data of the minor isomer from the methylation 
149 with that of de Oliveira’s “O-methylated nemorosone II” (156).  The data matched 
perfectly.  This established that nemorosone (4) has a type A PPAP structure and 
exists as two tautomers that correspond to two regioisomeric methyl enol ethers 157 
and 149, rather than the originally proposed type C structure 153.   
Helping to explain the lack of type C structures in nature is the proposed biogenetic 
pathway.  The pathway shows that cyclisation of grandone (158) by addition across 
the double bond of a prenyl group and further reaction with a phosphate can lead to 
either type A or type B PPAPs depending on direction of attack (Scheme 2.1.4). 
 
Scheme 2.1.4 Biogenetic pathway for nemorosone and clusianone formation. 
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It also demonstrates that type C structures are unable to be formed by this 
mechanism from grandone (158).  To form the type C structure the attacking prenyl 
group and the benzoyl group would have to be appended on the same carbon (on a 
grandone analogue 159) and then cyclise forming the geminal dimethyl adjacent to 
the C-1 prenyl (Scheme 2.1.5). 
 
Scheme 2.1.5 
 
Looking at the isolation papers of natural products an analogue of grandone with the 
acyl substituent and a prenyl group on the same carbon has yet to be discovered.  
This implies that the necessary precursor to the type C PPAPs is not available in 
nature and would explain the lack of type C PPAPs.  
In a follow up paper the de Oliveira group isolated more derivatives of nemorosone, 
which were referred to as “O-methylated 7-epi-nemorosone” (160) and “O-methylated 
nemorosone II” (156) and assigned them the structures shown in Figure 2.1.2.49  As 
mentioned above de Oliveira’s “O-methylated nemorosone II” (156) corresponds to 
the minor product of methylation of nemorosone (149), the structure proposed is 
correct, as confirmed by Cuesta-Rubio but the naming is not correct.54  Cuesta-Rubio 
also speculates that “O-methylated 7-epi-nemorosone (160) has also been mis-
assigned because of the confusion over the identity of nemorosone (4), it is most 
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likely that the true structure would fit Cuesta-Rubio’s assignment for nemorosone (4) 
(Figure 2.1.2) but with an epimeric prenyl substituent at the C-7 position. 
 
Figure 2.1.2 Nemorosone II and 7-epi-nemorosone as described by de Oliveira in 
1999. 
 
The second isolation of de Oliveira’s “nemorosone II” (155) took place in 2000 by 
Lokvam et al.  The change in assignment proposed by Cuesta-Rubio was yet to take 
place so the Lokvam group reported their data using the nemorosone II title rather 
than the corrected methyl enol ether of nemorosone (149).53  Their isolation was 
performed as the de Oliveira group had done, through extraction with ethyl acetate 
followed by extensive chromatography, with the NMR spectra matching that of minor 
methyl enol ether of nemorosone (149) as reported by de Oliveira and Cuesta-Rubio.   
Lokvam studied the antibacterial activity of their isolated “O-methylated nemorosone 
II” (156) (actually the methyl enol ether of nemorosone (4)) and as the tetra ketone 
against honeybee pathogens P. larvae and P. alvei.  The antibacterial effects were 
compared using a disc diffusion assay technique to those of chamone I (161) a 
structurally similar compound to nemorosone (4) but with further modification of the 
C-5 bridgehead prenyl substituent.51  The results showed that the methyl enol ethers 
of both nemorosone (4) and chamone I (161) had no antibacterial activity, however 
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by working with the natural tetra ketones it was shown that the prenylation pattern 
has a large effect on the antibacterial activity of these molecules, with nemorosone 
(4) proving much more active than chamone I (161) (Figure 2.1.3). 
 
Figure 2.1.3 
 
2.2 Natural Sources and Degradation Studies 
During the last decade interest in the PPAP family of compounds has risen 
considerably with new members frequently being isolated and many groups involved 
in the pursuit of synthetic routes to the bicyclo[3.3.1]nonane core.  This has led to a 
great deal of associated information about the characteristics and properties of these 
molecules.  For example, 2007 saw work by Cuesta-Rubio elucidating the content of 
PPAPs in propolis, a natural resinous substance produced by honey bees that has 
an antibacterial function in the bee’s nests.6,65  Interest in these substances has been 
generated by the use of propolis as a health drink which is thought to be effective 
against heart disease, diabetes and cancer.72  The proposed biological activity has 
spawned an interest in the chemical composition of these resins and their active 
ingredients.  HPLC study of propolis resins from Cuba has shown the major 
constituent in the resins are PPAPs and in particular nemorosone (4).  
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Having discovered the abundance of nemorosone (4) in propolis, Cuesta-Rubio was 
involved in a mass spectrometry study to determine the stability of nemorosone (4) 
and the nature of its degradation products.67  Previous studies of other PPAPs, and 
Danishefsky’s discovery that synthetic nemorosone (4) was unstable, suggested that 
PPAPs undergo further cyclisation and possibly polymerisation.62-63,66  Exposure to 
heat, light and air, as well as inorganic and organic acids, have been shown to 
produce oxidised derivatives.  Cuesta-Rubio’s previous studies had isolated the 
oxidised and cyclised products garcinielliptone I (162), hyperibone B (163), and 
propolones A-D (5 and 164-168) (Figure 2.2.1).60,73 
 
Figure 2.2.1 
 
Studies of the stability of nemorosone (4) were performed in n-hexane, chloroform, 
ethanol or methanol and as a solid at 40 °C.  HPLC-MS revealed that nemorosone 
(4) degraded to mainly garcinielliptone I (162) and hyperibone B (163) in less than 24 
Chapter 2  Synthesis of Nemorosone 
 
 55 
  
hours when dissolved in n-hexane.  Chloroform solutions mainly led to propolone D 
hydroperoxide (168) after 72 hours.  Ethanol solutions showed only 13% degradation 
after 60 days, and less than 1% degradation was observed in methanol.  No 
degradation of the solid sample was seen after 7 days.  From this study it is possible 
to say that many of the products that are structurally similar to nemorosone (4) are 
not in fact natural products but products of degradation during the extraction process. 
X-ray and quantum mechanical studies have also been performed by Pagano with 
the help of Cuesta-Rubio.64  Using X-ray crystallography they were able to confirm 
the molecular structure of nemorosone (4) matched that reported by Cuesta-Rubio.  
DFT calculations allowed insight into the chair boat equilibrium and showed that the 
chair conformation was 16 Kcal/mol more stable than the boat conformation 
(Figure 2.2.2). 
 
Figure 2.2.2 Chair conformation (a), boat conformation (b) of nemorosone (4) taken 
from B. Pagano et al., Chemical Physics Letters, 462, 2008, 158.64 
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2.3 Biological Activity of Nemorosone 
The Cuesta-Rubio group have studied propolis, its constituent parts and its biological 
activity.  As part of this work they studied the biological activity of nemorosone (4) 
and its methyl enol ether derivatives.69  This, coupled with the reports of bactericide 
activity of nemorosone (4) and chamone I (161) by Lokvam,53 led them to study the 
antioxidant and cytotoxic properties of nemorosone (4) and its methyl enol ethers 157 
and 149.6  They tested the compounds against four cancer cell lines, human cervix 
carcinoma (HeLa), human larynx carcinoma (HEp-2), prostate carcinoma (PC-3) and 
central nervous system carcinoma (U251).  The assays showed that nemorosone (4) 
was effective in the μM concentrations against each of these cell lines.  The methyl 
enol ether derivatives 157 and 149, however, were at least an order of magnitude 
less active and are therefore outside of what would be considered a biologically 
active IC50 value.  The antioxidant properties of the compounds were also tested by 
observing the scavenging effect of the compounds on the stable free radical of 1,1-
diphenyl-picryhydrazyl.  It was observed that nemorosone (4) had an IC50 of 44 μM 
for scavenging 1,1,-diphenyl-picryhydrazyl free radicals, where as the methyl enol 
ethers 157 and 149 showed no antioxidant activity. 
 
2.4 Results and Discussion 
To synthesise nemorosone (4) we envisaged a series of disconnections that 
employed bridgehead enolate chemistry to append the groups in the C-1 and C-5 
positions.  Formation of the bicyclo[3.3.1]nonane core 143 would be performed by 
the Effenberger cyclisation, as our group had already successfully used the 
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Effenberger cyclisation to synthesise clusianone (3).33,40  This led to the following 
retrosynthesis which would allow the application of our bridgehead enolate chemistry 
(Scheme 2.4.1). 
 
Scheme 2.4.1 
 
Our group had previously established that it was impossible to perform the 
Effenberger cyclisation and obtain a bicyclo[3.3.1]nonane 139 with an acyl group at 
the C-1 bridgehead position.  These conditions led to only starting material being 
recovered (Scheme 2.4.2).40  With this in mind we planned to install the acyl group 
after the cyclisation had been completed, using a bridgehead enolate.  Therefore, the 
acyl group would have to be installed at a bridgehead (C-1) adjacent to a geminal 
dimethyl group which would be an extreme test of bridgehead enolate methodology.   
 
Scheme 2.4.2 
 
Chapter 2  Synthesis of Nemorosone 
 
 58 
  
With these limitations in mind, synthesis of the required silyl enol ether 142 was 
embarked upon.  Starting with 3-ethoxy cyclohexenone (169), prenylation was 
achieved by enolate formation with lithium diisopropylamide (LDA) followed by 
electrophilic quenching with prenyl bromide (Scheme 2.4.3).  Addition of methyl 
lithium to this reaction mixture with a hydrochloric acid work up afforded enone 
product 89. Further deprotonation with LDA led to selective lithium enolate formation 
and an electrophilic quench using prenyl bromide gave diprenylated enone 140 as a 
9:1 diasteromeric mixture.   
 
Scheme 2.4.3 
 
Installation of the second methyl of the geminal dimethyl group was affected through 
copper mediated 1,4-Grignard addition (Scheme 2.4.4).   
 
Scheme 2.4.4 
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To perform the Effenberger annulation it would be necessary to form either a silyl or 
methyl enol ether of ketone 141.  Both can be formed and are effective in the 
subsequent reaction but the silyl enol ether forming reaction proved to be robust and 
high yielding.  Silyl enol ether 142 was accessed quickly under these thermodynamic 
conditions in near quantitative yield (Scheme 2.4.5).   
 
Scheme 2.4.5 
 
With silyl enol ether 142 in hand the Effenberger cyclisation was undertaken.  This 
cyclisation enables a rapid increase in molecular complexity which makes it an 
attractive route to the bicyclo[3.31]nonane system.  However, the yields are modest 
at best.  Ketone 141 was recovered as a side product of the reaction in 83% yield 
and this helps to ease the burden of the inefficiency of the step as it can be easily 
recycled (Scheme 2.4.6).   
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Scheme 2.4.6 
 
The triketone 143 product of the Effenberger reaction was unstable and highly polar 
which made its isolation difficult and therefore the triketone was protected as methyl 
enol ethers 144 and 145.  Initial attempts to form the methyl enol ether 145 under 
acidic conditions failed, recovering mainly decomposition products and very small 
quantities of the desired bicyclo[3.3.1]nonane 145 (Scheme 2.4.7). 
 
Scheme 2.4.7 
 
Basic conditions were therefore employed to methylate the enol 143, giving a 6:1 
mixture of regioisomers 144 and 145 favouring 144 the enol ether with methylation at 
C-2 (Scheme 2.4.8).   
Chapter 2  Synthesis of Nemorosone 
 
 61 
  
 
Scheme 2.4.8 
 
At this stage the two regioisomers 144 and 145 were separated by column 
chromatography and the major isomer taken on in the synthesis.  X-ray 
crystallography had been performed upon the major isomer (144) by us, which had 
confirmed the regio- and stereochemistry of this compound.40  1H NMR analysis of 
the methyl enol ether 144 shows characteristic signals for the protons at the C-1 
bridgehead and the C-3 vinyl position (Figure 2.4.1).  These signals could be used 
throughout the rest of the synthesis to confirm that transformations at these positions 
had been successful. 
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Figure 2.4.1 1H NMR of 144 (500 MHz, CDCl3) 
 
Further progress required installation of the bridgehead acyl group (C-1) and the 
vinylic prenyl group (C-5).  During some earlier preliminary studies in the group we 
discovered that the C-3 prenyl group would undergo deprotonation to form the 
conjugated diene 171 on treatment with reagents intended to iodinate the C-1 
bridgehead (Scheme 2.4.9).47  
 
Scheme 2.4.9 
Chapter 2  Synthesis of Nemorosone 
 
 63 
  
Therefore the acyl substituent at the C-1 bridgehead would have to be installed first 
using the previously established bridgehead enolate chemistry and the prenyl group 
at C-3 installed afterwards.  Previous attempts in the group to directly acylate at the 
C-1 bridgehead were unsuccessful as the C-3 vinylic position was acylated and no 
C-1 acylation was observed (Scheme 2.4.10). 
 
Scheme 2.4.10 
 
Based on the previous studies we had to selectively acylate at the bridgehead, 
therefore protection of the C-3 position had to be performed.  Deprotonation with 
LiTMP followed by electrophilic quench with TMSCl gave vinylsilane 173 in excellent 
yield (Scheme 2.4.11). 
 
Scheme 2.4.11 
 
The 1H NMR spectra for the silyl protected compound showed the C-3 proton signal 
at δ 5.71 had been replaced by a singlet at δ 0.16 corresponding to nine protons.  
This confirmed quickly that installation of the vinylic TMS group had been successful 
(Figure 2.4.2). 
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Figure 2.4.2 1H NMR of 173 (500 MHz, CDCl3) 
 
Initial attempts to acylate the bridgehead enolate under standard conditions of LDA at 
-78 °C in tetrahydrofuran with a benzoyl chloride quench proved unsuccessful, giving 
nothing but unreacted starting material.  Different bases (LDA, LiTMP, and NaOMe) 
and additives (LiCl, HMPA) were tried to activate the C-1 position towards acylation.  
Unfortunately, we were unable to install the necessary benzoyl group directly at the 
C-1 position (Scheme 2.4.12).   
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Scheme 2.4.12 
 
Having been unsuccessful in direct bridgehead acylation, we planned instead to 
install the C-1 benzoyl group using benzaldehyde as electrophilic quench for the 
bridgehead enolate, followed by oxidation of the so-formed secondary alcohol 
(Scheme 2.4.13).  Once more the C-1 position was not substituted, with only 
unreacted starting material being recovered.  
 
Scheme 2.4.13 
 
Having discovered the apparent lack of reactivity at the C-1 bridgehead a deeper 
study was conducted into the reactivity of this position the results of which are 
presented in Chapter 5.  Danishefsky had shown in his synthesis of garsubellin A (1) 
that it was possible to form a bridgehead iodide 96 in a similar system to ours 
(Scheme 2.4.14).39  
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Scheme 2.4.14 
 
This transformation used the somewhat odd reaction of chlorotrimethylsilane addition 
to the lithium enolate forming conditions followed by warming to 0 °C, for half an hour 
before cooling to -78 °C and adding I2.  By applying these conditions to our system, 
iodination of the C-1 bridgehead of 173 was achieved in reasonable yield 
(Scheme 2.4.15). 
 
Scheme 2.4.15 
 
Once more drawing attention to the 1H NMR spectra allows clarification that 
iodination was possible at the C-1 position, as the signal for the bridgehead proton is 
no longer visible (Figure 2.4.3).  The 1H NMR spectra is not definitive about the 
iodine incorporation however the mass spectrometry shows a m/z of 543.18 which 
corresponds to the [M + H]+ ion of the iodide 176. 
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Figure 2.4.3 1H NMR of 176 (500 MHz, CDCl3) 
 
To our surprise, the Danishefsky conditions appeared uniquely suitable for the 
preparation of the bridgehead iodide, and none of the lower temperature protocols, 
employed with great success by our research group in the past, gave any sign of the 
desired product.  Attempts to form the bridgehead iodide 176 with the omission of 
TMSCl from the reaction mixture were unsuccessful with only unreacted starting 
material (173) being obtained.  It was unclear at this stage what role the TMSCl 
played in the reaction so, further investigation was performed and is discussed in 
Chapter 5.   
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In his synthesis of garsubellin A (1) Danishefsky used iPrMgBr with LiCl to effect 
iodine-magnesium exchange on the bridgehead iodide 96, quenching with 
benzaldehyde.39  Oxidation of the resulting alcohol 97 gave the C-1 benzoylated 
product 177 (Scheme 2.4.16).   
 
Scheme 2.4.16 
 
However, these conditions were unsuccessful when applied to our nemorosone (4) 
system.  To our satisfaction, we found that direct bridgehead benzoylation could be 
performed by a more conventional iodine–lithium exchange, using nBuLi in THF, 
followed by addition of benzoyl chloride (Scheme 2.4.17). 
 
Scheme 2.4.17 
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With the C-1 bridgehead acylation completed, attention turned to prenylation of the 
C-3 position.  This required desilylation, to deprotect the vinylic position followed by 
prenylation.  Deprotection of the vinylic position proved trivial using 
tetrabutylammonium fluoride to give 178 (Scheme 2.4.18).  
 
Scheme 2.4.18 
 
Proton NMR spectra once more gives clear information proving the transformation 
has been successful as the C-3 proton returns at its characteristic δ 5.80 shift 
(Figure 2.4.4). 
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Figure 2.4.4 1H NMR of 178 (500 MHz, CDCl3) 
 
Deprotonation and an electrophilic quench with prenyl bromide were employed to 
complete the architecture of nemorosone (4).  A mixed order cuprate was employed 
for this addition, using conditions that had been developed previously within our 
research group (Scheme 2.4.19).40,47 
 
Scheme 2.4.19 
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The prenylation afforded O-methylated nemorosone (157) in 75% yield.  In this form 
nemorosone was stable and easy to manipulate.  At this stage it was compared with 
the data from natural sources and from the Danishefsky publication.  Below are our 
1H and 13C NMR spectra, with the proton spectra showing the corresponding 
compound numbering (Figure 2.4.5 and Figure 2.4.6). 
 
 
Figure 2.4.5 1H NMR of 157 (500 MHz, CDCl3) 
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Figure 2.4.6 13C NMR of 157 (125 MHz, CDCl3) 
 
To compare the data with the original isolation paper the Tables 2.4.1 and 2.4.2 have 
been made for direct easy comparison of the NMR data.  As can be seen the data 
match closely except for the assignment of the benzoyl (C-23) and the enone (C-4) 
carbonyls in the 13C NMR which have been interchanged.  Also the fully substituted 
carbons (C-20 and C-30) of the double bond in the vinylic (C-3) and bridgehead (C-5) 
prenyls were originally mis-assigned.  The assignments were clear from the HMBC 
and HMQC experiments that were performed on our sample and which are shown in 
appendix 11 and 12.   
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Carbon 
number 
de Oliveira’s 
O-methylated 
nemorosone 
(154) 
Our O-
methylated 
nemorosone 
(157) 
1 74.4 74 
2 169.9 169.9 
3 123.2 123.2 
4 193.1 197.1 
5 65.1 65.1 
6 43.1 43.1 
7 42.5 42.5 
8 47.8 47.8 
9 207.9 207.9 
10 61.6 61.5 
11 24.4 24.4 
12 16.1 16.2 
13 27.6 27.7 
14 122.5 122.5 
15 133.2 133.2 
16 26 26 
17 17.8 17.8 
18 29.5 29.5 
19 119.6 119.7 
20 133 134.4 
21 25.6 25.6 
22 18.1 18.1 
23 197.1 193.1 
24 137 137 
25 128.4 128.4 
26 127.9 127.9 
27 132.1 132 
28 23.2 23.2 
29 121.5 121.5 
30 134.4 133 
31 25.8 25.8 
32 18 18 
Table 2.4.1 
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The proton NMR spectra of our O-methylated nemorosone (157) and de Oliveira’s 
match very well.  Unfortunately, Danishefsky worked with a different regioisomer of 
O-methylated nemorosone (149) to our synthesis and the original isolations and it is 
therefore not easy to compare the data of each group. 
 
Carbon 
number 
de Oliveira’s O-methylated 
nemorosone (154) 
Our O-methylated 
nemorosone (157) 
6 
1.94 (1H, dd, J = 12.6, 3.4) 
1.42 (1H, t, J = 12.6) 
1.95 (1H, dd, J = 13.0, 3.9) 
1.45 (1H, t, J = 12.8) 
7 1.66 (1H, overlap) 1.72 -1.64 (1H, m) 
10  3.45 (3H, s) 3.46 (3H, s) 
11 1.34 (3H, s) 1.35 (3H, s) 
12 1.19 (3H, s) 1.19 (3H, s) 
13 
2.10 (1H, m) 1.66 (1H, 
overlap) 
2.14 - 2.08 (1H, m) 1.72 -1.64 
(1H, m) 
14 4.97 (1H, m) 4.95 - 4.90 (1H, m) 
16 1.66 (3H, s) 1.68 (3H, s) 
17 1.55 (3H, s) 1.56 (3H, s) 
18 
2.56 (1H, dd, J = 13.7, 7) 
2.50 (1H, dd, J = 13.7, 7.1) 
2.58 (1H, dd, J = 13.9, 6.6) 
2.48 (1H, dd, J = 13.9, 7.3) 
19 5.00 (1H, m) 5.02 (1H, t, J = 6.5) 
21 1.66 (3H, s) 1.68 (3H, s) 
22 1.66 (3H, s) 1.68 (3H, s) 
25 7.62 (1H, dd, J = 8, 1) 7.62 (2H, d, J = 7.3) 
26 7.32 (1H, t, J = 8) 7.30 (2H, t, J = 7.9) 
27 7.44 (1H, tt, J = 8, 1) 7.44 (1H, t, J = 7.3) 
28 
3.34 (1H, dd, J = 16, 6.8) 
3.25 (1H, dd, J = 16, 6.8) 
3.34 (1H, dd, J = 15.8, 6.6) 
3.23 (1H, dd, J = 15.8, 6.2) 
29 5.00 (1H, m) 5.01 (1H, t, J = 6.5) 
31 1.66 (3H, s) 1.68 (3H, s) 
32 1.66 (3H, s) 1.69 (3H, s) 
Table 2.4.2 
 
With the methyl enol ether of nemorosone 157 in hand all that remained was to 
deprotect the enol and obtain the tetra ketone.  A modification of the Krapcho type 
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conditions was employed for this transformation.58  Heating the methyl protected 
compound 157 to 120 °C in d6-DMSO with LiCl for 4 hours gave quantitative yields of 
nemorosone (4) without the need for extraction and purification by column 
chromatography (Scheme 2.4.20).  Isolation of the free compound proved non-trivial, 
since, as noted by other research groups nemorosone (4) is unstable to light and 
particularly acids.48,66  This meant that NMR spectroscopy using CDCl3 would 
decompose the compound.  Also 1H NMR spectra in CDCl3 show two separate 
tautomers, making NMR hard to interpret.  However, by recording the NMR spectra in 
d6-DMSO both of these problems were alleviated and clear NMR of only a single 
tautomer could be achieved straight from the reaction without the need for column 
chromatography purification. 
 
Scheme 2.4.20 
 
However some of the signals were obscured by the d6-DMSO in the 
1H NMR spectra.  
To obtain full characterisation nemorosone (4) was extracted from the crude reaction 
mixture and the NMR performed in d4-MeOD which gave unobscured spectra 
showing only one tautomer.  With our synthetic nemorosone (4) in hand we obtained 
a sample of natural nemorosone (4) from Frank Holtrup at The German Cancer 
Research Centre.  This enabled us to perform NMR experiments in d4-MeOD on 
Chapter 2  Synthesis of Nemorosone 
 
 76 
  
natural nemorosone (4) and compare them to our synthetic sample (Figure 2.4.7 and 
Figure 2.4.8).  
 
Figure 2.4.7 Comparison of 1H NMR of natural and synthetic nemorosone (4) (500 
MHz, MeOD) 
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Figure 2.4.8 Comparison of 13C NMR of natural and synthetic nemorosone (4) (125 
MHz, MeOD) 
 
The NMR spectra of natural nemorosone (4) and our synthetic sample match well, 
confirming that we have synthesised the type A PPAP nemorosone (4).  Nemorosone 
(4) had been synthesised in 13 steps and 6% overall yield (one step less and 5.5% 
improvement over Danishefsky) and was submitted for biological testing (Chapter 4).   
 
2.5 Danishefsky’s Synthesis 
Late 2007 saw the first published synthesis of nemorosone (4) by the Danishefsky 
group, building on from their earlier synthesis of garsubellin A (1) (Figure 2.5.1).39,66  
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The Danishefsky synthesis appeared after ours had been completed in the laboratory 
but had not been published.  Although conducted completely independently the two 
syntheses have some common features, particularly in the use of reactive 
bridgehead carbanions to install the crucial C-1 carbonyl function.     
 
Figure 2.5.1 
 
Danishefsky’s route was devised to make different PPAPs from the same core 
bicyclic system and had already been used to successfully synthesise garsubellin A 
(1) and clusianone (3). Starting from commercially available 3,5-dimethoxy phenol 
(179), diallylation was performed using allylpalladium chemistry to give 180.  Twofold 
cross metathesis led to the diprenylated derivative 181, and subsequent 
mono-demethylation was achieved using lithium iodide in 2,4,6-sym-collidine, to give 
diketone 182 (Scheme 2.5.1).   
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Scheme 2.5.1 
 
Cyclisation to the bicyclo[3.3.1]nonane 183 was performed using an iodonium 
induced carbocyclisation.  Although the overall yield for these first five steps is poor, 
accessing the bicyclo[3.3.1]nonane core in so few steps is a notable achievement.  
However, it would appear that Danishefsky (although he chooses not to comment) 
was unable to perform any selective chemistry upon this system and resorted to 
reductive elimination which gave the bridgehead fused cyclopropane 184. 
Nucleophilic ring opening of cyclopropane 184 with TMSI gave the iodinated product 
185.  Allylation was performed using a protocol inspired by Keck and Yates.57  This 
gave intermediate 122 which can be used to make both nemorosone (4) and 
clusianone (3).  Advancing the nemorosone (4) synthesis required the installation of 
the bridgehead acyl group (C-1) and the vinylic prenyl group (C-3).  Silylation of the 
vinylic position (C-3) was performed in one pot along with iodination of the 
bridgehead position (C-1) (Scheme 2.5.2).   
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Scheme 2.5.2 
 
For the key bridgehead iodination, deuterium incorporation studies were performed 
upon 122 to determine whether C-1 and C-3 could be differentiated during 
deprotonation and electrophilic quenching reactions.  The results of this study fit with 
those previously reported by ourselves.47  It was discovered that with one equivalent 
of LDA and a d4-MeOD quench that both positions were deuterated in 30% yield.  
Use of excess base yielded 70% of the monodeuterated products, which led to the 
conclusion that C-1 and C-3 could be lithiated in approximately equal amounts.  
Therefore, differential quenching reactions were exploited to distinguish the two 
positions.  The use of an in situ quench with TMSCl gave 74% of the C-3 silylated 
product.  Functionalisation of C-1 was attempted with LDA and an I2 quench but gave 
a low yield.  However, repeating the reaction with TMSCl in situ gave a 45% yield of 
the desired product.  Danishefsky then attempted to perform the silylation and 
iodination in one pot relying on the differential in quenching to afford a single product 
and was successful in 51% yield. 
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With the C-1 position now iodinated, installation of the benzoyl group at C-1 could be 
investigated.  The TMS group at the C-3 position would act as protecting group so 
that halogen metal exchange could be performed upon the C-1 position.  Installation 
of the acyl group was executed using iso-propyl magnesium chloride followed by 
addition of benzaldehyde which gave the secondary alcohol at the C-1 position and 
subsequent oxidation of this using Dess-Martin periodinane gave the ketone 188 
(Scheme 2.5.3).   
 
Scheme 2.5.3 
 
Desilylation of the C-3 position was performed successfully, using TBAF to give 
triketone 189.  Allylation of the vinylic (C-3) position was performed using LDA 
followed by addition of a mixed order cuprate and quenching with allyl bromide as we 
had demonstrated in our clusianone (3) synthesis.47  The allyl groups at C-5 and C-7 
were converted to the desired prenyl group by cross metathesis using Grubbs’ 
second generation catalyst to give O-methylated nemorosone (149) (Scheme 2.5.4). 
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Scheme 2.5.4 
 
Demethylation to give nemorosone (4) was performed upon O-methylated 
nemorosone (149) by hydrolysis with lithium iodide in 2,4,6-collidine.  When trying to 
characterise the tetra ketone it was discovered that nemorosone (4) is particularly 
unstable to chloroform used in NMR analysis.  This 14 step synthesis gave 
Danishefsky nemorosone (4) in 0.6% overall yield. 
 
2.6 Conclusion 
The natural product nemorosone (4) has been synthesised in 13 steps and a 6% 
overall yield. This was possible through a series of bridgehead functional group 
interconversions and enolate chemistry.  The data for the synthesised material 
matched that of the natural isolation data and Danishefsky’s synthetic sample. 
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Chapter 3 
Synthesis of Nemorosone II 
 
With the synthesis of clusianone (3) and nemorosone (4) successfully completed, we 
decided to synthesise nemorosone II (150), the unknown third regioisomer of this 
series of compounds.  It was hoped that a study of the three regioisomers would give 
some insight into the structure-activity relationship of this class of compounds.  
Nemorosone II (150) is the name we have assigned to the regioisomer that has the 
benzoyl group at the C-5 position and a prenyl at the C-1, which is the reverse of 
nemorosone (4) (Figure 3.0.1).  Although some reports of nemorosone II (150) exist 
in the literature, it is believed that they are mis-assignments caused by the confusion 
in the initial nemorosone (4) isolation and characterisation.48  The work described 
within this chapter aims to clarify these mis-assignments of nemorosone (4) and 
constitutes the first synthesis of a type C PPAP. 
 
Figure 3.0.1 
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3.1 Reported Isolation 
The first claim was made of the isolation of “O-methylated nemorosone II” (156) by 
de Oliveira et al. in a follow-up paper to their isolation of “O-methylated nemorosone” 
(154) (Figure 3.1.1).49  Using the same procedure as before (collection of the resin by 
scraping it off the flowers with a glass rod and dissolving it in diethyl ether or ethyl 
acetate, followed by treatment with diazomethane to make the methyl enol ethers), 
de Oliveira isolated a methyl enol ether protected PPAP that had the same mass as 
“O-methylated nemorosone” (154) but different NMR spectra. Analysis of the NMR 
spectra led de Oliveira to assign the structure as a type A PPAP, complementary to 
nemorosone (4) which was believed to have a type C structure at this point.   
 
Figure 3.1.1 de Oliveira’s assignment of “O-methylated nemorosone” (154) and 
“O-methylated nemorosone II” (156) 
 
However, it was later shown by Cuesta-Rubio, using more in-depth NMR 
experimentation, that the assignment of “O-methylated nemorosone” (154) was 
incorrect and nemorosone (4) really had the type A structure.73  This obviously left a 
question over the true structure of “nemorosone II” (155).  In their isolation the 
Cuesta-Rubio group had isolated two methyl enol ether regioisomers of nemorosone 
149 and 157, with the spectra of one already being shown to correspond to de 
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Oliveira’s “O-methylated nemorosone” (154).  By comparison of the NMR spectra for 
the other regioisomer of O-methylated nemorosone (149) to that of de Oliveira’s 
“O-methylated nemorosone II” (156), Cuesta-Rubio showed that they were in fact the 
same compound (Figure 3.1.2).  The result of this was that nemorosone II (150) as 
the type C regioisomer (with C-1 prenyl group and C-5 benzoyl group) of 
nemorosone (4) had not in fact been isolated at all.  
 
Figure 3.1.2 
 
Lokvam et al. studied what they believed to be nemorosone II (150) in 2000 and 
observed the biological effects on bacteria.51  Unfortunately, this compound was 
clarified by Cuesta-Rubio as the minor methyl enol ether derivative of nemorosone 
(149) during the nemorosone (4) re-assignment.   
Also around the time of the reassignment of nemorosone (4) to the type A structure, 
Henry et al. isolated a pair of tautomers which were regioisomeric with nemorosone 
(4).55  The tautomeric pair were named plukenetione D and E (191 and 192), isolated 
as the acetates and assigned a type A structure although the stereochemistry at C-7 
was left undefined (Figure 3.1.3). 
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Figure 3.1.3 
 
It would appear that Henry isolated the acetates of the tautomers of 7-epi-
nemorosone (195 and 196) and assigned them to a new compound as de Oliveira 
had not yet published the nemorosone II (150) assignment and Cuesta-Rubio had 
not highlighted the mistaken identity of these compounds.   
In 2000, Grossman and Jacobs tried to clarify the identity of plukenetione D and E 
(191 and 192) with regards to nemorosone (4) and nemorosone II (150).52  In this 
paper they attempted to compare the NMR spectra for the methyl enol ethers of 
nemorosone (149 and 157) and one of 7-epi-nemorosone (160) with the acetates of 
plukenetione D and E (191 and 192).  As direct comparison could not be carried out, 
characteristic signals in the NMR spectra were compared, in particular the Δδ of the 
ring CH2 (
1H) and geminal methyls (13C) and the C-7 (13C) shifts of O-methylated 
nemorosone (149 and 157), and one methyl enol ether of 7-epi-nemorosone (160) 
(Figure 3.1.4). 
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Figure 3.1.4 
 
Through these comparisons they concluded that plukenetione D and E (191 and 192) 
related to O-methylated 7-epi-nemorosone (194).  Since the structure of nemorosone 
(4) and O-methylated 7-epi-nemorosone (160) have been corrected Grossman’s 
assignment of plukenetione D and E actually shows that plukenetione D and E are 
the tautomers of 7-epi-nemorosone (195 and 196) (Figure 3.1.5). 
 
Figure 3.1.5 
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After thorough analysis of the literature it would appear that no type C regioisomer of 
nemorosone (4) has yet been isolated from natural sources.  Therefore, the 
challenge of making a novel unknown type C PPAP was undertaken.  
 
3.2 Retrosynthesis 
Much of the ground work for this synthesis was already in place from our synthesis of 
clusianone (3).40  During the synthesis of clusianone (3) the 
bicyclo[3.3.1]nonane-trione core was formed by the Stoltz modification of the 
Effenberger cyclisation, giving the bicyclo[3.3.1]nonane system 114 with a prenyl 
group appended to the C-1 position (Chapter 1.5).25,33  Acylation of the C-5 position 
could be envisaged by direct deprotonation of the bridgehead and an electrophilic 
quench using benzoyl chloride.  The final C-3 prenyl group would be added using a 
cuprate mediated deprotonation and reaction of the anion with prenyl bromide 
(Scheme 3.2.1).   
 
Scheme 3.2.1 
 
3.3 Synthesis of Nemorosone II 
Using chemistry described previously during the synthesis of clusianone (3) the 
bicyclo[3.3.1]nonane-trione core was built up.40  Starting with 1,3-cyclohexanone 
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(98), prenylation was affected by copper catalysed deprotonation and enolate 
formation.  The enolate underwent an electrophilic quench with prenyl bromide, to 
give the desired product 3-hydroxy-2-(3-methyl-but-2-enyl)-cyclohex-2-enone (197) in 
a disappointing 18% yield (Scheme 3.3.1). 
 
Scheme 3.3.1 
 
Prenylated enone 197 was protected as the methyl enol ether 99.  This was formed 
by refluxing the substrate in acetone with dimethyl sulphate and potassium carbonate 
to give a 61% conversion to the desired product 
3-methoxy-2-(3-methyl-but-2-enyl)-cyclohex-2-enone (99) (Scheme 3.3.2).  The yield 
for these reactions was low compared to those performed by Dr. Rodeschini but 
produced enough material for them not to need repeating. 
 
Scheme 3.3.2 
 
Selective prenylation of the C-4 position was carried out by enolate formation and 
quenching the anion by addition of prenyl bromide.  This gave a diprenylated product 
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100 which was sufficiently pure for use in subsequent reactions without further 
purification (Scheme 3.3.3). 
 
Scheme 3.3.3 
 
Methyl vinylogous ester 100 with prenyl substituents at C-2 and C-4 (that would 
become the C-1 and C-7 prenyl groups in nemorosone II (150)) possessed almost all 
the functionality required prior to the Effenberger cyclisation.  The only further 
elaboration required was the installation of the methyl groups that would become the 
C-8 geminal dimethyls in the bicyclo[3.3.1]nonane system.  Treatment of the crude 
methyl vinylogous ester 100 with MeLi followed by an HCl workup installed the first 
methyl at the C-3 position in excellent overall yield to give enone 110 
(Scheme 3.3.4). 
 
Scheme 3.3.4 
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The second of the methyl groups was then introduced using a copper mediated 
reaction with a Grignard reagent to give selective addition at the C-3 position.  The 
reaction afforded the ketones 111 and 112 as two stereoisomers in a ratio of 85:15 in 
81% yield (Scheme 3.3.5). 
 
Scheme 3.3.5 
 
The ketones 110 and 111 were transformed into methyl enol ethers 101 and 113 
using potassium butoxide and dimethyl sulphate in DMSO.  The transformation 
proceeded in 96% yield forming two regioisomers which were separable by 
chromatography (Scheme 3.3.6). 
 
Scheme 3.3.6 
 
For the Effenberger annulations it had been demonstrated that it was not necessary 
to separate the two isomers 101 and 113.  Hence, the mixture of isomers was treated 
under our standard Effenberger-type conditions (one equivalent of malonyl dichloride 
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for 24 h at -20 °C followed by KOH solution for 5 h at rt) to form the C-1, C-7 
diprenylated bicyclo[3.3.1]nonane core 114.  The bicyclo[3.3.1]nonane-trione 114 
was not purified at this stage due to its high polarity and relative instability, but was 
instead methylated directly.  Methylation of the bicyclo[3.3.1]nonane-trione 114 was 
performed under acidic conditions, which gave just one regioisomer 108 with the 
methyl group installed at the C-4 oxygen, distal to the bulk of the prenyl substituent at 
C-1.  Although the Effenberger cyclisation was low yielding we continued to use it as 
it enables rapid access to a well developed bicyclo[3.3.1]nonane system.  
Furthermore ketones 111 and 112 are recovered alongside the desired product 108 
and can be recycled (Scheme 3.3.7). 
Scheme 3.3.7 
 
At this stage the synthesis diverges from that of the clusianone (3) synthesis.  The 
yields were comparable to those of Dr. Rodeschini for each of the above steps. 
Clusianone (3) has a prenyl at C-5 and a benzoyl group in the C-3 position whereas 
nemorosone II (150) has these groups interchanged.  At this point a project student 
in our lab, Peter Crick, took over the synthesis and established the steps necessary 
to synthesise nemorosone II (150) but was unable to perform the final deprotection.  
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Direct acylation at C-5 was initially attempted using a benzoyl chloride quench of the 
bridgehead enolate, however only starting material was recovered (Scheme 3.3.8). 
 
Scheme 3.3.8 
 
Therefore, it was decided to treat the bicyclo[3.3.1]nonane 108 with benzaldehyde to 
make the secondary alcohol products 198 and 199 that could be oxidised to the 
ketone 151.  The secondary alcohol was formed successfully using LDA and 
benzaldehyde, giving the product as two diastereoisomers 195 and 196.  Selectivity 
was not an issue as the stereocentre would be lost during the oxidation to the desired 
ketone (Scheme 3.3.9). 
 
Scheme 3.3.9 
 
The oxidation of the mixture of secondary alcohols 198 and 199 was achieved using 
Dess-Martin periodinane in DCM at rt.  The reaction proceeded smoothly and the 
product was sufficiently pure to be used without further purification (Scheme 3.3.10). 
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Scheme 3.3.10 
 
The final prenyl group was added at the vinylic position (C-3) using a mixed higher 
order cuprate reaction.  Selective deprotonation of the C-3 position was performed 
with LiTMP.  Transmetallation to the cuprate gave the organometallic which 
underwent successful reaction with prenyl bromide to give O-methylated nemorosone 
II (152) (Scheme 3.3.11). 
 
Scheme 3.3.11 
 
As its methyl vinylogous ester 152, nemorosone II was stable and could be easily 
handled and purified.  The 1H NMR spectra at this stage shows no signal around δ 
6.00 which would correspond to the C-3 proton.  Furthermore the δ 5.00 region 
shows a multiplet with the integration of one proton that relates to vinylic proton of a 
prenyl group which corresponds with the desired product (Figure 3.3.1). 
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Figure 3.3.1 1H NMR of O-methylated nemorosone II (152) (500 MHz, CDCl3) 
  
At the methyl vinylogous ester stage, the 1H and 13C NMR spectra could easily be 
compared to those of nemorosone (4); as expected they show distinct differences.  
Looking at the proton NMR spectra it would be hard to confuse the two compounds.  
Although both spectra show similar signals from the protons, the δ values are not 
coincident (Figure 3.3.2).  
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Figure 3.3.2 Comparison of 1H NMR of O-methylated nemorosone (157) and O-
methylated nemorosone II (152) (500 MHz, CDCl3) 
 
The same is true of the 13C NMR spectra.  Again these shows similar signals for the 
various carbon environments in the areas that one would expect them but the shifts 
are different between the two compounds (Figure 3.3.3).  It is clear from these NMR 
spectra that nemorosone (4) and nemorosone II (150) are spectroscopically very 
different molecules and may be differentiated by NMR analysis.  
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Figure 3.3.3 Comparison of 13C NMR of O-methylated nemorosone (157) and O-
methylated nemorosone II (152) (125 MHz, CDCl3) 
 
The final step in the synthesis required O-methylated nemorosone II (152) to be 
deprotected, leading to the first synthetically produced type C PPAP, nemorosone II 
(150).  Based on our previous work on this class of compounds the Krapcho 
conditions were favoured once more (Scheme 3.3.12).58   
 
Scheme 3.3.12 
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Our previous work with nemorosone (4) had shown that the tetra ketone products 
could be very sensitive to acidic conditions, light and air.  This difficulty had been 
overcome by performing the final deprotection in d6-DMSO, which allowed NMR 
experiments to be performed upon the crude reaction mixture without the need for 
work up or exposure to air.  In this way it was possible to obtain NMR spectra for 
nemorosone II (150), which appears to exist as a single tautomer as evidenced by 
the presence of just one compound in the NMR spectra.  As with the nemorosone (4) 
synthesis the final compound was extracted from the d6-DMSO and NMR spectra 
obtained in d4-MeOD (Figure 3.3.4 and Figure 3.3.5).  
 
Figure 3.3.4 1H NMR of nemorosone II (150) (500 MHz, MeOD) 
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Figure 3.3.5 13C NMR of nemorosone II (150) (125 MHz, MeOD) 
 
3.4 Conclusion 
The first successful synthesis of nemorosone II (150), a type C PPAP, as yet 
unknown in nature, was completed in 10 steps from commercially available 
1,3-cyclohexanone (98) in a 1.5% yield.  This compound completes the set of type A, 
B and C regioisomers.  Nemorosone II (150) was sent for biological screening along 
with nemorosone (4) and clusianone (3) in the hope that some insight into the 
structure-activity relationship of these compounds could be gained.  The results of 
these studies can be found in Chapter 4.  
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Chapter 4 
Biological Studies 
 
Part of the reason for synthesising nemorosone (4) and nemorosone II (150) was to 
study the structure-activity relationship for PPAPs.  As clusianone (3) had already 
been separated into its enantiomers by kinetic resolution, these could be used 
alongside the separated enantiomers of nemorosone (4) and nemorosone II (150) to 
study the relative activity of the type A, B and C PPAPs.  Biological studies were 
performed by Frank Holtrup at The German Cancer Research Centre. 
 
4.1 Previous Biological Studies on Nemorosone 
The Diaz-Carballo group have investigated the activity of nemorosone (4) against 
various cancers including breast, colon, ovary, liver and lung cancer.61  More 
recently, they have investigated the effect of nemorosone (4) on neuroblastoma 
cancer cell lines (LAN-1 and NB69).70  It was shown that nemorosone (4) was active 
in parental neuroblastoma cells (LAN-1) as well as clones (NB69) that were resistant 
to adriamycin, cisplatin, etoposide or 5-fluorouracil.  The cell studies showed that 
nemorosone (4) treatment at an 8 μM concentration induced an accumulation of cells 
in the G0/G1 phase and subsequent reduction in cells in the S phase of the cell cycle 
after 24 h incubation.  It was proposed that this effect was due to the dose dependent 
(seen from 4 μM upwards) up-regulation of p21, an important protein in the control of 
cell cycle progression.  Their cytotoxicity studies also showed that nemorosone (4) 
treatment caused a reduction in cell numbers (IC50 value in the region of 6.5 μM) due 
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to the initiation of apoptosis, producing DNA fragmentation and caspase 
up-regulation and activation.  It was also discovered that simultaneously treated 
fibroblasts were more resistant to nemorosone (4) than the neuroblastoma cells, 
making nemorosone a suitable selective agent for treatment of neuroblastoma 
tumours.   
In a recently published work, Frank Holtrup has extensively studied the activity of 
nemorosone (4) on a selection of pancreatic cancer cell lines.59  The studies were 
carried out on MIA-PaCa-2 (an early stage pancreatic cancer cell line) alongside the 
later stage cancer cell lines AsPC-1 (gut lining) and Capan-1 (liver).  Studies were 
performed to demonstrate the selective action of nemorosone (4) against cancer cell 
lines, while leaving non-cancerous fibroblasts relatively untouched.  Nemorosone (4) 
shows cytotoxicity in a dose and time dependent manner with a much greater effect 
on the pancreatic cancer cells than on the fibroblasts.  There was an 80% reduction 
in the cancer cell number after 10 μM treatment, with only a negligible effect seen on 
fibroblast numbers (Figure 4.1.1.A).  Further flow cytometry and assays provided 
some insight into the mode of action of nemorosone (4) against these cancer cells.  
Nemorosone (4) targets the cell cycle checkpoints that exert control over the 
progression of cells through the cell cycle required for them to grow and divide.  At 
low concentrations, nemorosone (4) exhibits a G1 blocking effect, but a G2 blocking 
effect is seen at higher concentrations (Figure 4.1.1.B).  The G1 block is controlled 
by the p21 (protein) which normally binds to the cyclin D1,2,3/CDK4,6 complex and 
inactivates it.  If the cell is ready for progression into S phase, the p21 dissociates, 
allowing the complex to activate and phosphorylate a downstream protein (Rb).  The 
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phosphorylated Rb then activates E2F, a gene transcription factor (DNA synthesis 
initiator), to start DNA synthesis.  Studies demonstrated that nemorosone (4) 
up-regulates p21 and down-regulates E2F, decreasing the progression into DNA 
synthesis (S phase).  The G2 block is controlled by the GADD45α protein which 
normally binds to the cyclin B/cdc-2 complex.  If the cell is allowed to progress into 
G2 the GADD45α dissociates from the complex allowing cdc-25 to activate it. 
Nemorosone (4) up-regulates the production of GADD45α causing the proportion of 
cyclin B/cdc-2 bound to increase, inactivating it and halting the cell cycle.  Targeting 
cell replication is important in cancer treatment due to the different replication rates of 
cancerous and non-cancerous cells.  Cancer cells replicate at a much higher rate 
than normal cells, and so will be affected to a greater degree by agents that regulate 
replication. 
Figure 4.1.1 with permission of Frank Holtrup.59  Effects of nemorosone (4) on the 
viability and cell cycle of pancreatic cancer cells and fibroblasts.  A: Cell viability assay.  B: Cell cycle 
analysis.
 
 
Apoptosis is programmed cell death which is initiated if a cell is unable to repair 
damage to its DNA or organelles.  It is a highly controlled process involving regulated 
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signalling pathways and the activation of a cascade of specific enzymes called 
caspases.  DNA staining using propidium iodide was used to examine the DNA 
fragmentation in the cells treated with nemorosone (4).  This was seen to be dose 
dependent, with higher concentrations producing more fragmentation.  The largest 
amount of fragmentation was seen in the MIA-PaCa-2 cell line (early stage cancer in 
the pancreas) but the fibroblasts were spared any DNA fragmentation even at 50 μM 
doses. 
Activation of caspases was investigated using fluorescent probes (FLICA assay) that 
bind covalently to only the activated forms of the enzymes offering great sensitivity 
(can detect normal levels of apoptosis in untreated cells).  The addition of 
nemorosone (4) to the different cancer cell lines showed that caspase activation is 
dose dependent, but selective in different cell types.  The early stage cancer cells 
(MIA-PaCa-2) showed only caspase 3/7 activation while the later stage cancer cells 
(AsPC-1 and Capan-1) showed the presence of caspase 8 as well as 3/7 
(Figure 4.1.2).  This difference is explained since caspase 3/7 is activated as part of 
the intrinsic apoptotic pathway while caspase 8 is part of a different, extrinsic, 
apoptotic pathway. 
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Figure 4.1.2 with permission of Frank Holtrup.59  Analysis of nemorosone (4)-induced 
apoptosis in pancreatic cancer cells and fibroblasts by flow-cytometric assessment of apoptotic DNA 
fragmentation and caspase acitivation.  A: Percentage of cells demonstrating nemorosone (4) specific 
apoptotic DNA fragmentation.  B: Percentage of cells demonstrating nemorosone (4) specific 
activation of caspase 3/7.  C: Percentage of cells demonstrating nemorosone (4) specific activation of 
caspase 8. 
 
Collapse of the electrochemical gradient across the mitochondrial wall is one of the 
first events to occur when apoptosis is initiated in a cell.  JC-1 is a fluorescent 
cationic dye used to show this collapse.  In healthy cells, the dye localises to the 
mitochondria and aggregates causing it to fluoresce red.  Once the mitochondrial 
gradient collapses, the JC-1 cannot localise in the mitochondria and thus remains in 
the cytoplasm as monomers which fluoresce green.  Nemorosone (4) shows a shift of 
JC-1 into the cytoplasm starting at 5 μM in the cancer cell lines with full collapse at 
20 μM, but no shift from the mitochondrial localisation is seen in fibroblasts until 20 
μM with full collapse not observed until 160 μM (Figure 4.1.3).  A time study in which 
prestained cells were treated with 20 μM nemorosone (4) was set up and the 
fluorescence measured every ten seconds after treatment.  The response was very 
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rapid with the membrane potential reducing within seconds and the red/green ratio 
was inverted within two minutes. 
 
Figure 4.1.3 with permission of Frank Holtrup.59  Analysis of effects of nemorosone (4) 
on mitochondrial membrane potential ΔΨm and cytosolic calcium concentration [Ca
2+
]c in pancreatic 
cancer cells and fibroblasts.  A: Cells were treated with the indicated concentrations of nemorosone 
(4) or vehicle for 4 h and stained with voltage-dependent dye JC-1 prior to fluorescence microscopy.  
Intact mitochondria fluoresce red while cells with aborated mitochondrial membrane potential ΔΨm 
exhibit cytosolic green fluorescence. 
 
MIA-PaCa-2 cells were treated with 100 μM and 200 μM nemorosone (4) and 
assayed for changes in intracellular Ca2+ concentration.  Ca2+ plays an essential role 
in the control of many intracellular pathways and altering Ca2+ homeostasis could 
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explain the action of nemorosone (4) on the apoptosis initiation.  Again, a lower effect 
is observed on fibroblasts compared with cancer cells but much higher 
concentrations of nemorosone (4) are required for an effect to be seen on Ca2+ 
concentrations in any of the cancerous cell lines.  Previous research has shown that 
mitochondria take up Ca2+ to preserve intracellular concentration, but that this can 
lead to Ca2+ overload and collapse of the membrane potential possibly linking to the 
activity of nemorosone (4).74-75  It is believed that the increase in intracellular Ca2+ is 
caused by release from the endoplasmic reticulum (ER).  
Genetic analysis of the three cell lines, using RNA collected from treated cells, shows 
which genes are affected by the treatment with nemorosone (4); either being 
up-regulated or down-regulated.  Modelling was used to find out how the affected 
genes expressed in all three cell lines were linked.  They all appeared in the signal 
pathways of the ER stress response or further downstream.  These responses are 
initiated by the occurrence of a build-up of unfolded or misfolded proteins in the ER 
caused by alterations in the Ca2+ homeostasis.  After a prolonged period of stress, 
the cell ceases repair and enters apoptosis instead. 
DDIT3 is one gene strongly induced as a result of nemorosone (4) treatment and 
produces a transcription factor controlling the expression of the BCL2 family of genes 
involved in apoptosis.  Accumulation of DDIT3 in a cell initiates the ER stress 
response to cause cells to enter apoptosis.  This occurs due to an alteration in the 
balance of anti- and pro-apoptotic BCL2 family members in favour of apoptosis, 
eventually leading to the activation of the caspase enzyme cascade.  If the mRNA 
were prevented from being translated into proteins, silencing of DDIT3 would be 
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observed.  In studies, silencing was produced by incorporating siRNA (section of 
silencing double stranded RNA) into the mRNA causing it to be cleaved before 
translation took place.  When the production of DDIT3 in the MIA-PaCa-2 cells was 
stopped the effect of nemorosone (4) was reduced, demonstrated by a 75% 
decrease in apoptotic cells after 48 h incubation with 20 μM nemorosone (4).  The 
levels of active caspase 9 and 3/7 after 24 h were also reduced, supporting the link 
between DDIT3 and apoptosis initiation.  Capan-1 cells did not show any reduction in 
DNA fragmentation or in the activity of caspase 3/7 and 8, but decreased activity of 
caspase 9.  This is probably due to the differential activation of caspase 8, normally 
as a result of the intrinsic and extrinsic pathways for apoptosis.  None of the genes 
with altered expression in the MIA-PaCa-2 cell line were found to be significantly 
altered in fibroblasts, again supporting the preferential targeting of cancer cells. 
ER stress is very likely to occur due to the high metabolic stress (lack of oxygen and 
nutrients) that occurs within tumours, so control of the ER stress response signalling 
within tumour cells could be useful in preventing their repair and targeting them for 
induction into the apoptotic pathway.  Fibroblasts have a much lower energy 
requirement and are therefore less likely to suffer ER stress; meaning that they would 
be less affected by treatment with nemorosone (4). 
 
4.2 Proposed Biological Study 
The biological activities of nemorosone (4) and clusianone (3) have been noted 
already, but comparing the compounds’ activity against the MIA-PaCa-2 cancer cell 
line will allow more about the SAR to be determined, along with some insights into 
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the mode of action.  To accurately study the activity of a compound it is necessary to 
separate the enantiomers, as each enantiomer can exhibit widely different 
bio-activity.  With clusianone (3) we had separated the enantiomers using a kinetic 
resolution.41  Although the same could be tried with the nemorosone (4) and 
nemorosone II (150) systems, they were instead separated by chiral HPLC to access 
the enantiomers.  The benefit of HPLC is that relatively large quantities of material 
can be separated in a short period of time without fear of incomplete 
enantioselectivity, and with no need to introduce further synthetic steps.  With the 
enantiomers separated, it would be possible to accurately compare the cytotoxicity of 
the type A, B and C PPAPs. 
Alongside the study of the final compounds, some of the intermediates also 
presented interesting candidates for study, due to their different substitution around 
the bicyclo[3.3.1]nonane core.  This afforded an insight into the SAR of these 
molecules.  The intermediates were studied as their racemate and indicate which 
parts of the PPAP structure are necessary for activity against MIA-PaCa-2 cancer cell 
lines. 
 
4.3 Synthesis of Compounds 
Application of HPLC on the final compounds was not viable as they were unstable, 
particularly in the presence of acidic column media.  As a result, the compounds 
were separated into their enantiomers while protected as the methyl vinylogous 
esters 157 and 152 (Scheme 4.3.1 and Scheme 4.3.3).  By doing this, the 
compounds were stable and easy to manipulate, but it meant separating larger 
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quantities of material as the final hydrolysis step was performed on each individual 
enantiomer. 
 
Scheme 4.3.1 
 
The structures of the separate enantiomers are shown as in the hyperforin (2) 
system, in which the (+) isomer is the one displayed throughout this work.  However, 
nemorosone (4) has not had its absolute configuration assigned and the identities of 
the individual enantiomers have yet to be determined.  Nemorosone (4) has only 
been isolated from natural sources as the (+) enantiomer.   
A study of various chiral HPLC columns with different solvent systems showed that a 
Lux cellulose II column and a mobile phase of 1.5% MeOH in hexane offered a 
baseline separation of the two enantiomers of O-methylated nemorosone (157).  The 
hydrolysis was performed separately on each methyl vinylogous ester enantiomer 
and the enantiomers of nemorosone (4) were isolated in quantitative yields 
(Scheme 4.3.2).  
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Scheme 4.3.2 
 
In the clusianone (3) synthesis, we saw an inversion of the optical rotation between 
the methyl vinylogous ester 108 and the final compound (3).  However, nemorosone 
(4) does not display this trait.  The O-methylated nemorosone II (152) enantiomers 
were also separated by HPLC on the Lux cellulose II column using 1% IPA in hexane 
as the mobile phase (Scheme 4.3.3). 
  
Scheme 4.3.3 
 
The final hydrolysis step was performed on the O-methylated enantiomers of 
nemorosone II (152) separately (Scheme 4.3.4).  In this way the enantiomers of 
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nemorosone (4), nemorosone II (150) and clusianone (3) were separated and tested 
by Frank Holtrup against the MIA-PaCa-2 cancer cell lines. 
 
Scheme 4.3.4 
 
Having studied various intermediates (144, 157 and 173-176) from the synthesis, the 
effect of prenyl groups and bridgehead ketones on the activity of the molecules was 
investigated.  Thus, the double bonds in the prenyl side chains were hydrogenated.  
As O-methylated nemorosone (157) was a valuable product and in short supply, 
more abundant derivatives were considered.  Intermediate 173 possesses most of 
the functionality of nemorosone (4) and was in abundant supply so made a good 
candidate for further derivitisation.  The double bonds were reduced using H2 (g) over 
Pd/C catalyst (Scheme 4.3.5). 
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Scheme 4.3.5 
 
The hydrogenation was successful, although recovery of products was disappointing.  
The reaction gave a mixture of products; some with total hydrogenation (201) and 
others with only partial hydrogenation (200).  Analysis of the 1H NMR spectra allowed 
us to determine which of the prenyl groups is reduced.  The characteristic proton 
signals of the C-7 prenyl group, which do not coalesce with those of C-5 prenyl 
group, had been replaced by signals further upfield, including a pair of doublets 
relating to the C-16 and C-17 methyls.  Submission of both compounds for biological 
analysis allowed the relevance of each prenyl group to be assessed.  The same 
hydrogenation conditions were applied to intermediate 174 (Scheme 4.3.6). 
 
Scheme 4.3.6 
 
Intermediate 174 gave only one product (202) when hydrogenated, where the C-7 
prenyl group was fully saturated.  As before this was confirmed by a change in the 
characteristic signals in the 1H NMR spectra. 
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To investigate the importance of the bridgehead C-9 ketone, the ketone 173 was 
reduced and the resulting hydroxyl was subjected to biological testing.  Reduction 
was performed using an excess of sodium borohydride and gave intermediate 203 
(Scheme 4.3.7). 
 
Scheme 4.3.7 
 
It is assumed that the reduction takes place from the least hindered side of the 
molecule (across the methyl vinylogous ester rather than across the bulky prenyl 
group).  This would be consistent with what was found in the kinetic resolution of 
clusianone (3) (Scheme 1.5.6).41  
 
4.4 Results of Biological Study 
The samples were sent to Frank Holtrup at the German Cancer Research Centre for 
testing against MIA-PaCa-2 pancreatic cancer cells.  Using a Resazurin cell viability 
assay it was possible to compare the activity of the PPAPs.  The standard procedure 
for this assay was seeding the cells at 2000 cells/well in 100 μL of Dulbecco's 
Modified Eagle Medium (DMEM) and incubating them for 24 h at 37 °C with 5% CO2.  
The cells were then treated with different PPAP concentrations but the DMSO 
content was kept at 0.25%.  The cells were incubated for a further 72 h followed by 
medium exchange with 50 μL of assay medium (1 mg/mL resazurin 1:50 cell culture 
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medium).  The plates were read with a fluorescence mode plate reader (excited 
544 nm, emitted 590 nm) to give dose-response plots. 
Investigations of clusianone (3), nemorosone (4) and nemorosone II (150) showed 
that the position of the acyl group- and therefore the prenyl groups- had a small effect 
on the bio-activity of these molecules (Figure 4.4.1).  Clusianone (3) and 
nemorosone (4) showed the greatest activity, and nemorosone II (150) was 
approximately a factor of ten less active.  It also showed that neither the (+) nor the 
(-) enantiomers of the particular compounds were any more effective against the 
cancer cell line.  
 
Figure 4.4.1 Dose-response curves for the enantiomers of nemorosone (4), 
nemorosone II (150) and clusianone (3). 
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Figure 4.4.1 shows that the cell viability of the cancer cell line is decreased to less 
than 50% when treated with 7 μM of (+)-nemorosone (4), (-)-nemorosone (4) or 
(-)-clusianone (3).  (+)-Clusianone (3) is slightly less active with an IC50 of 10 μM.  
The (-) enantiomer of nemorosone II (150) has an IC50 of 25 μM and the (+) 
enantiomer (150) an IC50 35μM. 
Some of the derivatives that were produced during the synthesis of nemorosone (4) 
were studied to discover the effect on the molecules bio-activity with different 
functional groups appended to the bicyclo[3.3.1]nonane system (Figure 4.4.2).   
 
Figure 4.4.2 
 
Figure 4.4.3 shows that O-methylated nemorosone (157) is inactive against the 
MIA-PaCa-2 cancer cell line.  It also shows that by stripping the molecule of much of 
its functionality, as in the Effenberger product 144, activity is drastically reduced to an 
IC50 of 40 μM.  The compounds 173, 174 and 176 that have functionality at the C-3 
vinylic position show activity that was comparable to that of natural nemorosone (4). 
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Figure 4.4.3 Dose-response curves for 144, 157, 173, 174 and 176. 
 
Having observed the effect that changing the groups appended to the 
bicyclo[3.3.1]nonane system has on the bio-activity, and the effect of the methylation 
of the 1,3-diketone system, it was possible to look at the position of O-methylation 
(C-2 or C-4) of the 1,3-diketone part of the bicyclo[3.3.1]nonane.  This was done by 
comparing the activity of the O-methylated bicyclo[3.3.1]nonanes 144 and 145 from 
the Effenberger reaction (Figure 4.4.4).  
 
Figure 4.4.4 
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Figure 4.4.5 Dose-response curves for 144 and 145. 
 
There is a clear difference in the response to treatment with the two different 
isomers.  The C-2 O-methylated derivative 144 shows an IC50 of 35 μM and the C-4 
O-methylated derivative 145 has an IC50 of 19 μM (Figure 4.4.5).  This suggests that 
the site of methylation on the bicyclo[3.3.1]nonane is important to the anti-cancer 
activity of this class of compound.  The difference in activity of these enol ethers in 
cell tests could be due to their difference in susceptibility to hydrolysis. 
A final set of compounds were tested to investigate the effect of changes to the 
saturation of the PPAP prenyl groups and the change of oxidation level of the 
bridgehead ketone (Figure 4.4.6 and 4.4.7).  
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Figure 4.4.6 
 
By using the compounds 173 and 174, it was possible to compare the relationship 
between these compounds, their unsaturated/oxidised derivatives 200-203 and 
nemorosone (4). 
 
Figure 4.4.7 Dose-response curves for 200-203. 
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Figure 4.4.7 shows that a change in the saturation level of the prenyl chains in these 
molecules (200-202) has little effect on the IC50 values.  However, a greater effect 
was seen when using the hydroxyl compound 203, the IC50 value of 2 μM for 203 is 
less than that for the nemorosone (4) control. 
 
4.5 Conclusion 
This study has shown that the enantiomers of clusianone (3) and nemorosone (4) are 
of similar activity.  Nemorosone II (150) is less active against the (MIA-PaCa-2) 
cancer cell line.  By looking at the different derivatives, it is possible to gain some 
insight into the SAR of this class of compounds.  It has been shown that the 
presence of the 1,3-diketone system is important and that reduction of the 
bridgehead ketone can lead to lower IC50 values. 
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Chapter 5 
Investigation into C-1 Bridgehead Functionalisation 
 
During the synthesis of nemorosone (4) in Chapter 2 it was discovered that the C-1 
bridgehead of the bicyclo[3.3.1]nonane system would not undergo substitution using 
our previously established protocols.  However, using iodination followed by a 
halogen-metal exchange, substitution of the C-1 bridgehead could be achieved.  This 
chapter will discuss the chemistry that is available at the C-1 position and explain the 
limitations. 
 
5.1 Attempted C-1 Enolate Formation 
In the nemorosone (4) synthesis, the C-1 bridgehead was acylated using iodination 
followed by halogen-metal exchange and quenching with benzoyl chloride, since 
direct C-1 enolate acylation proved ineffective.  These conditions were adapted from 
Danishefsky’s synthesis of garsubellin A (1), when traditional enolate forming 
methods failed to enable access to further functionalised molecules 
(Scheme 5.1.1).39 
 
Scheme 5.1.1 
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To fully test the reactivity of the C-1 bridgehead position of 144, a range of bases, 
electrophiles and conditions were tried.  Bases that were tested included tBuLi, 
nBuLi, LDA, LiTMP, KOH and NaOMe, and the reactions quenched with MeI, 
benzoyl chloride or TMSCl.  In all cases the tell-tale colour change from a colourless 
solution to a yellow one occurred on addition of the base but the desired product was 
not observed after electrophile addition (Scheme 5.1.2).  This suggested that the 
bridgehead enolate was being formed although it could not be reacted successfully.   
 
Scheme 5.1.2 
 
One possible explanation for this would be that the enolates were forming 
aggregates that prevented the electrophile from attacking the C-1 position.  To test 
this hypothesis, LiCl was added to the LDA solution to make mixed aggregates 
before electrophile addition.76  Unfortunately, this failed to provide an isolatable 
product.  At this point we were unable to explain the lack of reactivity of the C-1 
bridgehead.  The final attempt, using a modification of Danishefsky’s intriguing 
bridgehead iodination reaction, gave the lead needed to complete the nemorosone 
(4) synthesis (Scheme 5.1.3). 
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Scheme 5.1.3 
 
With C-1 bridgehead iodination established we wanted to test the application of these 
unusual conditions with alternative electrophiles.  A range of different electrophiles 
were tried including acylating and alkylating agents (benzoyl chloride, benzaldehyde, 
prenyl bromide, methyl iodide and TMSCl).  In all cases none of the desired product 
was observed and starting material was recovered.  Thinking that TMSCl may be 
acting as a Lewis acid it was changed for BF3.Et2O and iodine was used as the 
electrophile.  This resulted in no reaction and only starting material was recovered.  
Isolation of intermediates for this reaction proved impossible but it is hypothesised 
that a silyl enol ether was formed that underwent quenching during the work up of the 
reaction (Scheme 5.1.4).   
 
Scheme 5.1.4 
 
These experiments have shown that the C-1 bridgehead can be iodinated but only 
under very specific conditions which we have been unable to adapt to other 
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electrophiles.  At this stage it is hard to explain these results although it may be due 
to the steric encumberment around the C-1 position allowing only small electrophiles 
close enough to react. 
 
5.2 Bridgehead Iodide Chemistry 
Having established that the only chemistry possible at the C-1 bridgehead of methyl 
enol ether 173 was iodination, the available chemistry of the resulting iodide 176 was 
investigated.  During the synthesis of nemorosone (4) it was shown that 
halogen-lithium exchange could be performed and the lithium anion quenched with 
deuterium (Scheme 5.2.1).   
 
Scheme 5.2.1 
 
The reaction produced a low recovery due to butyl addition to the C-9 bridging 
carbonyl but complete conversion to the deuterated product 206 was achieved.  This 
confirmed that the lithium anion was being formed at the C-1 bridgehead and could 
be quenched with an electrophile, which led to the successful benzoylation during the 
nemorosone (4) synthesis. 
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When performing halogen-metal exchange with nBuLi for the nemorosone (4) 
synthesis, moderate yields alongside some butyl addition to the bridgehead ketone 
207 and the protonation product 173 were observed (Scheme 5.2.2).   
 
Scheme 5.2.2 
 
It was therefore necessary to perform some optimisation of the conditions before 
screening a selection of electrophiles.  tBuLi was used to limit the amount of butyl 
addition to the bridging carbonyl since it is less nucleophilic.  Reactions were also 
performed at a lower temperature (-100 °C) to try and limit any undesired reactions 
taking place before the electrophile was added.   
Having shown that acylation was possible with benzoyl chloride to make 174 in the 
nemorosone (4) synthesis, a series of other acylating agents were tested.  Using 
methyl chloroformate as the electrophile it was possible to form the methyl formate 
intermediate 208 (Scheme 5.2.3). 
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Scheme 5.2.3 
 
Unfortunately, the reaction was low yielding, with the remainder of the material being 
isolated as the C-1 protonated product 173.  This suggested that the anion was either 
particularly basic and being protonated by solvents or the glass, or that it was very 
stable and was only quenched upon work up.  The trifluoroacetyl derivative 209 was 
made using trifluoroacetic anhydride as the electrophile (Scheme 5.2.4). 
 
Scheme 5.2.4 
 
The yield was good for this quench although some of the C-1 protonated product was 
isolated alongside the desired product.   
To investigate the reactivity of the C-1 anion further it was tested with a series of 
aldehydes to make the C-1 aldols.  Reaction with acetaldehyde afforded the 
secondary alcohol 210 in good yield (Scheme 5.2.5). 
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Scheme 5.2.5 
 
To discover something about the size of electrophile that could be reacted at the C-1 
position, a reaction with isobutyl aldehyde was performed.  The isobutyl aldehyde 
offered a more hindered electrophile, indicating whether larger electrophiles would 
substitute at the C-1 position of the iodide 176 (Scheme 5.2.6). 
 
Scheme 5.2.6 
 
The reaction produced a moderate yield of aldol product 211.  The natural 
progression of this series was reaction with pivaldehyde (Scheme 5.2.7). 
 
Scheme 5.2.7 
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On this occasion no reaction was observed.  The tertbutyl group proved too great a 
steric bulk for reactions to occur.  This series of reactions showed that for a reaction 
to be successful at the C-1 position the electrophile must be relatively small.  This is 
not unexpected due to the steric impingement caused by the C-8 geminal dimethyl 
group and the O-methylation at the C-2 position.  
Having shown that reactions with carbonyls were possible, producing the expected 
acylated products or alcohols, we also wanted to test the corresponding reactions 
using alkylating agents.  Thus, using our standard conditions for halogen-metal 
exchange at the C-1 position, MeI was tested as the reactive electrophile (Scheme 
5.2.8). 
 
Scheme 5.2.8 
 
No reaction was observed under our standard conditions and only the protonated 
product 173 was isolated.  Upon increasing the concentration of electrophile to ten 
equivalents no desired product was obtained.  The reaction was also tried using 
prenyl bromide as the alkylating agent (Scheme 5.2.9). 
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Scheme 5.2.9 
 
Again no reaction was seen and only the protonated product 173 was recovered.  In 
conclusion, the alkylation of the C-1 position was not possible.  Functionalisation of 
the C-1 position was further studied with attempts at silylation.  To test this TMSCl 
was used as the electrophile (Scheme 5.2.10). 
 
Scheme 5.2.10 
 
This showed no favourable reaction returning only the C-1 protonated product 173 so 
different silylating agents (TBSCl, TIPSCl) were tested and gave no improvement. 
Although the yields for this series of products did not match that of the benzoylation 
reaction they gave an insight into some of the chemistry possible at the C-1 position.  
The above results indicate that an effective electrophile needs to be small, highly 
reactive and acyl in character.  It was preferable that the electrophile be non-
enolisiable since the lithium anion could abstract a proton from the electrophile, 
protonating the C-1 position in the process. 
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These experiments showed that using typical enolate forming conditions it was not 
possible to substitute the C-1 bridgehead.  However, under very specific conditions 
C-1 bridgehead iodination could be performed.  The bridgehead iodide could then be 
substituted by a range of electrophiles using a halogen-metal exchange.  This was 
somewhat surprising as both sets of conditions would form the same lithium enolate.  
This suggested that something in the direct enolate forming conditions was 
interrupting the reaction.  A possible cause was complexation of the enolate with 
diisopropylamine, blocking the enolate from the electrophile.  To test this 
diisopropylamine was added before the electrophilic quench of the mixture, produced 
by bridgehead iodination and the halogen-metal exchange (Scheme 5.2.11).   
 
Scheme 5.2.11 
 
It was expected that if complexation was taking place then the addition of the benzoyl 
group would be restricted.  However, this was not the case and the reaction went to 
completion as normal.  Therefore, a stable complex with diisopropylamine was 
unlikely to be the reason substitution by direct enolate formation and quenching 
failed. 
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5.3 Computational Studies 
Although the C-1 bridgehead position could be substituted, it was desirable to 
understand how substitution was only possible via the bridgehead iodide 
intermediate.  Thus, Dr. Chris Hayes at the University of Nottingham performed some 
computational modelling of these systems.68,71  Using B3LYP calculations it was 
possible to predict which systems would undergo bridgehead deprotonation; viable 
reactions gave a negative ΔERXN and not viable reactions gave a positive ΔERXN.  
ΔERXN is the energy of reaction for the simplified deprotonation reaction using 
dimethyl amide, shown in Scheme 5.3.1.  The results of these calculations fit with 
what has been experimentally determined. 
 
Scheme 5.3.1 
 
Through computer modelling it was possible to look at simplified systems and have 
some insight into the actual system in question.  These calculations show that the 
anion of 219 would be unfavourable with a ΔERXN of +4.7 Kcal mol
-1.  This was due to 
the [3.3.1] system not offering enough flexibility to incorporate the double bond of an 
enolate (Scheme 5.3.2). 
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Scheme 5.3.2 
 
By studying systems that contain the ketone in a larger ring it was possible to show 
that bridgehead deprotonation can be a highly favoured reaction.  Calculation based 
on the [3.2.1] system 222 show a ΔERXN – 10.2 Kcal mol
-1.  The lower the value of 
ΔERXN the more stable the enolate produced (Scheme 5.3.3).   
 
Scheme 5.3.3 
 
By applying these results to the experimental system it can be shown that the 
bridgehead enolate cannot form at the C-9 oxygen.  In the experimental system 173 
the methyl vinylogous ester section offers a way of forming a dienolate from 
deprotonation of the C-1 position (Figure 5.3.1). 
 
Figure 5.3.1 
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Having performed calculations on model systems to demonstrate that bridgehead 
deprotonation can be a favourable reaction and that the resulting anion can be 
stable, calculations were performed on an O-methylated bicyclo[3.3.1]nonane system 
226.  The calculations show that the dienolate made from the deprotonation of 226 is 
particularly stable ΔERXN -27.7 Kcal mol
-1 and therefore may explain why the 
experimental system undergoes limited reaction (Scheme 5.3.4).   
 
Scheme 5.3.4 
 
NBO calculations were also performed upon the anionic deprotonated species.  It 
was discovered that these could be described as either bridgehead enolates or 
α-keto carbanions depending upon the system.  Our bicyclo[3.3.1]nonane model 
system was best described as the dienolate form.  With this in mind the experimental 
system could be described as two quite different resonance structures, with 229 
being thermodynamically more stable (Scheme 5.3.5). 
 
Scheme 5.3.5 
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Having made this definition, it was possible that different lithiated species were being 
produced in the two different sets of conditions.  It is hypothesised that the different 
lithiated species have different stability and therefore reactivity with the electrophiles, 
although more computational studies would have to be completed to prove this.  
Under LDA conditions the particularly stable lithium dienolate 225 was formed which 
undergoes very limited further reaction due to its stability and the steric bulk of the 
neighbouring substituents.  However, under halogen-metal exchange the bridgehead 
lithium 230 was formed instead which may be less stable and therefore more reactive 
(Figure 5.3.2).   
 
Figure 5.3.2 
 
It is also possible that the energy barrier between the two different lithiated species 
may be unexpectedly high therefore making the two resonance structures act as two 
independent systems, leading to the results we have seen experimentally. 
 
5.4 Conclusion 
During the synthesis of nemorosone (4) it was discovered that direct C-1 
deprotonation and substitution was only possible under the very specific conditions of 
iodination.  However, by using a halogen-metal exchange it was possible to 
functionalise this position.  Computational studies have also shown that the anion is 
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stable and a dienolate.  With this in mind it is proposed that the dienolate, through 
direct deprotonation, is stable and sterically hindered against electrophilic quenching.  
Whereas under the conditions of halogen-metal exchange a bridgehead lithiated 
species is formed, which is less stable and therefore more reactive. 
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Chapter 6 
Toward a Second Generation Synthesis of Nemorosone 
 
Having synthesised nemorosone (4) using the Effenberger annulation as the key 
bicyclo[3.3.1]nonane core forming reaction, we sought to improve the overall yield 
and decrease the number of steps in the synthesis.  Although only 13 steps in length 
our initial synthesis gave an overall yield of 6%.  In practical terms this would never 
be applicable to scale up and potential industrial use, therefore a second generation 
synthesis was devised. 
 
6.1 Retrosynthesis 
We envisaged a new strategy that would be distinct to those already established, 
shorten the route to nemorosone (4) and would improve the overall yield of the 
synthesis.  The following disconnections would lead to nemorosone (4) in just seven 
steps, and should improve the overall yield (Scheme 6.1.1). 
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Scheme 6.1.1 
 
The first three steps of the synthesis would be those of the first generation synthesis 
and would give diprenylated ketone 141 in circa 70% yield.  The next step would be 
to form the 1,3-diketone 234, through enolate formation followed by acylation with 
benzoyl chloride to afford the diketone system 234 expediently.  Further 
deprotonation and electrophilic quenches with acyl groups could be used to build up 
the architecture that would later form the diketone part of the ring in nemorosone (4).  
By installing an enolisable acyl group and one with a leaving group it was hoped that 
this would drive a Dieckmann cyclisation between them forward (Scheme 6.1.2). 
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Scheme 6.1.2 
 
Using this methodology would be a departure from our bridgehead enolate chemistry, 
but may offer benefits in terms of improved yield and more reliable reactions. 
Acylation of dicarbonyl compounds is not well known although a few procedures 
have been developed.77-80  Many of these procedures require stoichometric amounts 
of base and catalysis with d-block metal derivatives and are not applicable to cyclic 
systems.  We feel that it may be possible in this situation as the dicarbonyl 234 is not 
a traditional dicarbonyl.  The bulk of the phenyl group and the geminal dimethyl 
groups mean that the benzoyl group is forced out of the plane of the cyclohexanone 
carbonyl (Figure 6.1.1). 
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Figure 6.1.1 Chem 3D molecular model of 235 showing non-coplanar  
 
This results in poor orbital overlap and the system reacting more like a ketone than a 
dicarbonyl.  We hope to exploit this for our double acylation of the C-2 position. 
 
6.2 Synthesis of Nemorosone 
Formation of the 4,6-diprenylated ketone 141 followed the chemistry established in 
Chapter 2 and gave the product in multi gram quantities (Scheme 6.2.1). 
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Scheme 6.2.1 
 
To continue towards nemorosone (4) the C-2 acyl group which would become the 
C-1 bridgehead benzoyl group in nemorosone (4) would need to be installed.  Our 
initial aim was to deprotonate the less hindered position (C-2) and acylate the 
resulting enolate using benzoyl chloride.  Performing the deprotonation with LDA 
gave 78% conversion to a product with the correct mass, and a proton NMR with a 
singlet signal at δ = 5.26 that could correspond to the acidic C-2 proton between the 
two carbonyls.  However, 13C NMR spectra showed only one peak corresponding to 
the enol benzoate carbon, and IR spectroscopy confirmed this with only one stretch 
in the carbonyl region.  Rather than the desired product the reaction lead selectively 
to O-acylation, giving enol benzoate 237 as the only product (6.2.2). 
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Scheme 6.2.2 
 
It may be possible to perform a rearrangement of the enol benzoate 237 to a 
1,3-diketone 234 using triazole and potassium carbonate.  Attempts have been made 
using a protocol described by Bentley et al. but have as yet been unsuccessful and 
only starting material was recovered (6.2.3).81 
 
Scheme 6.2.3 
 
In an attempt to obtain the C-acylated product, thermodynamic conditions were 
investigated to perform the deprotonation, followed by an electrophilic quench with 
benzoyl chloride giving a 1,3-diketone 238.  Not unexpectedly this gave the product 
with the acyl group at the C-6 position along with the prenyl group (Scheme 6.2.4). 
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Scheme 6.2.4 
 
The 1H NMR spectra did not show a singlet signal in the 4-5 ppm region that 
confirmed that acylation was C-6 rather than C-2.  The 13C NMR shows two signals in 
the 200 ppm region that corresponds to the two carbonyl carbons, confirming that 
C-acylation has taken place rather than O-acylation. 
To continue the synthesis we retraced our steps and investigated the use of an 
indirect acylating approach previously developed in our group.47  It has been shown 
that it is possible to make a suitable aldol product, albeit in modest yield, through 
quenching an enolate with benzaldehyde.  Starting from enone 89 (Chapter 2.4), 
methylation of the C-3 position was performed by a 1,4-Michael addition and this was 
followed by immediate addition of benzaldehyde to give the keto-alcohols 239 and 
240 as a 1:1 diastereomeric mixture (Scheme 6.2.5). 
 
Scheme 6.2.5 
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Keto-alcohol 239 was then oxidised using Dess-Martin periodinane to give the 
1,3-diketone 135.  Dr. Rodeschini had reported a 58% yield over the two steps from 
89 to 135 and 136, however only a 21% yield for the two steps was possible on this 
occasion.47  Prenylation at the C-6 position to install the bridgehead C-5 prenyl of 
nemorosone (4) was performed by deprotonation with LDA and electrophilic quench 
with prenyl bromide, to give the diprenylated-1,3-diketone 234 (Scheme 6.2.6). 
 
Scheme 6.2.6 
 
Analysis by NOESY NMR allowed the stereochemistry to be defined.  The spectra 
showed correlation between the protons C-2 and C-4 confirming that the benzoyl 
group and C-4 prenyl group are on the same side.  No correlation was seen between 
the proton of C-2 and C-6 or C-4 and C-6, suggesting that the C-6 prenyl group was 
on the opposite side to the C-4 prenyl and benzoyl.  Further confirming this was the 
correlation between the C-14 protons and the C-2 proton. 
The next phase in our planned synthesis involved appending the required acyl 
groups at C-2 and C-6 that would be used to cyclise and form the 1,3-diketone ring 
system of nemorosone (4).  The question of which group to install first, the methyl 
formate or the pentenoyl chain, was answered by considering the reactivity of these 
groups.  Installation of the formate group first would give a product in which there 
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would be no competing centre for deprotonation and therefore no potential side 
reaction with the acid chloride when installing the C-2 acyl group.  The pentenoyl 
group however, can be easily enolised, which could lead to problems when using the 
intended deprotonation and enolate quench to install the final group.  For this reason 
reaction with LiTMP and quench with methyl cyanoformate was conducted 
(Scheme 6.2.7). 
 
Scheme 6.2.7 
 
Unfortunately, these conditions gave a mixture of the O-acylated 242 and C-acylated 
241 products, which proved co-polar in various solvent systems and were 
inseparable by normal column chromatography.  HPLC (C18 column) offered a 
solution to this problem.  This would not be suitable for our improved synthesis so 
conditions were adjusted and reagents changed to try to favour C-acylation.  
Different bases (LDA and dilithiated N,N’-diphenylethylenediamine) were tested but 
gave no change in product ratio and no improvement in yield.  The identity of the 
C-acylated compound was confirmed by the 13C NMR spectra containing three 
signals in the low field which correspond to the two ketones and the ester.  The IR 
confirmed this with three stretches in the carbonyl region.  NOSEY NMR spectra 
were used to confirm the stereochemistry, once more there was correlation between 
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the C-2 and C-4 protons establishing that they were on the same side.  Correlation 
between the C-4 and C-14 signals confirmed that the C-6 prenyl group was on the 
same side as the C-2 and C-4 protons. 
By changing to methyl chloroformate as the electrophile, selective O-acylation was 
achieved to give 242 in 25% yield (Scheme 6.2.8).   
 
Scheme 6.2.8 
 
Under softer thermodynamic conditions (iPr2NEt, MgBr2.EtO2, heat) no reaction was 
observed.  Again it may be possible to carry out O-acyl to C-acyl rearrangement 
using triazole, although test reactions have been unsuccessful in achieving this 
conversion to date.  This would at least allow for recovery of the desired product if 
selective C-acylation conditions could not be found. 
With the triketone 241 in hand installation of the final group, which would become the 
vinylic prenyl group, was attempted (Scheme 6.2.9).  The intention once more was to 
deprotonate and quench at the acidic proton between the ketones.  However 
attempts with LDA or tBuLi as the base gave no reaction and only starting material 
was recovered. 
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Scheme 6.2.9 
 
To try to confirm that the anion was being formed the deprotonations were performed 
with LDA and quenched with d4-MeOD or TMSCl.  It was hoped that this would lead 
to deuterium incorporation or O-silylation.  However, neither of these products was 
observed.  The C-2 proton is extremely hindered by the C-2 benzoyl group as well as 
the C-4 prenyl and formate groups.  It is likely that this was preventing deprotonation 
and therefore further substitution of the C-2 position has so far proved elusive. 
If acylation of the C-2 position can be affected successfully it would be desirable to 
perform the acylation with a prenyl ester.  By using the ester, the Dieckmann 
condensation could also be performed sequentially.  The released alkoxide from the 
ester addition would then deprotonate the α-proton of the prenyl group and affect 
cyclisation to nemorosone (4) (Scheme 6.2.10). 
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 Scheme 6.2.10 
 
6.3 Conclusions  
It has been shown that there is potential for a new and more expedient route to 
nemorosone (4).  However, at this stage the yields of several steps are modest and 
the final acylation process, which we hoped would lead to the 1,3-diketone bridge, 
has not been accomplished to date.  Although the route has not come to a 
satisfactory completion it is thought that further work could overcome these issues 
and afford a significantly more efficient route to nemorosone (4). 
Most of the reactions discussed in this chapter are not optimised, therefore the yields 
should improve.  There is much scope for adjusting additives and the bases used in 
the initial steps.  The benzoylation could be carried out via O-acylation followed by 
rearrangement to the C-acylated product all in one pot.  This hopefully would improve 
the yield of 1,3-diketone 234 greatly.  Having established that the 1,3-diketone can 
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be made quickly and in large quantities, testing different conditions to favour 
C-acylation with the formate group would become possible.  Even if the reaction 
cannot be made completely C-selective there is the possibility to O-acylate and then 
rearrange to the C-acylated product.  Hopefully using these procedures the triketone 
241 could be made in gram quantities.  If this were the case then testing various 
electrophiles could take place to see if any reactions are possible, and conditions 
could then be optimised to allow installation of the desired acyl group.  It is hoped 
that the resulting tetra ketone would undergo Dieckmann condensation and give a 
new short route to nemorosone (4). 
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Chapter 7 
Experimental 
 
General Procedures. All glassware was flame dried and all reactions were carried 
out under an atmosphere of dry N2 unless otherwise stated.  All reagents were used 
as received from the supplier with the exception of DCM (distilled from calcium 
hydride), THF (distilled from sodium and benzophenone), diisopropylamine (distilled 
from calcium hydride), prenyl bromide (distilled under reduced pressure), benzoyl 
chloride (distilled from quinoline), tetramethylpiperidine (distilled from calcium 
hydride), triethylamine (distilled from calcium hydride). 
 
1H and 13C NMR were performed on Bruker AC270, AC300, AV300, AV400 and 
DMX500 spectrometers.  Chemical shifts (δ) are quoted in ppm, coupling constants 
(J) in Hz.  All spectra are referenced to the CDCl3 peaks at 7.26 ppm for proton and 
77.0 ppm for carbon unless otherwise stated.  The following abbreviations apply: (br) 
broad, (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) multiplet, etc.  IR was 
performed either as a neat oil or as a solid using a Perkin-Elmer Spectrum 100 FTIR 
spectrometer.  Wavelengths (ν) are reported in cm-1.  Optical rotations were recorded 
as dilute solutions in the indicated solvent in 25 mm glass cell using a JASCO 
DIP370 digital polarimeter at 294 nm.  Mass spectra were obtained using a VG 
Micromass 70E or VG Micron Autospec spectrometer.  Melting points were 
performed using a Gallenkamp melting point apparatus and are uncorrected. 
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Reactions were monitored by thin layer chromatography on aluminium plates with 
Keiselgel F254, 0.2mm thick plates.  Visualisation was achieved through UV light 
(254nm) and anisaldehyde.  Flash column chromatography was performed using 
silica gel 60 (230-400 mesh, Merck and Co.).  HPLC was performed using a Dionex 
P580 pump with a Walters 996 photo diode array detector.  Columns and mobile 
phase are as stated.  All reaction temperatures refer to values recorded for an 
external bath and room temperature (rt) implies temperatures in the range 18-25 °C.  
Where it is stated that petrol or petroleum ether was used this refers to 40-60 
petroleum ether.  
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7.1 Experimental for Chapter 2 
(±)-(4R)-3-Methyl-4-(3’-methylbut-2’-enyl)cyclohex-2-enone (89)47 
 
nBuLi (33 mL of a 2.5 M solution in hexane, 78 mmol, 1.1 equiv.) was added to a 
solution of diisopropylamine (11 mL, 78 mmol, 1.1 equiv.) in THF (100 mL) at -78 °C 
and the solution stirred for 10 min.  To this 3-ethoxy-2-cyclohexane (9.6 mL, 
71 mmol) was added and the resulting solution stirred at -78 °C for 10 min.  After this 
time prenyl bromide (10 mL, 86 mmol, 1.2 equiv.) was added dropwise and the 
solution was stirred and allowed to warm to 0 °C over 2 h.  This solution was cooled 
to -40 °C then treated with MeLi (90 mL of a 1.6 M solution in Et2O, 144 mmol, 
2 equiv.) which was added dropwise. The solution was stirred and allowed to warm to 
rt over 3 h and then quenched with 2 M HCl (100 mL) and the mixture stirred for 
30 min.  This was extracted with Et2O (3 x 100 mL), the combined organic layers 
were dried (MgSO4) and the solvent was removed under reduced pressure.  The 
residue was purified by flash column chromatography (gradient of 9:1 to 8:2 
petroleum ether:EtOAc) to afford 89 (11.5 g, 91%) as a pale yellow oil. Rf = 0.32 
(20% EtOAc in petroleum ether); 1H NMR (300 MHz, CDCl3): δ = 5.82 (s, 1H, 
O=CCH=C), 5.09 (t, J = 7, 1H, C=CHCH2), 2.47-1.96 (m, 6H, CH2, CH), 1.95 (s, 3H, 
CH3C(CH)=CH), 1.90-1.76 (m, 1H, CH2), 1.69 (s, 3H, CH3C=CH), 1.60 (s, 3H, 
CH3C=CH); 
13C NMR (68 MHz, CDCl3): δ = 199.6, 165.7, 134.0, 127.0, 121.9, 40.1, 
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34.1, 29.8, 26.6, 25.9, 23.1, 17.9; ESI-HRMS (TOF): m/z calculated for C12H18O 
[M+Na]+: 201.1255; found 201.1243. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(4S,6S)-4,6-Bis(3’-methyl-but-2’-enyl)3-methyl-cyclohex-2-enone (140)47 
 
nBuLi (24.7 mL of a 2.5 M solution in hexane, 68 mmol, 1.1 equiv.) was added to a 
solution of diisopropylamine (8.6 mL 68 mmol, 1.1 equiv.) in THF (50 mL) at -78 °C 
and the solution stirred for 10min.  To this a solution of enone 89 (11.0 g, 62 mmol) 
was added dropwise.  The solution was stirred at -78 °C for 30 min., after which time 
prenyl bromide (7.2 mL, 68 mmol, 1.1 equiv.) was added dropwise.  The mixture was 
stirred and allowed to warm to rt over 3.5 h.  The reaction was quenched with 
saturated aqueous NH4Cl (20 mL) and stirred for a further 10 min.  The mixture was 
extracted with Et2O (3 x 25 mL), the combined organic layers dried (MgSO4) and the 
solvent was removed under reduced pressure. The residue was purified by flash 
column chromatography (gradient of 9:1 to 8:2 petrol ether:EtOAc) to afford 140 and 
246 (12.8 g, 84%) as an inseparable yellow oil.  Rf = 0.38 (20% EtOAc in petroleum 
ether).  Data for major compound 140, minor compound was not isolated separately.  
1H NMR (270 MHz, CDCl3): δ = 5.78 (s, 1H, C=CHC=O), 5.09 (m, 1H, C=CHCH2), 
Chapter 7 Experimental 
 
152 
 
5.03 (m, 1H, C=CHCH2), 2.52 (m, 1H, CHCH2CH), 2.32 (m, 2H, CHCH2CH), 
2.27-2.10 (m, 3H, CHCH2CH, CH2CH(CH2)(C)), 2.01 (m, 1H, CHCH2CH), 1.95-1.90 
(m, 1H, CHCH2CH), 1.93 (s, 3H, CH3C(CH)=CH), 1.70 (s, 3H, CH3C=CH), 1.67 (s, 
3H, CH3C=CH), 1.59 (s, 3H, CH3C=CH), 1.57 (s, 3H, CH3C=CH); 
13C NMR 
(100 MHz, CDCl3): δ = 201.0, 164.5, 133.6, 133.1, 126.3, 122.2, 121.9, 41.7, 39.7, 
31.2, 29.6, 27.8, 25.7 (2 C), 22.8, 17.7 (2 C); ESI-HRMS (TOF): m/z calculated for 
C17H26O [M+Na]
+: 269.1881; found 269.1882. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(4S,6S)-4,6-Bis(3’-methyl-but-2’-enyl)-3,3-dimethyl-cyclohexanone (141)47 
 
To a solution of Me2S (11.25 mL, 152 mmol, 5.6 equiv.) in THF (150 mL), CuI 
(0.515 g, 2.7 mmol, 10 mol%) was added.  This solution was cooled to 0 °C and a 
solution of enone 140 (6.74 g, 27 mmol) in THF (20 mL) was added and the solution 
stirred. To this MeMgBr (11 mL of a 3.1 M in Et2O, 33 mmol, 1.2 equiv.) was added 
dropwise and the solution stirred for a further 3 h and allowed to warm to rt.  The 
reaction was quenched with saturated aqueous NH4Cl (50 mL), and stirred for 10 
min. This was extracted with Et2O (3 x 100 mL), the combined organic layers were 
dried (MgSO4) and the solvent was removed under reduced pressure.  The residue 
was purified by flash column chromatography (9:1 petrol ether:EtOAC) to afford 141 
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(6.55 g, 93%) as a pale yellow oil.  Rf = 0.65 (10% EtOAc in petroleum ether); 
1H 
NMR (270 MHz, CDCl3): δ = 5.08 (t, J = 8, 1H, C=CHCH2), 4.98, (t, J = 8, 1H, 
C=CHCH2), 2.33-1.79 (m, 7H, CCH2C, CH2CH(CH2)(C), CHCH2CH), 1.70 (s, 3H, 
CH3C=CH), 1.66 (s, 3H, CH3C=CH), 1.72-1.64 (m, 2H, CHCH2CH), 1.59 (s, 3H, 
CH3C=CH), 1.57 (s, 3H, CH3C=CH), 1.57-1.55 (m, 1H, CH2CH(CH2)(C)), 0.98 (s, 3H, 
CCH3), 0.87 (s, 3H, CCH3); 
13C NMR (68 MHz, CDCl3): δ = 214.2, 133.3, 132.4, 
123.6, 121.6, 52.3, 48.0, 42.5, 39.1, 31.5, 29.4, 29.0, 27.3, 25.8, 25.8, 23.9, 17.9 
(2C); ESI-HRMS (TOF): m/z calculated for C18H30O [M+H]
+: 263.2369; found 
263.2368. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(4S)-4,6-Bis(3’-methyl-but-2’-enyl)-1-(tert-butyl-dimethyl-silyloxy)-3,3-
dimethyl-cyclohexene (142)47 
 
Ketone 141 (3.79 g, 14.5 mmol) was dissolved in dry MeCN (30 mL).  Freshly 
distilled Et3N (3 mL, 21 mmol, 1.5 equiv.) was added and the solution stirred. NaI 
(3.25 g, 22 mmol, 1.5 equiv.) and TBSCl (3.18 g, 21 mmol, 1.5 equiv.) were added 
and the mixture was heated to reflux for 2 h.  After this time the solvent was removed 
under reduced pressure.  The resulting brown residue was triturated using petroleum 
ether and concentrated to a pale yellow oil, which was purified by flash column 
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chromatography (99:1 petrol:Et2O), to afford 142 (5.42 g, 99%) as a colourless oil.  
Rf  = 0.22 (1% Et2O in petroleum ether); 
1H NMR (300 MHz, CDCl3) δ: = 5.09 (t, J = 
6.6, 1H, C=CHCH2), 5.03 (t, J = 7.0, 1H, C=CHCH2), 2.78 (dd, J = 14.5, 7.0, 1H, 
CHCH2C=C), 2.68 (dd, J = 14.5, 7.0, 1H, CHCH2C=C), 2.10 (d, J = 13.5, 1H, 
CHCH2CH), 1.99 (dd, J = 17.0, 5.5, 1H, CHCH2CH), 1.89 (d, J = 16.5, 1H, CCH2C), 
1.77 (d, J = 16.5, 1H, CCH2C), 1.70 (s, 6H, CH3C=CH), 1.70-1.58 (m, 2H, 
CHCH2CH), 1.62 (s, 3H, CH3C=CH), 1.59 (s, 3H, CH3C=CH), 1.22 (m, 1H, 
CH2CH(CH2)(C)), 0.95 (s, 9H, (CH3)3CSi), 0.93 (s, 3H,CH3C), 0.85 (s, 3H, CH3C), 
0.12 (s, 6H, (CH3)2Si); 
13C NMR (100 MHz, CDCl3) δ: = 141.4, 132.1, 131.7, 131.6, 
124.5, 123.0, 114.4, 113.1, 55.6, 45.0, 43.4, 33.6, 30.6, 28.9, 28.6, 28.0, 26.0, 25.9, 
25.8, 22.5, 18.3, 17.9, -3.6 (2C); ESI-HRMS (TOF): m/z calculated for C24H44OSi 
[M+Na]+: 399.3059; found 399.3042. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(5R,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-4-hydroxy-
bicyclo[3.3.1]non-3-ene-2,9-dione (143)47 
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A solution of the silyl enol ether 142 (0.954 g, 2.6 mmol) in Et2O (15 mL) was cooled 
to -20 °C (dry ice/CCl4 bath).  To this solution malonyl dichloride (246 µL, 2.6 mmol, 
1 equiv.) was added dropwise.  The mixture was stirred for 24 h at -20 °C.  After this 
time benzyltriethylammonium chloride (33.8 mg, 0.15 mmol, 0.06 equiv.) was added, 
followed by a solution of KOH (0.654 g, 11.7 mmol, 4.5 equiv.) in H2O (1 mL).  The 
mixture was stirred and allowed to warm to rt then stirred for a further 5 h.  This 
solution was then diluted with H2O (25 mL) and petroleum ether (25 mL).  The pH 
was adjusted to ~10 with 2 M NaOH.  This was extracted with petroleum ether 
(2 x 25 mL), the combined organic layers were dried (MgSO4) and the solvent was 
removed under reduced pressure to afford impure ketone 141 (0.580 g, 83%). 
The aqueous layer was cooled to 0 °C and carefully acidified with 2 M HCl.  This was 
extracted with DCM (4 x 25 mL), combined organic layers were dried (MgSO4) and 
solvent removed under reduced pressure, to afford 143 (301 mg) of crude yellow oil 
which was used without further purification.  
  
(±)-(5R,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-4-methoxy-
bicyclo[3.3.1]non-3-ene-2,9-dione (145)47 
 
To a solution of bicyclo[3.3.1]nonane 143 (300 mg, 1 mmol) in MeOH (7 mL), PTSA 
(17.4 mg, 0.1 mmol, 0.1 equiv.) in trimethyl orthoformate (3 mL, 27 mmol, 27 equiv.) 
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was added.  The mixture was heated to 50 °C for 38 h then cooled to rt and two 
drops of Et3N were added. The solvent was removed under reduced pressure.  The 
residue was purified by flash column chromatography (8:2 petrol:EtOAc) to afford 
145 (95.2 mg 11% yield over two steps) as a pale yellow solid.  m.p. = 71-74 °C; 
Rf = 0.35 (20% EtOAc in petroleum ether); 
1H NMR (270 MHz, CDCl3): δ = 5.73 (s, 
1H, C=CHCOMe), 4.98 (m, 2H, C=CH-CH2), 3.76 (s, 3H, CH3O), 2.84 (s, 1H, C3CH), 
2.42 (m, 2H, CHCH2C), 2.10 (m, 1H, CHCH2CH), 1.93 (d, J = 13.7, 1H, CCH2CH), 
1.72-1.61 (m, 2H, CHCH2CH, (CH2)2CHC), 1.70 (s, 3H, CH3C=C), 1.66 (s, 3H, 
CH3C=C), 1.65 (s, 3H, CH3C=C), 1.57 (s, 3H, CH3C=C), 1.37 (t, 1H, CCH2CH), 1.10 
(s, 3H, CH3C), 0.86 (s, 3H, CH3C); 
13C NMR (100 MHz, CDCl3): δ = 206.6, 193.8, 
177.8, 133.7, 133.1, 122.5, 119.3, 106.1, 74.6, 57.1, 56.8, 42.9, 40.7, 39.3, 29.6, 
27.6, 26.6, 25.9, 25.8, 20.7, 17.9, 17.8; ESI-HRMS (TOF): m/z calculated for 
C22H32O3 [M+H]
+: 345.2424; found 345.2420. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(5R,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-2-methoxy-
bicyclo[3.3.1]non-2-ene-4,9-dione (144) and (±)-(5R,7S)-5,7-Bis(3’-methyl-but-2’-
enyl)-8,8-dimethyl-4-methoxy-bicyclo[3.3.1]non-3-ene-2,9-dione (145)47 
 
Crude cyclic triketone 143 (450 mg, 1.3 mmol) was dissolved in acetone (25 mL).  To 
this K2CO3 (0.965 g, 6.5 mmol, 5 equiv.) was added followed by Me2SO4 (129 μL, 
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1.3 mmol, 1 equiv.).  This mixture was refluxed for 2 h and allowed to cool to rt.  The 
solid was removed by filtration and the solvent was removed under reduced 
pressure. The residue was purified by flash column chromatography (gradient of 9:1 
to 8:2 petrol:EtOAC) to afford 144 and 145 (219 mg, 32% over two steps) as a white 
solid of the mixed regioisomers in a 6:1 ratio. 
Major isomer (144) 
m.p. = 94-96 °C; Rf = 0.53 (20% EtOAc in petroleum ether); 
1H NMR (270 MHz, 
CDCl3): δ = 5.72 (s, 1H, C=CH-COMe), 4.98 (m, 2H, C=CH-CH2), 3.76 (s, 3H, 
CH3O), 2.83 (s, 1H, C3CH), 2.42 (m, 2H, CHCH2C), 2.06 (m, 1H, CHCH2CH), 1.93 
(dd, J = 13.0, 4.0, 1H, CCH2CH), 1.68 (s, 6H CH3C=CH), 1.64 (s, 3H CH3C=CH), 
1.72-1.59 (m, 2H, CHCH2CH, (CH2)2CHC), 1.58 (s, 3H, CH3C=CH), 1.35 (m, 1H, 
CCH2CH), 1.04 (s, 3H, CH3C), 0.92 (s, 3H CH3C); 
13C NMR (100 MHz, CDCl3): δ = 
207.5, 197.7, 174.4, 133.7, 133.1, 122.4, 119.8, 105.9, 65.9, 63.9, 56.4, 41.8, 40.8, 
39.7, 29.4, 28.1, 27.1, 25.9, 25.8, 20.5, 18.0, 17.9; ESI-HRMS (TOF): m/z calculated 
for C22H32O3 [M+H]
+: 345.2424; found 345.2425. 
Minor isomer as 145 above. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(5S,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-2-methoxy-3-
trimethylsilyl-bicyclo[3.3.1]non-2-ene-4,9-dione (173) 
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LiTMP (22.6 mL of a 0.5 M solution in THF, 11.3 mmol, 2 equiv.) was added 
dropwise to a solution of O-methylated trione 144 (1.95 g, 5.7 mmol) in THF (60 mL) 
at -78 °C.  The reaction mixture was stirred for 5 min. before addition of 
chlorotrimethylsilane (2.87 mL, 22.6 mmol, 4 equiv.).  The reaction mixture was 
stirred and allowed to warm to -40 °C over 2 h before quenching with saturated 
aqueous NH4Cl (30 mL). This was extracted with Et2O (3 × 40 mL), the combined 
organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure.  The residue was purified by flash column chromatography (9:1 
petrol:Et2O) to afford vinylsilane 173 (2.21 g, 94%) as a white solid.  m.p. = 46-48 °C; 
Rf = 0.34 (10% EtOAc in petroleum ether); FTIR (neat) 2975, 2911, 1731, 1641, 
1560, 1447, 1219, 1057, 842 cm-1; 1H NMR (500 MHz, CDCl3): δ = 4.96-4.92 (m, 2H, 
C=CHCH2), 3.73 (s, 3H, OCH3), 3.22 (s, 1H, HC-1), 2.40 (dd, J = 14.3, 7.7, 1H, 
CHCH2C), 2.32 (dd, J = 14.3, 7.7, 1H, CHCH2C), 2.04 (dd, J = 13.2, 5.1, 1H, 
CHCH2C), 1.91 (dd, J = 13.2, 4.0, 1H, CCH2CH), 1.66 (s, 3H, CH3C=CH), 1.63 (s, 
3H, CH3C=CH), 1.60 (t, J = 13.2, 1H, CHCH2C), 1.59 (s, 3H, CH3C=CH), 1.53 (s, 3H, 
CH3C=CH), 1.54-1.51 (m, 1H, CH2CH(CH2)(C)), 1.28 (app. t, J = 12.8, 1H, CCH2CH), 
1.09 (s, 3H, CH3C), 0.94 (s, 3H, CH3C), 0.16 (s, 9H, CH3Si); 
13C NMR (125 MHz, 
CDCl3): δ = 208.4, 201.9, 177.9, 133.6, 133.2, 123.5, 122.3, 119.6, 63.7, 61.1, 55.8, 
42.8, 41.0, 39.4, 29.6, 27.9, 25.8, 25.73, 25.72, 20.9, 18.0, 17.8, 0.33 (3C); 
ESI-HRMS (TOF): m/z calculated for C25H40O3Si [M+H]
+: 417.2820; found 417.2823.  
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(±)-(1S,5R,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-1-iodo-2-methoxy-3-
trimethylsilyl-bicyclo[3.3.1]non-2-ene-4,9-dione (176) and 
(±)-(5S,7S,9S)-5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-2-methoxy-3-
(trimethylsilyl)-9-((trimethylsilyl)oxy)bicyclo[3.3.1]non-2-en-4-one (247) 
 
To a solution of TMS protected enone 173 (253 mg, 0.61 mmol,) and 
chlorotrimethylsilane (0.31 mL, 2.44 mmol, 4 equiv.) in THF (2 mL) at -78 °C, LDA 
(4.9 mL of a 0.5 M solution in THF, 2.44 mmol, 4 equiv.) was added dropwise.  The 
reaction mixture was stirred at -78 °C for 10 min. before warming to 0 °C over 30 min.  
The reaction mixture was then cooled to -78 °C and a solution of iodine (0.709 g, 
5.5 mmol, 9 equiv.) in THF (2 mL) was added.  The reaction mixture was stirred at 
-78 °C for 10 min. before stirring at 0 °C for 30 min.  The reaction mixture was diluted 
with EtOAc (20 mL), washed with saturated aqueous Na2SO3 (3 × 10 mL) and brine 
(3 × 10 mL).  The combined organic layers were dried (MgSO4) and the solvent was 
removed under reduced pressure.  The residue was purified by flash column 
chromatography (95:5 petrol:EtOAc) to afford bridgehead iodide 176 (214 mg, 65%) 
as a white solid and by-product 247 (177 mg, 8%) as a white solid. 
Major (176) 
m.p. = 59-61 °C; Rf = 0.5 (10% EtOAc in petroleum ether); FTIR (neat) 2976, 1734, 
1654, 1548, 1437, 1250, 1034, 848, 758 cm-1; 1H NMR (500 MHz, CDCl3): δ = 5.04 
(t, J = 7.2, 1H, C=CHCH2), 4.95 (t, J = 7.2, 1H, C=CHCH2), 3.92 (s, 3H, CH3O), 2.46-
Chapter 7 Experimental 
 
160 
 
2.38 (m, 2H, CHCH2C), 2.17 (dd, J = 13.4, 5.3, 1H, CHCH2CH), 1.80-1.73 (m, 2H, 
CH2CH(CH2)(C), CCH2CH), 1.69-1.63 (m, 1H, CHCH2CH), 1.62 (s, 3H, CH3C=CH), 
1.60 (s, 6H, CH3C=CH), 1.51 (s, 3H, CH3C=CH), 1.39 (app. t, J = 14.3, 1H, 
CCH2CH), 1.23 (s, 3H, CH3C), 0.88 (s, 3H, CH3C), 0.22 (s, 9H, CH3Si); 
13C NMR 
(125 MHz, CDCl3): δ = 200.0, 199.9, 178.9, 134.0, 133.4, 125.2, 122.2, 119.6, 86.0, 
65.6, 65.5, 47.7, 40.9, 38.9, 30.4, 30.2, 29.0, 25.8, 25.6, 20.6, 17.9, 17.8, 0.3 (3C); 
ESI-HRMS (TOF): m/z calculated for C25H39IO3Si [M+H]
+: 543.1791; found 543.1779. 
By-product (247) 
m.p. = 159-160 °C; Rf = 0.66 (20% EtOAc in petroleum ether); FTIR (neat) 2954, 
1632, 1564, 1465, 1447, 1385, 1332, 1249, 1089, 952, 835 cm-1; 1H (300 MHz, 
CDCl3)  δ = 4.95 (dd, J = 6.3, 1H, C=CHCH2), 4.81 (dd, J = 6.5, 1H, C=CHCH2), 4.01 
(d, J = 2.3, 1H, OCH(C)(CH)), 3.70 (s, 3H, CH3O), 2.65 (d, J = 3.0, 1H, HC-1), 2.43 
(dd, J = 14.3, 6.4, 1H, CHCH2C), 2.07-1.94 (m, 2H, CHCH2C), 1-70-1.50 (m, 3H, 
CHCH2C, CCH2CH, CH2CH(CH2)(C)), 1.65 (s, 3H, CH3C=CH), 1.61 (s, 3H, 
CH3C=CH), 1.59 (s, 3H, CH3C=CH), 1.55 (s, 3H, CH3C=CH), 1.40 (dd, J = 12.9, 1H, 
CCH2CH), 1.13 (s, 3H, CH3C), 0.92 (s, 3H, CH3C), 0.15 (s, 9H, CH3Si), 0.14 (s, 9H, 
CH3Si); 
13C (100 MHz, CDCl3) δ = 206.2, 181.8, 132.4, 131.5, 123.1, 120.4, 119.2, 
70.8, 54.6, 51.8, 48.9, 39.3, 34.7, 32.0, 30.9, 28.3, 27.5, 25.3, 25.2, 23.7, 17.6, 17.3, 
0.0 (3C), -0.3 (3C); ESI-HRMS (TOF): m/z calculated for C28H50O3Si2 [M+Na]
+: 
513.3196; found 513.3199. 
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(±)-(1R,5S,7S)-1-Benzoyl-5,7-bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-2-methoxy-
3-trimethylsilyl-bicyclo[3.3.1]non-2-ene-4,9-dione (174) 
 
nBuLi (0.57 mL of a 2.5 M solution in hexane, 1.42 mmol, 1.2 equiv.) was added 
dropwise to a solution of bridgehead iodide 176 (0.643 g, 1.19 mmol) in THF (9 mL) 
at -78 °C.  The reaction mixture was stirred at -78 °C for 5 min. before addition of 
benzoyl chloride (159 μL, 1.42 mmol, 1.2 equiv.) dropwise.  The reaction mixture was 
stirred for 1 h at -78 °C and at rt for 30 min. before quenching with saturated aqueous 
NH4Cl (10 mL). This was extracted into Et2O (3 × 15 mL), the combined organic 
layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (9:1 petrol:Et2O) to afford 
the bridgehead benzoylated product 174 (446 mg, 72%) as a white solid.  m.p. = 
104-106 °C; Rf = 0.42 (20% Et2O in petroleum ether); FTIR (neat)
 2915, 1721, 1703, 
1650, 1559 (s), 1446, 1391, 1247, 1063, 848 cm-1; 1H NMR (500 MHz, CDCl3): δ = 
7.58 (d, J = 7.4, 2H, Hortho-ar), 7.41 (t, J = 7.4, 1H, Hpara-ar), 7.29 (t, J = 7.8, 2H, 
Hmeta-ar), 5.07 (t, J = 7.1, 1H, C=CHCH2), 4.99 (t, J = 7.8, 1H, C=CHCH2)  3.46 (s, 3H, 
CH3O), 2.52 (dd, J = 14.5, 7.45, 1H, CCH2C(H)=), 2.44 (dd, J = 14.0, 7.2, 1H, 
CCH2C(H)=), 2.13 (dd, J = 11.3, 5.1, 1H, CHCH2CH), 1.94 (dd, J = 13.4, 3.9, 1H, 
CCH2CH), 1.67 (s, 3H,CH3C=CH), 1.66 (s, 6H, CH3C=CH), 1.65 (m, 2H, CHCH2CH, 
CH2CH(C)(CH2)) 1.55 (s, 3H, CH3C=CH), 1.45 (dd, J = 12.6, 1H, CCH2CH), 1.36 (s, 
3H, CH3C=C), 1.18 (s, 3H, CH3C=C), 0.23 (s, 9H, (CH3)3Si); 
13C NMR (125 MHz, 
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CDCl3): δ = 208.2, 200.7, 193.1, 181.2, 137.0, 134.3, 133.4, 132.1, 128.5 (2C), 127.9 
(2C), 122.9, 122.4, 119.7, 75.0, 66.0, 64.1, 48.2, 43.4, 42.5, 29.4, 27.5, 26.0, 25.7, 
24.6, 18.1, 17.8, 16.3, 0.81 (3C); ESI-HRMS (TOF): m/z calculated for C32H44O4 
[M+H]+: 521.3082; found 521.3104. 
By-product (207) was isolated (53 mg, 9%) as a clear oil.  Rf = 0.83 (20% EtOAc in 
petroleum ether); 1H NMR (400 MHz, CDCl3): δ = 5.43 (t, J = 7.8, 1H, C=CHCH2), 
4.95 (t, J = 7.0, 1H, C=CHCH2), 3.76 (s, 3H, CH3O), 2.53 (s, 1H, HC-1), 2.40-2.35 
(m, 2H, CHCH2C), 2.10-2.02 (m, 1H, CHCH2CH), 1.86 (dd, J = 13.1, 1H, CCH2CH), 
1.86 (s, 1H, HO), 1.78-1.58 (m, 3H, CH2CH(C)(CH2), CHCH2CH, CCH2CH), 1.70 (s, 
3H, CH3C=CH), 1.63 (s, 6H, CH3C=CH), 1.54 (s, 3H, CH3C=CH), 1.52-1.20 (m, 6H, 
Buchain), 1.17 (s, 3H, CH3C), 0.90 (s, 3H, CH3C), 0.86 (t, J = 7.3, 3H, CH3CH2), 0.14 
(s, 9H); 13C NMR (100 MHz, CDCl3): δ = 205.7, 182.0, 133.1, 131.6, 123.0, 121.1, 
118.2, 78.4, 54.9, 54.3, 49.1, 38.9, 37.9, 35.4, 32.1, 30.3, 28.0, 27.0, 25.6, 25.1, 24.2 
(2C), 22.7, 17.4, 17.2, 13.2, 0.0 (3C); ESI-HRMS (TOF): m/z calculated for 
C29H50O3Si [M+Na]
+: 497.3427; found 497.3434. 
 
(±)-(1R,5R,7S)-1-Benzoyl-5,7-bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-2-methoxy-
bicyclo[3.3.1]non-2-ene-4,9-dione (178) 
 
A solution of TBAF (0.33 mL of a 1 M solution in THF, 0.33 mmol, 1.5 equiv.) was 
added to a solution of 174 (117 mg, 0.22 mmol) in THF (3 mL) at -78 °C.  The 
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reaction mixture was allowed to warm to rt over 1.5 h before quenching with 
saturated aqueous NH4Cl (10 mL).  The product was extracted with Et2O (3 × 15 mL), 
the combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure. The residue was purified by flash column chromatography 
(CH2Cl2) to afford the benzoylated product 178 (80 mg, 81%) as a white solid. m.p. = 
141-142 °C (sublim.); Rf = 0.40 (8:2 petrol:EtOAc); FTIR (neat) 2931, 1720, 1655, 
1606, 1445, 1344, 1237, 1218 cm-1; 1H NMR (500 MHz, CDCl3): δ = 7.59 (d, J = 7.3, 
2H, Hortho-ar), 7.42 (t, J = 7.3, 1H, Hpara-ar), 7.27 (app. t, J = 7.9, 2H, Hmeta-ar), 5.94 (s, 
1H, C=CHC(=O)), 5.00 (t, J = 7.0, 1H, C=CHCH2), 4.96 (t, J = 7.0, 1H, C=CHCH2), 
3.50 (s, 3H, CH3O), 2.56 (dd, J = 14.3, 7.0, 1H, CCH2CH), 2.44 (dd, J = 14.2, 7.2, 
1H, CCH2CH), 2.12 (dd, J = 13.2, 5.1, 1H, CHCH2CH), 1.98 (dd, J = 13.2, 4.4, 1H, 
CCH2CH), 1.79-1.72 (m, 1H, CH2CH(C)(CH2)), 1.71-1.62 (m, 1H, CHCH2CH), 1.66 
(s, 3H, CH3C=CH), 1.65 (s, 3H, CH3C=CH), 1.64 (s, 3H, CH3C=CH), 1.55 (s, 3H, 
CH3C=CH), 1.45 (app. t, J = 13.0, 1H, CCH2CH), 1.34 (s, 3H, CH3C), 1.18 (s, 3H, 
CH3C); 
13C NMR (125 MHz, CDCl3): δ = 207.3, 196.1, 192.5, 173.8, 137.0, 134.4, 
133.3, 132.1, 127.92 (2C), 127.91 (2C), 122.3, 119.5, 106.5, 72.4, 65.6, 56.5, 47.5, 
42.6, 42.5, 29.0, 27.7, 25.9, 25.8, 24.3, 18.1, 17.8, 15.8; ESI-HRMS (TOF): m/z 
calculated for C29H36O4 [M+H]
+: 449.2692; found 449.2691.   
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(±)-(1R,5R,7S)-1-Benzoyl-8,8-dimethyl-2-methoxy-3,5,7-tris(3’-methyl-but-2’-
enyl)-bicyclo[3.3.1]non-2-ene-4,9-dione (157) 
 
LiTMP (2.6 mL of a 0.1 M solution in THF, 0.26 mmol, 2 equiv.) was added to a 
solution of enone 178 (58.9 mg, 0.13 mmol) in THF (2 mL) at -78 °C and stirred for 
10 min.  The reaction mixture was stirred for a further 30 min. at -40 °C before 
addition of Li(2-Th)CuCN (2.6 mL of a 0.1 M solution in THF, 0.26 mmol, 2 equiv.).  
The reaction mixture was stirred at -78 °C for 10 min. and at -40 °C for 30 min.  The 
reaction mixture was then cooled to -78 °C and prenyl bromide (0.077 mL, 
0.66 mmol, 5 equiv.) was added.  The reaction mixture was warmed to 0 °C over 3 h 
before quenching with NH4Cl/NH4OH(aq) (10% w/w, 20 mL).  This was extracted with 
Et2O (3 × 20 mL), the combined organic layers were dried (MgSO4) and the solvent 
was removed under reduced pressure.  The residue was purified by flash column 
chromatography (1:1 DCM:petrol) to afford O-methylated nemorosone 157 (50 mg, 
75%) as a colourless oil.  Rf = 0.35 (20% Et2O in petroleum ether); FTIR (neat) 2914, 
1721, 1702, 1655, 1598, 1446, 1240, 690 cm-1; 1H (500 MHz, CDCl3): δ = 7.62 (d, J = 
7.3, 2H, Hortho-ar), 7.44 (t, J = 7.3, 1H, Hpara-ar), 7.30 (t, J = 7.9, 2H, Hmeta-ar), 5.02 (t, J = 
6.5, 1H, C=CHCH2), 5.01 (t, J = 6.5, 1H, C=CHCH2), 4.95-4.90 (m, 1H, C=CHCH2), 
3.46 (s, 3H, CH3O), 3.34 (dd, J = 15.8, 6.6, 1H, CHCH2C), 3.23 (dd, J = 15.8, 6.2, 
1H, CHCH2C), 2.58 (dd, J = 13.9, 6.6, 1H, CHCH2C), 2.48 (dd, J = 13.9, 7.3, 1H, 
CHCH2C), 2.14-2.08 (m, 1H, CHCH2CH), 1.95 (dd, J = 13.0, 3.9, 1H, CCH2CH), 
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1.72-1.64 (m, 2H, CHCH2CH, CH2CH(CH2)(C)), 1.69 (s, 3H, CH3C=CH) 1.68 (s, 12H, 
CH3C=CH), 1.56 (s, 3H, CH3C=CH), 1.45 (t, J = 12.8, 1H, CCH2CH), 1.35 (s, 3H, 
CH3C), 1.19 (s, 3H, CH3C); 
13C (125 MHz, CDCl3): δ = 207.9, 197.1, 193.1, 169.9, 
137.0, 134.4, 133.2, 133.0, 132.0, 128.4 (2C), 127.9 (2C), 123.2, 122.5, 121.5, 
119.7, 74.0, 65.1, 61.5, 47.8, 43.1, 42.5, 29.5, 27.7, 26.0, 25.8, 25.6, 24.4, 23.2, 
18.1, 18.0, 17.8, 16.2; ESI-HRMS (TOF): m/z calculated for C34H44O4 [M+H]
+: 
517.3312; found 517.3305. 
Enantiomers separated by chiral HPLC: 1.5% MeOH in hexane on Lux cellulose II 
column 14.11, 18.13 min. 
[α]D
22 = -133 (c 0.018, MeOH) (component 1 from HPLC). 
[α]D
22 = +139 (c 0.018, MeOH) (component 2 from HPLC). 
 
Nemorosone (4) 
 
O-Methylated nemorosone (157) (41 mg, 79 μmol) and lithium chloride (29 mg, 
0.68 mmol) were dissolved in d6-DMSO (0.75 mL) and heated to 120 °C for 2 h.  The 
reaction mixture was then cooled to rt diluted with H2O (5 mL) and extracted with 
Et2O (3 × 5 mL). The combined organic layers were washed with brine (5 mL) and 
dried (MgSO4) and the solvent was removed under reduced pressure to afford 
nemorosone 4 (39 mg, quant.) as a colourless oil which did not require further 
purification. Rf = 0.7 (DCM) ; FTIR (neat) 3400, 2923, 1722, 1699, 1626, 1597, 1447, 
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1373, 1223 cm-1; 1H NMR (500 MHz, d4-methanol): δ = 7.58 (d, J = 8.4, 2H, H
ortho-ar), 
7.47 (t, J = 7.3, 1H, Hpara-ar), 7.29 (t, J = 7.7, 2H, Hmeta-ar), 5.12 (t, J = 7.3, 1H, 
C=CHCH2), 5.06-5.02 (m, 2H, C=CHCH2), 3.17 (dd, J = 14.7, 7.3, 1H, CHCH2C), 
3.12 (dd, J = 14.7, 7.3, 1H, CHCH2C), 2.57 (dd, J = 14.3, 7.0, 1H, CHCH2C), 2.52 
(dd, J = 14.3, 7.0, 1H, CHCH2C), 2.21-2.17 (m, 1H, CHCH2CH), 2.06 (dd, J = 13.6, 
3.7, 1H, CCH2CH), 1.82-1.74 (m, 2H, CHCH2CH, CH2CH(CH2)(C)), 1.72 (s, 3H, 
CH3C=C), 1.693 (s, 3H, CH3C=C), 1.685 (s, 9H, CH3C=C), 1.63 (s, 3H, CH3C=C), 
1.47 (app. t, J = 13.2, 1H, CCH2CH), 1.37 (s, 3H, CH3C), 1.14 (s, 3H, CH3C).  The 
resonance for the hydroxy proton could not be identified in the 1H NMR spectrum.  
13C NMR (125 MHz, d4-methanol): δ = 209.5, 195.1, 138.4, 135.3, 134.3, 133.7, 
133.2, 129.7 (2C), 128.9 (2C), 124.1, 122.4, 121.3, 121.0, 78.2, 62.1, 49.1, 44.8, 
42.4, 30.6, 28.4, 26.4, 26.18, 26.16, 24.5, 22.5, 18.5, 18.3, 18.1, 16.4.  The 
resonances for C-2 and C-4 could not be identified in the 13C NMR spectrum due to 
tautomeric exchange. ESI-HRMS (TOF): m/z calculated for C33H42O4 [M+H]
+: 
503.3161; found 503.3159. 
[α]D
22 = -77 (c 0.024, MeOH) (component 1 from O-Meth Nem (157) HPLC). 
[α]D
22 = +86 (c 0.022, MeOH) (component 2 from O-Meth Nem (157) HPLC). 
Lit [α]D
23 = +113 (c 0.1, CHCl3)
54 
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7.2 Experimental for Chapter 3 
(±)-3-Methoxy-2-(3’-methylbut-2’-enyl)cyclohex-2-enone (99)47 
 
Known enol ether 197 (5.69 g, 32 mmol) was dissolved in acetone (180 mL) and to 
this was added potassium carbonate (21.83 g, 158 mmol, 5 equiv.) followed by 
dimethyl sulphate (3.6 mL, 38 mmol, 1.2 equiv).  The mixture was heated to reflux for 
3 h, allowed to cool and the solid removed by filtration. The solvent was removed 
under reduced pressure.  The residue was purified by flash column chromatography 
(8:2 petrol:EtOAc) to afford 99 (3.78 g, 61%) as a pale yellow oil.  Rf = 0.11 (20% 
EtOAc in petroleum ether); 1H NMR (300 MHz, CDCl3): δ = 5.05 (t, J = 7.2, 1H, 
C=CHCH2), 3.81 (s, 3H, CH3O), 2.96 (d, J = 7.0, 2H, CHCH2C), 2.57 (t, J = 6.3, 2H, 
CCH2CH2), 2.33 (t, J = 7.0, 2H, CH2CH2C), 2.05-1.94 (m, 2H, CH2CH2CH2), 1.70 (s, 
3H, CH3C=C), 1.65 (s, 3H, CH3C=C); 
13C NMR (68 MHz, CDCl3): δ = 198.0, 171.6, 
131.1, 122.7, 119.1, 55.1, 36.4, 25.7, 24.8, 21.2, 20.8, 17.7; ESI-HRMS (TOF): m/z 
calculated for C12H18O2 [M+Na]
+: 217.1199; found 217.1203. 
Data were in accord with that of Dr. Rodeschini.47 
 
 
 
 
 
Chapter 7 Experimental 
 
168 
 
(±)-(6R)-2,6-Bis(3’-methylbut-2’-enyl)-3-methoxycyclohex-2-enone (100)47 
 
nBuLi (8.6 mL of a 2.5 M solution in hexane, 21.4 mmol, 1.1 equiv.) was added to a 
solution of diisopropylamine (3 mL, 21.4 mmol, 1.1 equiv.) in THF (100 mL) at -78 °C 
and the solution stirred for 10 min. To this methyl enol ether 99 (3.78 g, 19.4 mmol) 
was added and the resulting solution was stirred at this temperature for 30 min.  After 
this time prenyl bromide (2.7 mL, 23.3 mmol, 1.2 equiv.) was added dropwise and the 
solution was stirred and allowed to warm to rt over 3 h before quenching with 
saturated aqueous NH4Cl. This was extracted with Et2O (3 x 75 mL), the combined 
organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure to afford 100 (5.48 g) of crude yellow oil which was used without further 
purification.  Rf = 0.36 (20% EtOAc in petroleum ether); 
1H NMR (300 MHz, CDCl3):  
δ = 5.11 (t, J = 7.35, 1H, C=CHCH2), 5.04 (t, J = 7.17, 1H, C=CHCH2), 3.80 (s, 3H, 
CH3O), 3.03-2.88 (m, 2H, CHCH2C), 2.69-2.42 (m, 3H, CHCH2CH, CCH(CH2)2), 
2.22-1.99 (m, 3H, CH2CH2CH, CCH2CH2), 1.71 (s, 6H, CH3C=C), 1.67 (m, 1H, 
CH2CH2CH), 1.65 (s, 3H, CH3C=C), 1.62 (s, 3H, CH3C=C); 
13C NMR (100 MHz, 
CDCl3): δ = 199.5, 170.7, 133.0, 130.8, 122.8, 122.1, 118.4, 54.9, 44.9, 28.2, 25.7, 
25.6, 25.3, 23.8, 21.5, 17.7, 17.6; ESI-HRMS (TOF): m/z calculated for C17H26O2 
[M+H]+: 263.2006; found 263.2012. 
Data were in accord with that of Dr. Rodeschini.47 
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(±)-(4R)-2,4-Bis(3’-methylbut-2’-enyl)-3-methylcyclohex-2-enone (110)47 
 
100 (5.48 g, ~21 mmol) was dissolved in THF (50 mL).  The solution was cooled to 
-78 °C and treated with MeLi (19.6 mL of a 1.6 M solution, 31.3 mmol, ~1.5 equiv.).  
The reaction was stirred and allowed to warm to rt over 3 h, after which time 1 M HCl 
(40 mL) was added and the mixture stirred for 10 min.  This was extracted with Et2O 
(3 x 50 mL), combined organic layers were dried (MgSO4) and solvent removed 
under reduced pressure.  The mixture was purified by flash column chromatography 
(9:1 petrol:Et2O) to afford 110 (4.22 g, 88% over two steps) as a yellow oil.  Rf = 0.62 
(20% EtOAC in petroleum ether); 1H NMR (300 MHz, CDCl3): δ = 5.17-5.09 (m, 1H, 
C=CHCH2), 4.95-4.86 (m, 1H, C=CHCH2), 3.08-2.90 (m, 2H, CHCH2C), 2.56-2.41 
(m, 1H, CCH(CH2)2), 2.38-2.12 (m, 4H, CHCH2CH, CCH2CH2), 2.07-1.97 (m, 1H, 
CH2CH2CH), 1.95 (s, 3H, CH3C=C), 1.89-1.78 (m, 1H, CH2CH2CH), 1.73 (s, 3H, 
CH3C=C), 1.71 (s, 3H, CH3C=C), 1.67 (s, 3H, CH3C=C), 1.63 (s, 3H, CH3C=C); 
13C 
NMR (68 MHz, CDCl3): δ = 198.2, 158.8, 134.9, 133.6, 131.4, 122.4, 122.1, 41.7, 
33.8, 29.7, 25.8, 25.7, 25.5, 24.5, 20.0, 17.8 (2C); ESI-HRMS (TOF): m/z calculated 
for C17H26O [M+Na]
+: 269.1881; found 269.1860. 
Data were in accord with that of Dr. Rodeschini.47 
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(±)-(2S,4R)-Bis(3’-methylbut-2’-enyl)-3,3-dimethylcyclohexanone (111) and (±)-
(2R,4R)-Bis(3’-methylbut-2’-enyl)-3,3-dimethylcyclohexanone (112) 
 
A suspension of CuBr.Me2S (181 mg, 0.88 mmol, 0.5 equiv.) in THF (100 mL) was 
cooled to -78 °C.  This solution was treated with MeMgBr (14.2 mL of a 3 M solution, 
43 mmol, 2.5 equiv.) and HMPA (6 mL, 34 mmol, 2 equiv.) and was stirred for 
10 min.  After which time a solution of enone 110 (4.22 g, 17 mmol) and TMSCl 
(4.4 mL, 34 mmol, 2 equiv.) in THF (17 mL) was added to the reaction mixture.  The 
solution was stirred and allowed to warm to rt over 2.5 h before quenching with 2 M 
HCl (~40 mL).  This was extracted with Et2O (3 x 50 mL), the combined organic 
layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
The mixture was purified by flash column chromatography (9:1 petrol:Et2O) to afford 
111 and 112 (3.61 g, 81%) as a yellow oil which were not separated.  Rf = 0.5 (10% 
EtOAc in petroleum ether). 
Major (111) 
1H NMR (300 MHz, CDCl3): δ = 5.13 (m, 1H, C=CHCH2), 5.04 (m, 1H, C=CHCH2), 
2.39 (m, 1H, CHCH2CH), 2.32 (m, 2H, CCH2CH2), 2.23 (m, 1H, CHCH2CH), 2.17 (dd, 
J = 9.5, 2.0, 1H, CH2CH(C)2), 2.08-1.99 (m, 2H, CHCH2CH, CH2CH2CH), 1.71 (s, 3H, 
CH3C=C), 1.69 (m, 1H, CHCH2CH), 1.63 (s, 6H, CH3C=C), 1.60 (s, 3H, CH3C=C), 
1.55 (m, 1H, CCH(CH2)2), 1.41 (m, 1H, CHCH2CH2), 1.15 (s, 3H, CH3C), 0.63 (s, 3H, 
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CH3C); 
13C NMR (100 MHz, CDCl3): δ = 212.4, 132.5, 131.5, 124.3, 123.7, 62.0, 
48.2, 43.4, 42.5, 29.2, 28.6, 26.8, 25.8, 25.7, 21.9, 17.8, 17.7, 15.4; ESI-HRMS 
(TOF): m/z calculated for C18H30O [M+H]
+: 263.2369; found 263.2368. 
Minor (112) 
1H NMR (300 MHz, CDCl3): δ = 5.14 (m, 1H, C=CHCH2), 4.96 (m, 1H, C=CHCH2), 
2.34 (m, 2H, CH2CH2C, CHCH2CH), 2.21 (m, 3H, CCH2CH, CH2CH2C, CHCH2CH), 
2.05 (dd, J = 11.0, 4.0, 1H, CCH(CH2)(C)), 1.97 (m, 1H, CHCH2CH2), 1.83 (m, 1H, 
CHCH2CH), 1.72 (s, 3H, CH3C=C), 1.67 (m, 1H, CCH(CH2)2), 1.65 (s, 3H, CH3C=C), 
1.62 (s, 3H, CH3C=C), 1.60 (s, 3H, CH3C=C), 1.51 (m, 1H, CHCH2CH2), 0.98 (s, 3H, 
CH3C), 0.89 (s, 3H, CH3C); 
13C NMR (100 MHz, CDCl3): δ = 214.8, 132.6, 132.5, 
123.7, 121.8, 62.0, 42.1, 40.3, 37.9, 27.5, 27.3, 26.0, 25.9, 25.8, 25.1, 23.4, 17.9, 
17.8; ESI-HRMS (TOF): m/z calculated for C18H30O [M+H]
+: 263.2369; found 
263.2370. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(4R)-Bis(3-methylbut-2-enyl)-3,3-dimethyl-1-methoxycyclohex-1-ene (101) 
and (±)-(4S)-Bis(3-methylbut-2-enyl)-5,5-dimethyl-1-methoxycyclohex-6-ene 
(113)47 
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tBuOK (2.33 g, 21 mmol, 1.5 equiv.) was dissolved in DMSO (30 mL).  A solution of 
111 and 112 (3.61 g, 13.8 mmol) in DMSO (30 mL) were added.  The solution was 
stirred for 1 h.  After this time Me2SO4 (2 mL, 20.7 mmol, 1.5 equiv.) was added and 
the mixture stirred for a further 15 min.  The reaction mixture was extracted with 2 
portions of petrol (2 x 20 mL) and petrol:Et2O (8:2) (20 mL).  The combined organic 
layers were washed with water and brine, dried (MgSO4) and the solvent was 
removed under reduced pressure.  The mixture was purified by flash column 
chromatography (8:2 petrol:EtOAc) to afford 101 and 113 (3.67 g, 96%) as a yellow 
oil. Rf = 0.77 and 0.67 (20% Et2O in petroleum ether). 
Major (101) 
1H NMR (300 MHz, CDCl3): δ = 5.12 (m, 1H, C=CHCH2), 5.03, (m, 1H, C=CHCH2), 
3.45 (s, 3H, CH3O), 2.81 (m, 1H, CHCH2C), 2.62 (m, 1H, CHCH2C), 2.15-2.08 (m, 
3H, CH2CH2C, CHCH2CH), 1.76-1.69 (m, 2H, CHCH2CH, CHCH2CH2), 1.71 (s, 3H, 
C=CCH3), 1.67 (s, 6H, C=CCH3), 1.61 (s, 3H, C=CCH3), 1.39-1.31 (m, 1H, 
CCH(CH2)2), 1.22-1.15 (m, 1H, CHCH2CH2), 1.03 (s, 3H, CCH3), 0.86 (s, 3H, CCH3); 
13C NMR (100 MHz, CDCl3): δ = 148.5, 131.9, 129.0, 126.1, 124.9, 124.5, 55.3, 45.5, 
37.6, 28.5, 26.6, 25.9, 25.8, 25.0, 24.3, 23.2, 21.9, 17.8, 17.7; ESI-HRMS (TOF): m/z 
calculated for C19H32O [M+H]
+: 277.2526; found 277.2523. 
Minor not isolated separately. 
Data were in accord with that of Dr. Rodeschini.47 
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(±)-(1R,7S)-1,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-4-
methoxybicyclo[3.3.1]non-3-ene-2,9-dione (108)47 
A mixture of 101 and 113 (3.67 g, 13.2 mmol) was dissolved in Et2O (7.5 mL), cooled 
to -20 °C and treated with malonyl dichloride (1.3 mL, 13.2 mmol, 1 equiv.).  This 
solution was stirred at -20 °C for 24 h and then treated with BnEt3NCl (150 mg, 
0.6 mmol, 0.05 equiv.) and KOH (2.96 g, 53 mmol, 4 equiv.) in H2O (7.5 mL).  The 
solution was stirred for 3.5 h and allowed to warm to rt.  The mixture was diluted with 
H2O (50 mL) and petrol (50 mL), the solution was basified (~12 pH) with 2 M NaOH 
and extracted with petrol.  The combined organic layers were dried (MgSO4) and the 
solvent was removed under reduced pressure to afford the ketones 111 and 112. 
The aqueous layer was cooled to 0 °C and carefully acidified using 2 M HCl.  The 
solution was extracted with DCM, the combined organic layers dried (MgSO4) and 
the solvent was removed under reduced pressure to afford 1.25 g of crude 
bicyclo[3.3.1]nonane 114 which was used directly without further purification.  
Bicyclo[3.3.1]nonane 114 (1.25 g, max 3.79 mmol) was dissolved in MeOH (30 mL) 
and treated with PTSA (76 mg, 10 mol%, 0.379 mmol) and trimethyl orthoformate 
(4.1 mL, 37.9 mmol, 10 equiv.).  The solution was heated to 50 °C for 2 days and 
then cooled to rt.  Four drops of Et3N were added and the solvent was removed 
under reduced pressure. The residue was purified by flash column chromatography 
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(9:1 petrol:EtOAC) to afford 108 (0.68 g, 15% over two steps) as a colourless oil.  
Rf  = 0.4 (20% EtOAc in petroleum ether); 
1H NMR (300 MHz, CDCl3): δ = 5.73 (s, 
1H, HC-3), 4.96 (t, J = 8.0, 1H, C=CHCH2), 4.66 (t, J = 7.1, 1H, C=CHCH2), 3.76 (s, 
3H, CH3O), 3.18 (s, 1H, HC-5), 2.59 (dd, J = 13.8, 7.2, 1H, CHCH2C), 2.41 (dd, 
J = 13.9, 6.0, 1H, CHCH2C), 2.18-1.98 (m, 2H, CHCH2CH, CHCH2CH), 1.75-1.65 (m, 
3H, CHCH2CH, CCH(CH2)2, CHCH2CH), 1.67 (s, 6H, CH3C=C), 1.58 (s, 3H, 
CH3C=C), 1.55 (s, 3H, CH3C=C), 1.08 (s, 3H, CH3C), 0.77 (s, 3H, CH3C); 
13C NMR 
(100 MHz, CDCl3): δ = 207.4, 195.2, 177.6, 133.5, 133.3, 122.5, 119.7, 107.7, 64.4, 
61.7, 56.3, 45.2, 41.3, 34.2, 28.6, 25.9, 25.8, 23.9, 23.8, 18.0, 17.9, 16.1; ESI-HRMS 
(TOF): m/z calculated for C22H32O3 [M+Na]
+: 367.2244; found 367.2239. 
Data were in accord with that of Dr. Rodeschini.47 
 
(±)-(1R,5S,7S)-1,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-5-((R)-hydroxyphenyl-
methyl)-4-methoxybicyclo[3.3.1]non-3-ene-2,9-dione (199) and (±)-(1R,5S,7S)-
1,7-Bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-5-((S)-hydroxyphenyl-methyl)-4-
methoxybicyclo[3.3.1]non-3-ene-2,9-dione (198) 
 
nBuLi (0.3 mL of a 1.6 M solution, 0.48 mmol, 1.5 equiv.) was added to a solution of 
diisopropylamine (67 μL, 0.48 mmol, 1.5 equiv.) in THF (1.5 mL) at -78 °C and the 
solution was stirred for 10 min. To this bicyclo[3.3.1]-nonane 108 (110 mg, 
Chapter 7 Experimental 
 
175 
 
0.32 mmol) was added and the resulting solution was stirred at -78 °C for 30 min. 
After which time benzaldehyde (65 μL, 0.64 mmol, 2 equiv.) was added and the 
solution stirred for 2 h and allowed to warm to rt before quenching with saturated 
aqueous NH4Cl (5 mL). This was extracted with Et2O (3 x 5 mL), the combined 
organic layers were dried (MgSO4) and the solvent was removed under reduced 
pressure. The mixture was purified by flash column chromatography (9:1 to 7:3 
petrol:EtOAc) to afford two isomers 198 and 199 (1:3 ratio, combined 166 mg, 81%) 
as a colourless viscous oil.  Rf = 0.74 and 0.66 (40% EtOAc in petroleum ether). 
Major (199) 
FTIR (neat) 3500, 2913, 1719, 1643, 1601, 1375, 1235, 1043, 728 cm-1; 1H NMR 
(500 MHz, CDCl3): δ = 7.30 (d, J = 7.6, 2H, H
ortho-ar), 7.22 (t, J = 7.0, 2H, Hmeta-ar), 
7.17 (t, J = 7.1, 1H, Hpara-ar), 5.78 (s, 1H, CCH=C), 5.32 (s, 1H, CCH(C)(OH)), 
4.94-4.88 (m, 1H, C=CHCH2), 4.68-4.62 (m, 1H, C=CHCH2), 3.61 (s, 3H, CH3O), 
3.31 (br s, 1H, HO), 2.55 (dd, J = 13.9, 6.5, 1H, CHCH2C), 2.42 (dd, J = 13.9, 6.1, 
1H, CHCH2C), 2.12 (dd, J = 14.1, 3.5, 1H, CCH2CH), 2.08-2.02 (m, 1H, CHCH2CH), 
1.64 (s, 6H, CH3C=C), 1.62-1.58 (m, 2H, CHCH2CH, CH2CH(CH2)(C)), 1.57 (s, 3H, 
CH3C=C), 1.48 (s, 3H, CH3C=C), 1.37 (t, J = 12.5, 1H, CHCH2CH), 1.01 (s, 3H, 
CH3C), 0.61 (s, 3H, CH3C); 
13C NMR (125 MHz, CDCl3): δ = 209.5, 195.3, 174.9, 
141.0, 133.7, 133.2, 127.8 (2C), 127.5 (2C), 127.2, 122.5, 120.1, 108.4, 74.2, 71.7, 
59.9, 56.8, 46.4, 41.8, 37.3, 27.9, 25.9, 25.8, 24.3, 22.6, 18.1, 17.6, 15.8; ESI-HRMS 
(TOF): m/z calculated for C29H38O4 [M+Na]
+: 473.2662; found 473.2673. 
Minor (198) was not isolated separately. 
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(±)-(1R,5R,7S)-5-Benzoyl-1,7-bis(3’-methyl-but-2’-enyl)-8,8-dimethyl-4-
methoxybicyclo[3.3.1]non-3-ene-2,9-dione (151) 
 
A mixture of stereoisomers 198 and 199 (255 mg, 0.57 mmol) was dissolved in DCM 
(5 mL) and stirred at rt.  To this was added Dess-Martin periodinane (2.4 mL of a 
15 % wt in DCM solution, 1.14 mmol, 2 equiv.).  The mixture was stirred at room 
temperature for 1.5 h before quenching with saturated aqueous NaHCO3 (5 mL) and 
saturated aqueous Na2S2O3 (5 mL) and stirred for 1 h.  The mixture was extracted 
with DCM (3 x 10mL), the combined organic layers were dried (MgSO4) and the 
solvent was removed under reduced pressure to afford 151 (299 mg) of crude 
material as a white solid which was used without further purification.  m.p. = 128-
130 °C; Rf = 0.43 (20% EtOAc in petroleum ether); FTIR (neat) 2980, 1717, 1699, 
1650, 1609, 1450, 1355, 1345, 1251, 1236, 1177 cm-1; 1H NMR (300 MHz, CDCl3): 
δ = 7.64 (d, J = 7.2, 2H, Hortho-ar), 7.47 (t,  J = 7.4, 1H, Hpara-ar), 7.31 (t, J = 7.7, 2H, 
Hmeta-ar), 5.91 (s, 1H, CCH=C), 4.97 (t, J = 7.1, 1H, C=CHCH2), 4.79 (t, J = 6.8, 1H, 
C=CHCH2), 3.52 (s, 3H, CH3O), 2.60 (dd, J = 13.6, 6.6, 1H, CCH2C), 2.46 (dd, 
J = 13.5, 6.9, 1H, CCH2C), 2.25 (dd, J = 14.2, 4.4, 1H, CCH2CH), 2.20-2.10 (m, 1H, 
CHCH2CH), 2.08 (t, J = 13.4,1H, CCH2CH), 1.89- 1.75 (m, 1H, CHCH2CH), 1.72-1.67 
(m, 1H, CH2CHC), 1.66 (s, 3H, CH3C=C), 1.62 (s, 3H, CH3C=C), 1.61 (s, 3H, 
CH3C=C), 1.59 (s, 3H, CH3C=C), 1.08 (s, 3H, CH3C), 0.75 (s, 3H, CH3C); 
13C NMR 
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(100 MHz, CDCl3): δ = 207.0, 195.4, 193.9, 173.4, 135.8, 134.7, 133.5, 132.8, 128.2 
(2C), 128.1 (2C), 122.4, 119.8, 106.3, 72.7, 65.7, 56.8, 47.6, 41.8, 35.9, 27.9, 26.1, 
25.8, 23.9, 23.0, 18.2, 18.0, 15.7; ESI-HRMS (TOF): m/z calculated for C29H36O4 
[M+Na]+: 471.2506; found 471.2496. 
 
(±)-(1R,5R,7S)-5-Benzoyl-8,8-dimethyl-4-methoxy-1,3,7-tris(3’-methyl-but-2’-
enyl)-bicyclo[3.3.1]non-3ene-2,9-dione (151) 
 
TMP (0.12 mL, 0.73 mmol, 2 equiv.) in THF (4 mL) was cooled to 0 °C and treated 
with nBuLi (0.29 mL of a 2.5 M solution, 0.73 mmol, 2 equiv.).  The solution was 
cooled to -78 °C and 151 (162 mg, 0.36 mmol) in THF (12 mL) was added via 
cannula.  After stirring for 30 min. 2-Th(Cu)CNLi (7.25 mL of a 0.1 M solution, 
0.73 mmol, 2 equiv.) was added and the mixture warmed to -40 °C and stirred for a 
further 30 min.  After this time the solution was cooled once more to -78 °C and 
prenyl bromide (0.21 mL, 1.8 mmol, 5 equiv.) was added.  The mixture was stirred 
and allowed to warm to rt over 2 h before quenching with NH4Cl/NH4OH(aq) 
(10% w/w, 20 mL). This was extracted with Et2O (3 x 20 mL), the combined organic 
layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (gradient of 98:2-9:1, 
petrol:EtOAc) to afford 152 (89.5 mg, 48% over 2 steps) as a white solid. m.p. 92-
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93 °C; Rf = 0.65 (20% EtOAc in petroleum ether); FTIR (neat) 2925, 1722, 1692, 
1651, 1613, 1448, 1328, 1253, 1045 cm-1; 1H NMR (500 MHz, CDCl3): δ = 7.70 (dd, J 
= 8.6, 1.3, 2H, Hortho-ar), 7.49 (t, J 7.5, 1H,  Hpara-ar), 7.34 (t, J 7.9, 2H, Hmeta-ar), 5.05-
5.01 (m, 2H, C=CHCH2), 4.75 (t, J = 6.8, 1H, C=CHCH2), 3.56 (s, 3H, CH3O), 3.27 
(dd, J = 14.7, 7.0, 1H, CHCH2C), 3.18 (dd, J = 14.7, 7.0, 1H, CHCH2C), 2.63 (dd, J = 
13.6, 7.0, 1H, CHCH2C), 2.47 (dd, J = 13.4, 6.8, 1H, CHCH2C), 2.32 (dd, J = 14.3, 
4.4, 1H, CCH2CH), 2.19-2.09 (m, 2H, CCH2CH, CHCH2CH), 1.87-1.78 (m, 1H, 
CHCH2CH), 1.69 (s, 3H, CH3C=C), 1.67 (s, 6H, CH3C=C), 1.64 (s, 3H, CH3C=C), 
1.62 (s, 6H, CH3C=C), 1.63-1.59 (m, 1H, CH2CHC), 1.08 (s, 3H, CH3C), 0.76 (s, 3H, 
CH3C); 
13C NMR (100 MHz, CDCl3): δ = 207.4, 195.8, 195.1, 168.0, 135.9, 134.5, 
133.5, 132.8, 132.7, 128.6 (2C), 128.1 (2C), 126.0, 122.6, 121.3, 120.0, 72.1, 66.7, 
60.6, 47.7, 42.0, 35.8, 27.6, 26.0, 25.74, 25.68, 24.3, 23.0, 22.9, 18.16, 17.92, 17.89, 
15.6; ESI-HRMS (TOF): m/z calculated for C34H44O4 [M+H]
+: 539.3137; found 
539.3011. 
Enantiomers separated by chiral HPLC: 1% IPA in hexane on Lux cellulose II 
column.  8.11 and 10.17 min. 
[α]D
22 = -56 (0.001 c, CDCl3) component 1 from HPLC 
[α]D
22 = +36 (0.001 c, CDCl3) component 2 from HPLC 
 
 
 
 
 
Chapter 7 Experimental 
 
179 
 
Nemorosone II (150) 
 
O-methylated nemorosone II (152) (22.6 mg, 43.7 μmol) was dissolved in d6-DMSO 
(0.75 mL), and LiCl (20 mg, 0.47 mmol, 1.1 equiv.) added.  The solution was stirred 
and heated to 120 °C for 2 h.  The reaction was cooled to rt and diluted with Et2O 
(2 mL) and H2O (2 mL). The solution was extracted with Et2O (3 x 10mL), the 
combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure to afford crude nemorosone II 150 (15 mg, 68%) as an unstable 
solid. Rf = 0.34 (20% EtOAc in petroleum ether) ; FTIR (neat) 3334, 2919, 1724, 
1681, 1626, 1449, 1376, 1258, 1046 cm-1; 1H NMR (500 MHz, d4-Methanol): δ = 7.60 
(d, J = 7.7, 2H, Hortho-ar), 7.54 (t, J =7.4, 1H, Hpara-ar), 7.35 (t, J = 7.8, 2H, Hmeta-ar), 5.14 
(t, J = 7.3, 2H, C=CHCH2), 5.07 (t, J = 7.2, 1H, C=CHCH2), 4.92 (t, J = 6.0, 1H, 
C=CHCH2), 3.16 (d, J = 7.1, 2H, CHCH2C), 2.66 (d, J =6.6, 2H, CHCH2C), 2.27 (dd, 
J = 13.7, 4.3, 1H, CCH2CH), 2.22 (dd, J = 14.4, 5.3, 1H, CHCH2CH), 1.96 (t, J = 13.5, 
1H, CHCH2CH), 1.89-1.82 (m, 1H, CCH2CH), 1.77-1.73 (m, 1H, CH2CHC), 1.73 (s, 
3H, CH3C=C), 1.71 (s, 3H, CH3C=C), 1.69 (s, 9H, CH3C=C), 1.67 (s, 3H, CH3C=C), 
1.20 (s, 3H, CH3C), 0.81 (s, 3H, CH3C); 
13C NMR (125 MHz, d4-Methanol): δ = 208.9, 
196.3, 136.8, 135.4, 134.3, 133.8, 133.6, 129.7 (2C), 129.1 (2C), 124.0, 122.3, 
121.8, 121.3, 71.4, 69.0, 47.4, 43.0, 38.2, 29.3, 26.4, 26.04, 26.00, 24.9, 24.2, 22.3, 
Chapter 7 Experimental 
 
180 
 
18.4, 18.1, 18.0, 16.0; ESI-HRMS (TOF): m/z calculated for C33H42O4 [M+H]
+: 
503.3156; found 503.3158. 
[α]D
22 = -28 (0.003 c, MeOH) component 1 from HPLC of 151 
[α]D
22 = +14 (0.01 c, MeOH) component 2 from HPLC of 151 
 
7.3 Experimental for Chapter 4 
(±)-(5S,7S)-8,8-Dimethyl-7-isopentyl-2-methoxy-5-(3’-methylbut-2’-en-1’-yl)-3-
(trimethylsilyl)bicyclo[3.3.1]non-2-ene-4,9-dione (200) and (±)-(5S,7S)-5,7-
Diisopentyl-8,8-dimethyl-2-methoxy-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-
4,9-dione (201) 
 
Bicyclo[3.3.1]nonane 173 (62 mg, 0.15 mmol) and Pd/C (17 mg, 10% w/w, 
0.02 mmol) were placed in a round bottom flask and the atmosphere exchanged for 
H2.  To this EtOH (5 mL) was added and the suspension was stirred for 24 h under 
H2 atmosphere.  The solution was filtered through a celite plug and washed with 
EtOAc. The solvent was removed under reduced pressure.  The residue was purified 
by flash column chromatography (9:1 petrol:Et2O) to afford two products, 200 (12 mg, 
19%) and 201 (7 mg, 11%) as colourless oils. 
Major (200) 
Rf = 0.46 (20% EtOAc in petroleum ether); FTIR (neat) 2955, 1729, 1645, 1565, 
1466, 1334, 1245, 1215, 844 cm-1; 1H NMR (300 MHz, CDCl3): δ = 4.91 (t, J = 7.2, 
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1H, C=CHCH2), 3.71 (s, 3H, CH3O), 3.21 (s, 1H, HC-1), 2.40 (dd, J = 14.1, 7.7, 1H, 
CHCH2C), 2.31 (dd, J = 14.1, 6.6, 1H, CHCH2C), 1.93 (dd, J = 12.8, 4.1, 1H, 
CCH2CH), 1.62 (s, 3H, CH3C=C), 1.58 (s, 3H, CH3C=C), 1.52-1.32 (m, 
7H,CH2CH(C)(CH2), (CH3)2CHCH2, CCH2CH, CHCH2CH2, CH2CH2CH), 1.03 (s, 3H, 
CCH3), 0.89 (s, 3H, CCH3), 0.83 (d, J = 6.6, 3H, CHCH3), 0.80 (d, J = 6.6, 3H, 
CHCH3, 0.15 (s, 9H, CH3Si); 
13C NMR (100 MHz, CDCl3): δ = 208.5, 202.1, 177.9, 
133.7, 123.5, 119.6, 63.6, 61.2, 55.8, 43.2, 41.2, 38.8, 37.1, 29.7, 28.0, 26.9, 25.7, 
23.0, 22.4, 22.1, 20.9, 18.0, 0.34 (3C); ESI-HRMS (TOF): m/z calculated for 
C25H42O3Si [M+H]
+: 441.2801; found 441.2800. 
Minor (201) 
Rf = 0.5 (20% EtOAc in petroleum ether); FTIR (neat) 2954, 1729, 1647, 1567, 1465, 
1245, 1214, 844 cm-1; 1H NMR (300 MHz, CDCl3): δ = 3.71 (s, 3H, CH3O), 3.20 (s, 
1H, HC-1), 1.92 (dd, J = 12.9, 4.1, 1H, CCH2CH), 1.68-1.00 (m, 12H, CCH2CH, 
(CH2)2CHC, CH2CH2CH, CHCH2CH2, (CH3)2CHCH2, CH2CH2C), 1.03 (s, 3H, CH3), 
0.88 (s, 3H, CH3), 0.84 (d, J = 4.6, 3H, CH3CH), 0.82 (d, J = 6.0, 3H, CH3CH), 0.81 
(d, J = 5.1, 3H, CH3CH), 0.79 (d, J = 6.7, 3H, CH3CH), 0.17 (s, 9H, CH3Si); 
13C NMR 
(100 MHz, CDCl3): δ = 208.7, 202.5, 178.1, 123.6, 63.5, 61.2, 55.9, 43.3, 42.3, 38.6, 
37.0, 33.4, 29.3, 28.7, 27.9, 26.8, 25.7, 23.0, 22.4 (2C), 22.0, 20.8, 0.4 (3C); 
ESI-HRMS (TOF): m/z calculated for C25H44O3Si [M+Na]
+: 443.2957; found 
443.2961. 
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(±)-(1S,5S,7S)-1-Benzoyl-8,8-dimethyl-7-isopentyl-2-methoxy-5-(3’-methylbut-2’-
en-1’-yl)-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-4,9-dione (202) 
 
Bicyclo[3.3.1]nonane 174 (25.8 mg, 0.05 mmol) and Pd/C (7 mg, 10% w/w, 
0.005 mmol) were placed in a round bottom flask and the atmosphere exchanged for 
H2.  To this EtOH (5 mL) was added and the suspension was stirred for 24 h under 
H2 atmosphere.  The solution was filtered through a celite plug and washed with 
EtOAc. The solvent was removed under reduced pressure.  The residue was purified 
by flash column chromatography (9:1 petrol:Et2O) to afford 202 (16.8 mg, 64%) as a 
colourless oil. Rf = 0.61 (20% EtOAc in petroleum ether); FTIR (neat) 2954, 1721, 
1703, 1650, 1558, 1446, 1251, 849 cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.58 (d, J = 
7.3, 2H, Hortho-ar), 7.41 (t, J = 7.4, 1H, Hpara-ar), 7.28 (t, J = 7.8, 2H, Hmeta-ar), 5.04 (t, J = 
7.1, 1H, C=CHCH2), 3.48 (s, 3H, CH3O), 2.53 (dd, J = 14.1, 7.4, 1H, CHCH2C), 2.44 
(dd, J = 14.0, 7.0, 1H, CHCH2C), 1.97 (dd, J = 12.8, 4.2, 1H, CCH2CH), 1.64 (s, 6H, 
CH3C=C), 1.60-1.35 (m, 4H, CCH2CH, (CH2)2CHC, (CH3)2CHCH2, CHCH2CH2), 1.31 
(s, 3H, CH3C),1.25-1.15 (m, 1H, CHCH2CH2) 1.14 (s, 3H CH3C), 1.05-0.90 (m, 2H, 
CH2CH2CH), 0.85 (d, J = 6.6, 3H, CH3CH), 0.83 (d, J = 6.6, 3H, CH3CH) 0.21 (s, 9H, 
CH3Si); 
13C NMR (100 MHz, CDCl3): δ = 208.4, 201.0, 193.2, 181.2, 137.1, 134.4, 
132.1, 128.6 (2C), 127.9 (2C), 122.9, 119.7, 75.1, 65.8, 64.0, 48.6, 43.0, 42.7, 37.5, 
29.5, 28.2, 26.8, 26.0, 24.6, 22.9, 22.2, 18.1, 16.3, 0.93 (3C); ESI-HRMS (TOF): m/z 
calculated for C32H46O4Si [M+Na]
+: 545.3063; found 545.3054. 
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(±)-(5S,7S,9S)-5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-9-hydroxy-2-
methoxy-3-(trimethylsilyl)bicyclo[3.3.1]non-2-en-4-one (203) 
 
Bicyclo[3.3.1]nonane 173 (43.8 mg, 0.11 mmol) was dissolved in 2:1 DCM:MeOH 
(1.9 mL) and cooled to -78 °C.  The solution was treated with NaBH4 (6 mg, 
0.16 mmol) in MeOH (0.54 mL) and the reaction stirred at -78 °C for 2 h.  After this 
time further NaBH4 (10 mg) was added and the solution stirred and allowed to warm 
to rt overnight before quenching with saturated aqueous NH4Cl (5 mL). This was 
extracted with Et2O (3 x 5 mL), the combined organic layers were dried (MgSO4) and 
the solvent was removed under reduced pressure. The residue was purified by flash 
column chromatography (9:1 petrol:Et2O) to afford 203 (27.7 mg, 60%) as a 
colourless oil.  Rf = 0.38 (20% EtOAc in petroleum ether); FTIR (neat) 3401, 2927, 
1617, 1556, 1332, 1218, 842 cm-1; 
1H NMR (300 MHz, CDCl3): δ = 4.96-4.83 (m, 2H, 
C=CHCH2), 4.01 (t, J = 3.1, 1H, OCH(C)(CH)), 3.70 (s, 3H, CH3O), 2.75 (d, J = 3.1, 
1H, HC-1), 2.50 (dd, J = 14.3, 6.1, 1H, CHCH2C), 2.09 (dd, J = 14.3, 8.9, 1H, 
CHCH2C), 2.06-1.96 (m, 1H, CHCH2CH), 1.75 (d, J = 3.9, 1H, HO), 1.70-1.50 (m, 2H, 
CCH2CH, CHCH2CH), 1.63 (s, 3H, CH3C=C), 1.61 (s, 6H, CH3C=C), 1.52 (s, 3H, 
CH3C=C), 1.41-1.17 (m ,2H, CCH2CH, CH2CHC), 1.15 (s, 3H, CH3C), 0.92 (s, 3H, 
CH3C), 0.12 (s, 9H, CH3Si); 
13C NMR (100 MHz, CDCl3): δ = 206.2, 182.7, 133.7, 
132.4, 123.4, 120.7, 119.9, 71.3, 55.4, 52.1, 49.0, 39.8, 34.9, 32.2, 32.0, 28.8, 27.4, 
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26.0, 25.8, 23.9, 17.8 (2C), 0.6 (3C); ESI-HRMS (TOF): m/z calculated for 
C25H42O3Si [M+Na]
+: 441.2801; found 441.2806. 
 
7.4 Experimental for Chapter 5 
(±)-(1S,5R,7S)-5,7-Bis(3’-methyl-but-2’-enyl)-1-deteruio-8,8-dimethyl-2-methoxy-
3-trimethylsilanyl-bicyclo[3.3.1]non-2-ene-4,9-dione (206) 
 
Iodide 176 (28.9 mg, 53 μmol) was dissolved in THF (0.5 mL) and cooled to -78 °C.  
To this solution nBuLi (7 μL of a 1.6 M solution, 107 μmol, 2 equiv.) was added 
dropwise.  The solution was stirred for 10 min. after which time D2O (11 μL, 
533 μmol, 10 equiv.) was added dropwise.  The solution was stirred and allowed to 
warm to rt over 2 h, then stirred at room temperature for 1 h before quenching with 
saturated aqueous NH4Cl (~2.5 mL).  This was extracted with EtOAc (3 x 10 mL), the 
combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure.  The residue was purified by flash column chromatography (9:1 
petrol:EtOAc) to afford 203 (10 mg, 45%) as a pale yellow oil. Rf = 0.34 (10% EtOAc 
in petroleum ether); FTIR (neat) 2964, 2920, 1723, 1642, 1559, 1455, 1372, 1268, 
1242, 1220, 1162, 1066, 925, 838 cm-1; 1H (500 MHz, CDCl3): δ = 4.96-4.93 (m, 2H, 
C=CHCH2), 3.73 (s, 3H, CH3O), 2.40 (dd, J = 14.1, 7.8, 1H, CHCH2C), 2.33 (dd, 
J = 14.1, 6.6, 1H, CHCH2C), 2.06-2.03 (m, 1H, CHCH2CH), 1.92 (dd, J = 13.3, 4.2, 
1H, CCH2CH), 1.66 (s, 3H, CH3C=C), 1.63 (s, 3H, CH3C=C), 1.60 (t, J = 13.2, 1H, 
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CHCH2C), 1.60 (s, 3H, CH3C=C), 1.53 (m, 1H, (CH2)2CHC), 1.53 (s, 3H, CH3C=C), 
1.28 (dd, J = 12.9, 1H, CCH2CH), 1.09 (s, 3H, CH3C), 0.94 (s, 3H, CH3C), 0.17 (s, 
9H, CH3Si); 
13C (125 MHz, CDCl3): δ = 208.5, 202.0, 177.9, 133.7, 133.3, 123.5, 
122.3, 119.6, 63.7, 60.73 (t, J = 20.3), 55.8, 42.8, 41.0, 39.4, 29.6, 27.9, 25.83, 25.77 
(2C), 20.9, 18.0, 17.8, 0.4 (3C); ESI-HRMS (TOF): m/z calculated for C25H39DO3Si 
[M+2H]+: 440.2707; found 440.2690.  
 
(±)-(1S,5S,7S)-5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-4,9-dioxo-2-
methoxy-methyl-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-1-carboxylate (208) 
 
Iodide 176 (117.4 mg, 0.22 mmol) was dissolved in THF (1 mL) and cooled to -78 °C.  
To this solution tBuLi (0.13 mL of a 1.7 M solution, 0.23 mmol, 1.05 equiv.) was 
added dropwise.  The solution was stirred for 15 min. upon which methyl 
chloroformate (0.17 mL, 2.17 mmol, 10 equiv.) was added dropwise.  The solution 
was stirred and allowed to warm slowly over 3 h, then stirred at rt for 30 min. before 
quenching with saturated aqueous NH4Cl (~2.5 mL).  This was extracted with Et2O, 
the combined organic layers were dried (MgSO4), and the solvent was removed 
under reduced pressure.  The residue was purified by flash column chromatography 
(9:1 petrol:Et2O) to afford 208 (22.6mg, 22% yield, 54% brsm) as a colourless oil. 
Rf = 0.51 (20% EtOAc in petroleum ether); FTIR (neat) 2951, 1755, 1728, 1651, 
1565, 1437, 1247, 1223, 844, 752 cm-1; 1H NMR (300 MHz, CDCl3): δ =  5.06 (t, 
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J = 6.9, 1H, C=CHCH2), 4.97 (t, J = 7.9, 1H, C=CHCH2), 3.86 (s, 3H, CH3O), 3.74 (s, 
3H, CH3O), 2.39 (d, J = 6.8, 2H, CHCH2C), 2.12 (dd, J = 11.2, 5.6, 1H CHCH2CH),  
1.76 (dd, J = 13.0, 4.0, 1H, CCH2CH), 1.68-1.58 (m, 2H, CHCH2CH, (CH2)2CHC), 
1.65 (s, 6H, CH3C=C), 1.63 (s, 3H, CH3C=C), 1.54 (s, 3H, CH3C=C), 1.43 (t, J = 12.8, 
1H, CCH2CH), 1.27 (s, 3H, CH3C), 1.10 (s, 3H, CH3C), 0.27 (s, 9H, CH3Si); 
13C NMR 
(100 MHz, CDCl3): δ = 204.4, 199.9, 179.5, 168.0, 133.7, 133.4, 125.7, 122.3, 119.9, 
74.9, 64.9, 64.8, 51.8, 45.1, 42.8, 40.0, 29.3, 27.6, 25.9, 25.7, 24.1, 18.0, 17.8, 16.0, 
0.5 (3C); ESI-HRMS (TOF): m/z calculated for C27H42O5Si [M+Na]
+: 497.2699; found 
497.2694.   
 
(±)-(1S,5S,7S)-5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-2-methoxy-1-
(2’,2’,2’-trifluoroacetyl)-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-4,9-dione (209) 
 
Iodide 176 (44.8 mg, 0.08 mmol) was dissolved in THF (0.5 mL) and cooled to 
-100 °C (liquid N2 Et2O bath).  To this solution tBuLi (97 μL of a 1.7 M solution, 
0.165 mmol, 2 equiv.) was added dropwise.  The solution was stirred for 30 min. after 
which time TLC showed no remaining starting material.  Trifluoroacetic anhydride 
(117 μL, 0.826 mmol, 10 equiv.) was added dropwise.  The solution was stirred and 
allowed to warm slowly over 2 h to -40 °C before quenching with saturated aqueous 
NH4Cl (~2.5 mL). This was extracted with Et2O (3 x 10 mL), the combined organic 
layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
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The residue was purified by flash column chromatography (9:1 petrol:Et2O) to afford 
209 (25 mg, 59%) as a colourless oil.  Rf = 0.32 (5% EtOAc in petroleum ether); FTIR 
(neat) 2917, 1768, 1723, 1655, 1561, 1233, 1194, 1163, 845, 720 cm-1; 1H NMR 
(CDCl3, 300 MHz): δ = 5.02-4.88 (m, 2H, C=CHCH2), 3.96 (s, 3H, CH3O), 2.54-2.31 
(m, 2H, CHCH2C), 2.19-2.04 (m, 1H, CHCH2CH), 1.86 (dd, J = 13.2, 3.9, 1H, 
CCH2CH), 1.70-1.52 (m, 2H, CHCH2CH, (CH2)2CHC), 1.67 (s, 3H, CH3C=C), 1.63 (s, 
6H, CH3C=C), 1.55 (s, 3H, CH3C=C), 1.41 (dd, J = 12.9, 1H, CCH2CH), 1.25 (s, 3H, 
CH3C), 1.07 (s, 3H, CH3C), 0.30 (s, 9H, CH3Si); 
19F NMR (CDCl3, 282 MHz): 
δ = -74.7 (s); 13C NMR (CDCl3, 100 MHz): δ = 205.8, 199.4, 188.9 (q, 
2JC-F = 33.8), 
176.3, 134.2, 133.9, 122.2, 121.9, 119.2, 115.0 (q, JC-F = 294.8), 75.5, 64.9, 64.1, 
46.6, 42.7, 40.9, 29.1, 27.4, 25.8, 25.7, 23.9, 18.0, 17.8, 15.8, 1.1 (3C); ESI-HRMS 
(TOF): m/z calculated for C27H39O4F3Si [M+Na]
+: 535.2467; found 535.2473.   
 
(±)-(1S,5S,7S)5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-1-(1’-hydroxyethyl)-
2-methoxy-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-4,9-dione (210) 
 
Iodide 176 (95.7 mg, 0.18 mmol) was dissolved in THF (1.5 mL) and cooled to 
-78 °C.  To this solution nBuLi (0.12 mL of a 1.6 M solution, 0.19 mmol, 1.05 equiv.) 
was added dropwise.  The solution was stirred for 10 min. after which time 
acetaldehyde (99 μL, 1.8 mmol, 10 equiv.) was added dropwise.  The solution was 
stirred and allowed to warm to rt over 2 h before quenching with saturated aqueous 
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NH4Cl (~ 2.5 mL).  This was extracted with Et2O (2 x 5 mL) and EtOAc (5 mL), the 
combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure. The residue was purified by flash column chromatography (9:1 
petrol:Et2O) to afford 210 (48.4 mg, 58%) as a colourless oil. Rf = 0.47 (20% EtOAc 
in petroleum ether); FTIR (neat) 3529, 2969, 1710, 1649, 1547, 1228, 1107, 843, 754 
cm-1; 1H NMR (500 MHz, CDCl3): δ = 5.00 (t, J = 6.6, 1H, C=CHCH2), 4.95 (t, J = 5.9, 
1H, C=CHCH2), 4.50 (sextet, J = 6.3, 1H, CH3CH(OH)C), 3.95 (s, 3H, CH3O), 3.65 
(d, J = 12.0, 1H, HO), 2.42 (dd, J = 14.5, 7.7, 1H, CHCH2C),  2.34 (dd, J = 14.5, 6.4, 
1H, CHCH2C), 2.10-2.07 (m, 1H, CHCH2CH), 1.82 (dd, J = 13.2, 4.2, 1H, CCH2CH), 
1.70-1.58 (m, 1H, CHCH2CH), 1.66 (s, 3H, CH3C=C), 1.64 (s, 3H, CH3C=C), 1.62 (s, 
3H, CH3C=C), 1.54 (s, 3H, CH3C=C), 1.52-1.48 (m, 1H, (CH2)2CHC), 1.40 (dd, 
J = 13.0, 1H, CCH2CH), 1.28 (d, J = 6.3, 3H, CH3CH), 1.23 (s, 3H, CH3C), 1.11 (s, 
3H, CH3C), 0.22 (s, 9H, CH3Si); 
13C NMR (125 MHz, CDCl3): δ = 214.6, 200.2, 185.0, 
133.9, 133.1, 124.8, 122.5, 119.8, 69.0, 67.5, 65.2, 63.3, 46.2, 44.1, 41.2, 29.9, 27.7, 
25.9, 25.8, 23.9, 21.8, 18.4, 18.0, 17.9, 0.8 (3C); ESI-HRMS (TOF): m/z calculated 
for C27H44O4Si [M+Na]
+: 483.2907; found 483.2902.    
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(±)-(1S,5S,7S)-5,7-Bis(3’-methylbut-2’-en-1’-yl)-8,8-dimethyl-1-(1’-hydroxy-2’-
methylpropyl)-2-methoxy-3-(trimethylsilyl)bicyclo[3.3.1]non-2-ene-4,9-dione 
(211) 
 
Iodide 176 (40.6 mg, 0.075 mmol) was dissolved in THF (0.5 mL) and cooled to 
-100 °C (liquid N2, Et2O bath).  To this solution tBuLi (88 μL of a 1.7 M solution, 
0.15 mmol, 2 equiv.) was added dropwise.  The solution was stirred for 30 min. after 
which time TLC showed no remaining starting material.  Isobutyl aldehyde (71 μL, 
0.75 mmol, 10 equiv.) was added dropwise.  The solution was stirred and allowed to 
warm slowly over 2 h to -40 °C before quenching with saturated aqueous NH4Cl 
(~ 2.5 mL). This was extracted with Et2O (3 x 10 mL), the combined organic layers 
were dried (MgSO4) and the solvent was removed under reduced pressure. The 
residue was purified by flash column chromatography (9:1 petrol:Et2O) to afford 211 
(18.8 mg, 51%) as a colourless oil. Rf = 0.52 (20% EtOAc in petroleum ether); FTIR 
(neat) 3484, 2958, 1708, 1649, 1548, 1421, 1229, 1017, 844, 756 cm-1; 1H (300 MHz, 
CDCl3): δ = 4.92 (m, 2H, C=CHCH2), 4.56 (d, J = 11.8, 1H, (CH)(OH)CHC), 4.26 (dd, 
J = 11.8, 2.0, 1H, (CH3)2CHCH), 3.95 (s, 3H, CH3O), 2.45 (dd, J = 14.0, 8.3, 1H, 
CHCH2C), 2.31 (dd, J = 14.0, 5.8, 1H, CHCH2C), 2.07 (d, J = 12.3, 1H, CHCH2CH), 
1.92-1.85 (m, 1H, CHCH2CH), 1.88 (dd, J = 12.2, 3.4, 1H, CCH2CH), 1.73-1.51 (m, 
1H, (CH2)2CHC), 1.66 (s, 6H, CH3C=C), 1.58 (s, 3H, CH3C=C), 1.53 (s, 3H, 
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CH3C=C), 1.34 (dd, J = 12.5, 1H, CCH2CH), 1.25 (s, 3H, CH3C), 1.15 (s, 3H, CH3C), 
1.02 (d, J = 6.8, 3H, CH3CH), 0.65 (d, J = 6.9 Hz, 3H, CH3CH), 0.22 (s, 9H, CH3Si); 
13C NMR (100 MHz, CDCl3): δ = 216.2, 199.9, 185.0, 134.0, 133.1, 124.0, 122.5, 
119.7, 65.7, 65.6, 63.0, 48.0, 44.3, 42.7, 32.0, 30.0, 29.7, 27.8, 25.9, 25.8, 24.3, 
22.2, 18.7, 18.0, 17.9, 17.3, 0.7 (3C); ESI-HRMS (TOF): m/z calculated for 
C29H48O4Si [M+Na]
+: 511.3220; found 511.3228.  
 
7.5 Experimental for Chapter 6 
(±)-(4S,6S)-4,6-Bis(3’-methylbut-2’-en-1’-yl)-3,3-dimethyl-cyclohex-1-en-1-yl-
benzoate (237) 
 
nBuLi (2.79 mL of a 1.6 M, 4.46 mmol, 1.1 equiv.) was added to a solution of 
diisopropylamine (0.63 mL, 4.46 mmol, 1.1 equiv.) in THF (20 mL) at -78 °C and the 
solution stirred for 15 min. To this ketone 141 (1.063 g, 4.06 mmol) was added and 
the resulting solution stirred at -78 °C for 15 min.  After which time benzoyl chloride 
(0.68 mL, 6.08 mmol, 1.5 equiv.) was added.  The solution was stirred and allowed to 
warm over 2.5 h followed by 30 min. at rt before quenching with saturated aqueous 
NH4Cl (~25 mL).  This was extracted with Et2O (3 x 25 mL), the combined organic 
layers were dried (MgSO4) and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (9:1 petrol:EtOAc) to 
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afford 237 (1.14 g, 78%) as a colourless oil.  Rf = 0.58 (20% EtOAc in petroleum 
ether); FTIR (neat) 2914, 1732, 1451, 1267, 1112, 1026, 705 cm-1; 1H NMR (500 
MHz, CDCl3): δ = 8.08 (d, J = 7.1, 2H, H
ortho-ar), 7.57 (t, J = 7.4, 1H, Hpara-ar), 7.45 (t, 
J = 7.7, 2H, Hmeta-ar), 5.26 (s, 1H, C=CHC), 5.13 (dd, J = 7.7, 1H, C=CHCH2), 5.07 
(dd, J = 7.4, 1H, C=CHCH2), 2.43-2.38 (m, 1H, (CH2)2CHC), 2.26-2.05 (m, 3H, 
CHCH2CH), 1.79-1.53 (m, 3H, CHCH2CH, CHCH2CH), 1.73 (s, 3H, CH3C=C), 1.65 
(s, 3H, CH3C=C), 1.64 (s, 3H, CH3C=C), 1.59 (s, 3H, CH3C=C), 1.46 (tt, J = 11.2, 2.5, 
1H, CCH(CH2)2), 1.13 (s, 3H, CH3C), 0.97 (s, 3H, CH3C); 
13C NMR (100 MHz, 
CDCl3): δ = 165.1, 149.5, 133.0, 132.6, 132.0, 130.3, 129.8 (2C), 128.3 (2C), 126.1, 
124.1, 123.0, 40.2, 36.5, 35.3, 30.9, 29.2, 28.0, 27.9, 25.8, 25.7, 23.2, 17.81, 17.79; 
ESI-HRMS (TOF): m/z calculated for C25H34O2 [M+H]
+: 367.2634; found 367.2632. 
 
 (±)-(4S,6S)-6-Benzoyl-4,6-bis(3’-methylbut-2’-en-1'-yl)-3,3-dimethyl-
cyclohexanone (238) 
 
Cyclohexanone 141 (258.1 mg, 0.99 mmol) and MgBr.Et2O (639.0 mg, 2.46 mmol, 
2.5 equiv.) were suspended in DCM (10 mL) and stirred for 5 min.  To which iPr2NEt 
(0.52 mL, 3.0mmol, 3 equiv.) was added and the suspension stirred for 30 min.  The 
suspension changed from pale yellow to deep orange in this time.  Benzoyl chloride 
(0.17 mL, 1.48 mmol, 1.5 equiv.) was added and the solution was heated to 50 °C for 
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20 h before quenching with 2 M HCl (10 mL). This was extracted with DCM 
(3 x 10 mL), the combined organic layers were dried (MgSO4) and the solvent was 
removed under reduced pressure.  The residue was purified by flash column 
chromatography (8:2 petrol:Et2O) to afford 238 (234 mg, 64%) as a yellow oil.  
Rf = 0.57 (20% EtOAc in petroleum ether); FTIR (neat) 2914, 1711, 1671, 1597, 
1581, 1447, 1376, 1114, 706 cm-1; 1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = , 2H, 
Hortho-ar), 7.50 (t, J = , 1H, Hpara-ar), 7.39 (t, J = , 2H, Hmeta-ar), 5.24 (t, J = 7.0, 1H, 
C=CHCH2), 4.92 (t, J = 8.1, 1H, C=CHCH2), 2.87-2.79 (m, 2H, CHCH2C, CHCH2CH), 
2.56-2.49 (dd, J = 15.1, 7.6, 1H, CHCH2C), 2.19-2.03 (m, 3H, CHCH2CH, CCH2C), 
1.76 (s, 3H, CH3C=C), 1.80-1.50 (m, 3H, CCH(CH2)2, CHCH2CH2), 1.60 (s, 6H, 
CH3C=C), 1.37 (s, 3H, CH3C=C), 0.96 (s, 3H, CH3C), 0.78 (s, 3H, CH3C); 
13C NMR 
(100 MHz, CDCl3): δ = 210.8, 197.2, 136.9, 134.9, 132.8, 132.3, 128.7 (2C), 128.6 
(2C), 123.3, 117.9, 67.1, 57.1, 43.1, 41.0, 38.8, 34.0, 29.9, 28.5, 25.9 (2C), 19.8, 
17.9, 17.7; ESI-HRMS (TOF): m/z calculated for C25H34O2 [M+Na]
+: 389.2451; found 
389.2451. 
 
 (±)-(2S,4S,6S)-2-Benzoyl-4,6-bis(3’-methylbut-2’-en-1’-yl)-3,3-dimethyl-
cyclohexanone (234) 
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Diketone 135 (247 mg, 0.83 mmol) was dissolved in THF (3 mL) and cooled to -78 °C 
and then treated with LDA (2 mL of a 0.5 M solution, 1.00 mmol, 1.2 equiv.) and 
stirred for 15 min. at -78 °C.  To the resulting solution, prenyl bromide (0.24 mL, 
2.08 mmol, 2.5 equiv.) was added, the solution was stirred and allowed to reach 
-20 °C over 2 h, then stirred at rt for 30 min. before quenching with saturated 
aqueous NH4Cl (5 mL).  This was extracted with Et2O (3 x 10 mL), the combined 
organics were dried (MgSO4) and the solvent was removed under reduced pressure. 
The residue was purified by flash column chromatography (9:1 petrol:Et2O) to afford 
234 (0.211 g, 70%) as a colourless oil.  Rf = 0.59 (20% EtOAc in petroleum ether); 
FTIR (neat) 3402, 2926, 1709, 1687, 1597, 1448, 1369, 1231, 985, 765, 690 cm-1; 1H 
NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 7.1, 2H, H
ortho-ar), 7.50 (t, J = 7.4, 1H, Hpara-
ar), 7.39 (t, J = 7.6, 2H, Hmeta-ar), 5.08 (t, J = 7.1, 1H, C=CHCH2), 5.02 (t, J = 7.1, 1H, 
C=CHCH2), 4.50 (s, 1H, CCH(C)2), 2.57-2.50 (m, 1H, CHCH2CH), 2.45-2.38 (m, 2H, 
CHCH2CH, (CH2)2CHC), 2.23 (dd, J = 12.1, 6.8, 1H, CHCH2CH), 1.90-1.59 (m, 3H, 
CHCH2CH, CHCH2CH), 1.71 (s, 3H, CH3C=C), 1.68 (s, 3H, CH3C=C), 1.67 (s, 3H, 
CH3C=C), 1.61 (s, 3H, CH3C=C), 1.60-1.55 (m, 1H, CCH(CH2)2), 1.14 (s, 3H, CH3C), 
1.11 (s, 3H, CH3C); 
13C NMR (100 MHz, CDCl3): δ = 210.8, 197.6, 139.0, 134.3, 
132.8, 132.8, 128.5 (2C), 127.9 (2C), 123.3, 121.0, 64.5, 49.9, 44.2, 43.8, 31.6, 30.7, 
27.6, 27.5, 25.9, 25.8, 18.1, 17.9, 17.2; ESI-HRMS (TOF): m/z calculated for 
C25H34O2 [M+Na]
+: 389.2457; found 389.2447. 
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(±)-(2R,4S,6R)-2-Benzoyl-4,6-bis(3’-methylbut-2’-en-1’-yl)-3,3-dimethyl-methyl-1-
oxocyclohexanecarboxylate (241)  + (±)-(4S)-2-Benzoyl-3,3-dimethyl-4S,6-bis(3’-
methylbut-2’-en-1’-yl)cyclohex-6-en-6-yl methyl carbonate (242)  
  
1,3-diketone 234 (68.9 mg, 0.188 mmol) was dissolved in THF (0.5 mL) and cooled 
to -78 °C.  This was treated with LiTMP (0.94 mL of a 0.5 M solution, 0.471 mmol, 
2.5 equiv.) and stirred at -78 °C for 15 min.  After which time methyl cyanoformate 
(0.15 mL, 1.88 mmol, 10 equiv.) was added, the resulting solution stirred for 2 h at 
-78 °C before quenching with saturated aqueous NH4Cl (5 mL). This was extracted 
with Et2O (3 x 5 mL), the combined organic layers dried (MgSO4) and the solvent was 
removed under reduced pressure. The mixture was purified by flash column 
chromatography (9:1 petrol:Et2O) to afford deacetylated product 141 (12.6 mg) and 
mixed O-acylated and C-acylated products 241 and 242 (36.2 mg, 43%).  The mixed 
acylation products could be separated by HPLC (water:MeCN gradient) to afford 
C-acylated 241 (20.1 mg, 27%) and  O-acylated 242 (16.1 mg, 21%).  Rf = 0.41 (20% 
EtOAc in petroleum ether). 
Major (241) 
1H NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 7.1, 2H, H
ortho-ar), 7.53 (t, J = 7.3, 1H, 
Hpara-ar), 7.43 (t, J = 7.4, 2H, Hmeta-ar), 5.16 (t, J = 6.7, 1H, C=CHCH2), 5.06 (t, J = 8.3, 
1H, C=CHCH2), 4.49 (s, 1H, (C)2CHC), 3.77 (s, 3H, CH3O), 2.54-2.47 (m, 2H, 
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CHCH2C), 2.35-2.15 (m, 2H, CHCH2CH, CHCH2C), 1.75-1.63 (m, 2H, CHCH2CH, 
CHCH2C), 1.76 (s, 3H, CH3C=C), 1.67 (s, 3H, CH3C=C), 1.62 (s, 3H, CH3C=C), 1.57 
(s, 3H, CH3C=C), 1.45-1.35 (m, 1H, CCH(CH2)2), 1.12 (s, 3H, CH3C), 1.05 (s, 3H, 
CH3C); 
13C NMR (100 MHz, CDCl3): δ = 203.0, 196.8, 172.4, 139.0, 135.2, 133.0, 
132.8, 128.5 (2C), 127.9 (2C), 122.8, 118.2, 66.5, 61.7, 52.3, 46.1, 44.4, 36.9, 33.4, 
27.4, 26.7, 25.9, 25.8, 18.0, 17.8, 16.1; ESI-HRMS (TOF): m/z calculated for 
C27H36O4 [M+Na]
+: 447.2511; found 447.2512. 
Minor (242) 
FTIR (neat) 2967, 1751, 1683, 1440, 1259, 1218 cm-1; 1H NMR (300 MHz, CDCl3): 
δ = 7.92 (d, J = 7.1, 2H, Hortho-ar), 7.54 (t, J = 7.3, 1H, Hpara-ar), 7.44 (t, J = 7.4, 2H, 
Hmeta-ar), 5.15-5.02 (m, 2H, C=CHCH2), 4.68 (s, 1H, CCH(C)2), 3.56 (s, 3H, CH3O), 
2.81 (dd, J = 14.2, 7.7, 1H, CHCH2C), 2.67 (dd, J = 14.0, 7.1, 1H, CHCH2C), 2.17 
(dd, J = 17.3, 3.8, 1H, CHCH2CH), 1.85-1.65 (m, 4H, CCH(CH2)2, CHCH2C, 
CHCH2CH), 1.70 (s, 3H, CH3C=C), 1.63 (s, 3H, CH3C=C), 1.60 (s, 3H, CH3C=C), 
1.56 (s, 3H, CH3C=C), 0.92 (s, 3H, CH3C), 0.85 (s, 3H, CH3C); 
13C NMR (100 MHz, 
CDCl3): δ = 199.9, 154.0, 140.0, 139.4, 133.2, 132.7, 132.5, 128.6 (2C), 128.5 (2C), 
126.7, 123.3, 120.4, 55.7, 54.9, 44.6, 38.0, 31.1, 29.3, 28.7, 27.8, 27.4, 25.8, 17.8, 
17.7, 16.6; ESI-HRMS (TOF): m/z calculated for C27H36O4 [M+Na]
+: 447.2511; found 
447.2512. 
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(±)-(4S)-2-Benzoyl-3,3-dimethyl-4S,6-bis(3’-methylbut-2’-en-1’-yl)cyclohex-6-en-
6-yl methyl carbonate (242)  
 
1,3-diketone 234 (34.1 mg, 0.09 mmol) was dissolved in THF (0.5 mL) and cooled to 
-78 °C and stirred for 15 min.  The resulting solution was treated with LiTMP 
(0.47 mL of a 0.5 M solution, 0.23 mmol, 2.5 equiv.) and stirred for a further 5 min. 
After which time methyl chloroformate (72 μL, 0.93 mmol, 10 equiv.) was added.  The 
solution was stirred and allowed to warm to -20 °C over 2 h before quenching with 
saturated aqueous NH4Cl (10 mL). This was extracted with Et2O (3 x 10 mL), the 
combined organic layers were dried (MgSO4) and the solvent was removed under 
reduced pressure.  The residue was purified by column chromatography (9:1 
petol:Et2O) to afford 242 (9.8 mg, 25%) as a colourless oil. 
Data as quoted for O-acylation product 242 from above. 
 Appendix 
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Appendix 1: 1H NMR of 173 (500 MHz, CDCl3) 
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 Appendix 2: 13C NMR of 173 (125 MHz, CDCl3)   
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Appendix 3: 1H NMR of 176 (500MHz, CDCl3)  
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Appendix 4: 13C NMR of 176 (125 MHz, CDCl3)  
  
 Appendix 
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Appendix 5: 1H NMR of 174 (500 MHz, CDCl3)  
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Appendix 6: 13C NMR of 174 (125 MHz, CDCl3)   
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Appendix 7: 1H NMR of 178 (500 MHz, CDCl3)  
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Appendix 8: 13C NMR of 178 (125 MHz, CDCl3)  
  
 Appendix 
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Appendix 9: 1H NMR of 157 (500 MHz, CDCl3)   
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Appendix 10: 13 C NMR of 157 (125 MHz, CDCl3)   
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Appendix 11: HSQC NMR of 157 (CDCl3)  
  
 Appendix 
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Appendix 12: HMBC NMR of 157 (CDCl3)  
  
 Appendix 
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Appendix 13: 1H NMR of nemorosone (4) (500 MHz, MeOD)   
 Appendix 
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Appendix 14: 13 C NMR of nemorosone (4) (125 MHZ, MeOD)   
 Appendix 
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Appendix 15: 1H NMR of 199 (500 MHz, CDCl3)    
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Appendix 16: 13C NMR of 199 (125 MHz, CDCl3)   
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Appendix 17: 1H NMR of 152 (500 MHz, CDCl3)   
 Appendix 
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Appendix 18: 13C NMR of 152 (125 MHz, CDCl3)   
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Appendix 19:  1H NMR of 150 (500 MHz, MeOD)  
  
 Appendix 
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Appendix 20: 13C NMR of 150 (125 MHz, MeOD)   
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Appendix 21: HPLC trace for O-methylated nemorosone (157).  Lux cellulose II 
column (1.5% MeOH in hexane) 
 
Appendix 22: HPLC trace of synthetic nemorosone (4) and natural nemorosone (4).  
AD column (10% IPA in hexane) 
 
---- = natural nemorosone 
__ = synthetic nemorosone  
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Appendix 23: HPLC trace for O-methylated nemorosone II (152).  Lux cellulose II 
column (1% IPA in hexane) 
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